Wolfram Syndrome

Mendelian MONDO:0018105 Pathograph 36 Show in embeddings browser Neurodegenerative Disease Monogenic Diabetes

Wolfram syndrome is an autosomal recessive neurodegenerative disorder caused by failure of either of two endoplasmic-reticulum and organelle-contact proteins. The cells that suffer most are insulin-secreting pancreatic beta cells and long-projection neurons. Biallelic loss-of-function variants in WFS1 account for the large majority of cases; biallelic CISD2 variants cause the rarer Wolfram syndrome 2. Wolframin normally restrains the unfolded protein response by stabilizing the E3 ubiquitin ligase HRD1 and routing ATF6-alpha to the proteasome, maintains endoplasmic reticulum calcium stores, and supports endoplasmic-reticulum to mitochondria contact sites. CISD2 loss reaches the same calcium-transfer and mitochondrial compartment through a distinct route. These defects converge on beta-cell dysfunction or loss and neuronal injury. In WS1, this typically reads out as the DIDMOAD sequence: insulin-requiring autoantibody-negative diabetes mellitus in the first decade, then optic atrophy, then sensorineural hearing loss and central diabetes insipidus, then neurogenic bladder and brainstem or cerebellar dysfunction. WS2 shares diabetes mellitus, optic atrophy, and hearing impairment but usually lacks diabetes insipidus and instead adds upper intestinal ulceration and a bleeding tendency. In the historical, predominantly WS1 natural-history cohort, death occurred at a median age around 30 years and was usually from central respiratory failure with brainstem atrophy. Brain volume abnormalities are already measurable at the earliest clinical presentation, so part of the deficit is failed development rather than degeneration alone. There is no approved disease-modifying therapy.

Ask OpenScientist

Ask a research question about Wolfram Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Autosomal Recessive HP:0000007

Classic Wolfram syndrome, both WFS1-related and CISD2-related, is autosomal recessive. UK family studies indicate a carrier frequency of about 1 in 354, with no maternal history of diabetes or deafness and no mitochondrial tRNA-Leu 3243 variant, which is what separates this from the maternally inherited mitochondrial mimics. Consanguinity is a major driver of case load in regions where it is common. Heterozygous WFS1 variants cause a separate, dominantly inherited spectrum that is out of scope for this entry.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

"Family studies indicate autosomal recessive inheritance with a carrier frequency of one in 354, an absence of a maternal history of diabetes or deafness, and an absence of the mitochondrial tRNA Leu (3243) mutation."

Establishes autosomal recessive inheritance and the carrier frequency, and excludes the mitochondrial mimic.

◆

Subtypes

Wolfram syndrome 1 (WFS1-related) MONDO:0009101

WFS1 hgnc:12762

The classic and by far the commoner form, caused by biallelic WFS1 variants, accounting for roughly 90% of cases. Diabetes mellitus and optic atrophy before age 16 are the defining pair; diabetes insipidus, sensorineural deafness, neurogenic bladder, and brainstem or cerebellar neurodegeneration follow.

Show evidence (1 reference)

PMID:39202345 SUPPORT Human Clinical

"Mutations in the WFS1 gene, located on chromosome 4p16, account for approximately 90% of WS1 cases."

Quantifies the share of Wolfram syndrome attributable to WFS1 variants.

Wolfram syndrome 2 (CISD2-related) MONDO:0011502

CISD2 hgnc:24212

A rarer form caused by biallelic variants in CISD2, which encodes ERIS, a small protein of the mitochondria-associated endoplasmic reticulum membrane. ERIS localizes to the same organelle as wolframin but does not interact with it directly, so the two genes converge on the same compartment by separate routes. Clinically WS2 typically lacks diabetes insipidus and adds upper intestinal ulceration and a bleeding tendency.

Show evidence (1 reference)

PMID:39527371 SUPPORT Human Clinical

"Additionally, a second gene, CISD2, located on chromosome 4q22, has been identified in individuals with WFS type 2 (WFS2), which leads to early onset optic atrophy, diabetes mellitus, deafness, bleeding tendency and upper intestinal ulcers, a shortened lifespan, but notably not diabetes insipidus."

Defines the CISD2-related subtype and its clinical discriminators, including the characteristic absence of diabetes insipidus.

Discussions and Knowledge Gaps

Are there established genotype-phenotype correlations in Wolfram syndrome, or only emerging ones?

CONTROVERSY wfs_genotype_phenotype_tension

Attached to

genetic#WFS1 Biallelic Loss of Function

GeneReviews takes the conservative position that no correlations are established, and that remains defensible. A meta-analysis of 412 published patients reported genotypic-class correlations, and a 2026 registry analysis found a six-level WFS1 severity score informative for diabetes onset and more modestly for optic atrophy, but not for hearing loss or central diabetes insipidus. The newer analysis lacked time-to-event censoring and derived its three-tier simplification in the same dataset, so the score is a research instrument rather than a validated individual prognostic test.

Show evidence (2 references)

PMID:23429432 SUPPORT Human Clinical

"New genotype-phenotype correlations were established, disease progression rate for the general population and for the genotypic classes has been calculated, and new diagnostic criteria have been proposed."

The meta-analysis states that it established new correlations, which is the claim in tension with the conservative position.

PMID:42524523 SUPPORT Human Clinical

"The genotype-based severity score is most informative for diabetes mellitus, modestly informative for optic atrophy, and not currently useful for hearing loss or central diabetes insipidus."

A large recent registry analysis supports phenotype-specific predictive signal but not a general genotype-to-course prediction; PARTIAL reflects its exploratory, internally assessed design.

How much of the brain deficit in Wolfram syndrome is failed development rather than degeneration, and what does that imply for when a disease-modifying therapy must start?

OPEN QUESTION wfs_neurodevelopment_vs_neurodegeneration

Attached to

pathophysiology#Brainstem and Cerebellar Volume Loss

Longitudinal morphometry shows both stalled white-matter growth and frank degeneration, and abnormalities are present in the youngest and mildest patients. If a meaningful share of the deficit is growth that never happened, then a neuroprotective therapy started after symptoms appear can at best halt decline and can never recover what was not built, which moves the therapeutic window earlier than a purely degenerative model implies. The relative contribution of the two processes has not been quantified.

Show evidence (1 reference)

PMID:30979932 SUPPORT Human Clinical

"These patterns suggest that there may be early, stalled white matter development in Wolfram syndrome, with additional degenerative processes in both white and gray matter."

States the two-process interpretation whose relative weighting is the open question.

Does environmental or metabolic stress that raises the unfolded-protein load accelerate disease in WFS1-deficient cells in humans?

KNOWLEDGE GAP wfs_gene_environment_interaction

Attached to

pathophysiology#Unrestrained ER Stress Signaling Through ATF6-alpha

Because wolframin's job is buffering endoplasmic reticulum stress, any stressor that raises the unfolded-protein load (glucotoxicity, inflammation, hypoxia) should in principle hit harder in a WFS1-null cell. There is preclinical support in that WFS1 deficiency produces a chronic proinflammatory state, but no human data measure whether glycemic control or inflammatory burden modifies the rate of neurodegeneration. Until they do, better glycemic control should not be curated as a protective factor for the neurological disease.

Proposed experiments

Glycemic and inflammatory burden versus neurodegeneration rate

wfs_glycemic_burden_vs_progression

In an existing longitudinal Wolfram cohort with serial brain morphometry, relate cumulative glycemic exposure and circulating inflammatory markers to the rate of brainstem and ventral pontine volume loss, to test whether modifiable stress load changes the neurodegenerative trajectory.

Show evidence (1 reference)

PMID:33693650 SUPPORT Human Clinical

"The identification of a state of systemic chronic inflammation associated with WFS1 deficiency may pave the way to innovative and personalized therapeutic interventions in WS."

Establishes the chronic inflammatory state that makes the gene-environment question mechanistically plausible.

Can serum neurofilament light chain serve as a treatment-response marker in Wolfram syndrome, given that it is elevated but does not track progression?

KNOWLEDGE GAP wfs_nfl_as_progression_marker

Attached to

biochemical#Elevated Serum Neurofilament Light Chain

Neurofilament light chain is clearly elevated and glial fibrillary acidic protein is not, which is a clean biological signal about axonal injury. But within the Wolfram group it did not change over time and did not correlate with clinical severity or neuroimaging measures, so it fails as a monitoring biomarker on the evidence available. Whether it moves under an effective therapy is a different question and remains untested, and the field needs a progression marker badly because every trial so far has had to rely on slow clinical endpoints.

Show evidence (1 reference)

PMID:41929703 SUPPORT Human Clinical

"Future studies may be warranted to determine if NfL could be a treatment-response marker in Wolfram syndrome clinical trials."

States the open question in the authors' own terms.

Does the PB&TURSO result in WFS1-related Wolfram syndrome generalize to the CISD2-related subtype, which this entry models as reaching the same organelle-contact and calcium-transfer compartment by an independent route?

KNOWLEDGE GAP OPEN wfs_cisd2_treatment_generalization

Attached to

pathophysiology#Loss of CISD2 at Organelle Contact Membranes pathophysiology#ER-Mitochondria Contact and Calcium Transfer Dysregulation pathophysiology#Mitochondrial Dysfunction

The HELIOS trial restricted enrollment to WFS1 Wolfram syndrome deliberately, to reduce heterogeneity, and the authors state that CISD2 Wolfram syndrome shares similar pathophysiology and may benefit. That is a hypothesis, not a result: no CISD2 participant was treated. The question matters here more than it would in most entries, because this entry already models CISD2 as an independent route into the shared ER-mitochondria contact compartment rather than as a WFS1 phenocopy — so convergence at that node is exactly the premise the generalization rests on, and exactly what an untested extrapolation would be assuming. Note also that the two subtypes diverge clinically (CISD2 disease notably lacks diabetes insipidus and adds bleeding tendency), so shared upstream mechanism does not by itself predict a shared treatment response profile across endpoints. The contact-site direction sharpens this further, and cuts against a simple read-across. WFS1-null patient fibroblasts show *reduced* ER-mitochondria interactions and calcium exchange; a CISD2 missense variant causing classical Wolfram phenotype instead shows *increased* ER-mitochondria contact with a hyperfused mitochondrial network and no overt ER stress, while complete CISD2 loss in human cortical neurons shows loss of contact sites again. So the direction of the contact-site abnormality is not uniform even within CISD2, let alone shared with WFS1 — which is exactly why this entry models the convergence node as direction-neutral dysregulation. A chemical chaperone and ER-stress modulator tuned to the WFS1 arm has no guaranteed effect on a lesion that perturbs the same compartment in the opposite direction, and the CISD2 missense finding explicitly reports the absence of overt ER stress that PB&TURSO is meant to relieve.

Proposed experiments

PB&TURSO response in CISD2-related Wolfram syndrome

exp_wfs_cisd2_pbturso_response

Extend an open-label PB&TURSO cohort to genetically confirmed CISD2 Wolfram syndrome with residual beta cell function, using the same stimulated C-peptide primary endpoint, and compare the response trajectory against the WFS1 cohort. Given the rarity, an n-of-1 series with pre-treatment natural-history run-in is more realistic than a parallel-group design.

Decision criterion

Whether a stimulated C-peptide response in CISD2 participants falls within the range observed in the WFS1 cohort discriminates convergence at the shared contact-site node from a WFS1-specific chaperone effect.

Supporting outcome

A comparable stimulated C-peptide and glycemic response in CISD2 participants, supporting the shared-compartment premise and licensing subtype-agnostic treatment claims.

Refuting outcome

Absent or markedly attenuated response in CISD2 participants, which would indicate the benefit depends on something specific to wolframin loss rather than on the shared ER-mitochondria contact defect.

Recorded as a gap, not as a treatment claim: PB&TURSO is deliberately not curated onto the CISD2 subtype anywhere in this entry, and should not be until a CISD2 participant has actually been treated.

Show evidence (3 references)

PMID:42138079 SUPPORT Human Clinical

"The trial focused on WFS1 WS to reduce heterogeneity, though CISD2 WS shares similar pathophysiology and may benefit."

The authors' own statement of both the restriction and the untested generalization, which is what makes this a gap rather than a finding.

PMID:28335035 SUPPORT In Vitro

"This Ca2+ dysregulation was associated with increased ER-mitochondria contact, a swollen ER lumen and a hyperfused mitochondrial network in the absence of overt ER stress."

The CISD2 missense arm perturbs the shared compartment in the opposite direction from WFS1 loss and without overt ER stress, which is the concrete reason a WFS1-tuned ER-stress modulator may not transfer.

PMID:30352948 SUPPORT In Vitro

"In addition, we found that NCS1 abundance was reduced in WFS1-null patient fibroblasts, which showed reduced ER-mitochondria interactions and Ca2+ exchange."

The WFS1 comparator direction — reduced interactions and exchange — against which the CISD2 missense finding is opposite.

⚙

Pathophysiology

Loss of Wolframin at the Endoplasmic Reticulum Membrane

Biallelic loss-of-function variants in WFS1 remove wolframin, a multipass transmembrane glycoprotein of the endoplasmic reticulum. Wolframin holds three jobs at once: it negatively regulates the unfolded protein response, it maintains endoplasmic reticulum calcium stores, and it supports the contact sites where the endoplasmic reticulum meets mitochondria. Nothing downstream in this entry is a separate insult; every later node is one of those three jobs going unattended.

WFS1 hgnc:12762

endoplasmic reticulum membrane GO:0005789

Downstream

Unrestrained ER Stress Signaling Through ATF6-alpha Loss of the wolframin brake releases ATF6-alpha and the unfolded protein response.

ER-Mitochondria Contact and Calcium Transfer Dysregulation Loss of wolframin removes its contribution to endoplasmic reticulum calcium handling and to the NCS1-IP3R complex at contact sites.

Hypothalamic Magnocellular Neuron Loss In WS1, wolframin deficiency is associated with selective degeneration of vasopressin-producing magnocellular neurons in the supraoptic and paraventricular hypothalamic nuclei.

Cochlear and Auditory Pathway Degeneration In WS1, wolframin deficiency is associated with degeneration from the organ of Corti through the cochlear nerve and central auditory nuclei.

Lower Urinary Tract Neural Dysfunction In WS1, neurologic and autonomic involvement can disrupt detrusor and sphincter control, producing the characteristic bladder phenotype.

Show evidence (2 references)

PMID:9771706 SUPPORT Human Clinical

"Mutations in a novel gene (WFS1) encoding a putative transmembrane protein were found in all affected individuals in six WFS families, and these mutations were associated with the disease phenotype."

The gene-identification study establishing WFS1 variants as the cause of Wolfram syndrome.

PMID:9771706 SUPPORT Human Clinical

"WFS1 appears to function in survival of islet beta-cells and neurons."

Identifies the two cell populations whose survival depends on wolframin, which is the whole shape of the clinical phenotype.

Loss of CISD2 at Organelle Contact Membranes

Biallelic loss-of-function variants remove CISD2, an integral membrane protein present at the endoplasmic reticulum, mitochondrial outer membrane, and mitochondria-associated endoplasmic-reticulum membranes. Unlike wolframin, CISD2 does not interact with WFS1 directly. Its loss independently disrupts intracellular calcium handling, organelle contacts, mitochondrial function, and beta-cell insulin secretion.

CISD2 hgnc:24212

mitochondria-associated endoplasmic reticulum membrane GO:0044233

Downstream

ER-Mitochondria Contact and Calcium Transfer Dysregulation CISD2 loss perturbs contact-site abundance and calcium transfer, with the measured direction depending on variant and model context.

Insulin Deficiency Beta-cell-specific Cisd2 loss impairs calcium-mediated insulin secretion.

Show evidence (2 references)

PMID:17846994 SUPPORT Human Clinical

"The ZCD2-encoded protein, ERIS (endoplasmic reticulum intermembrane small protein), is also shown to localize to the endoplasmic reticulum but does not interact directly with Wolframin."

Establishes the separate CISD2 route into the endoplasmic-reticulum compartment and its lack of direct interaction with wolframin.

PMID:40189101 SUPPORT Model Organism

"β-cell specific Cisd2KO in mice disrupts systemic glucose homeostasis via impairing β-granules synthesis and insulin secretion; hypertrophy of the β-islets and the presence of a loss of identity that affects certain β-cells."

Directly links beta-cell CISD2 loss to impaired insulin production and secretion in vivo.

Unrestrained ER Stress Signaling Through ATF6-alpha

Wolframin's mechanism of restraint is specific and now well defined. It stabilizes the E3 ubiquitin ligase HRD1, brings the transcription factor ATF6-alpha to the proteasome, and enhances its ubiquitination and degradation. Without wolframin, ATF6-alpha accumulates, its target genes are derepressed, and the endoplasmic reticulum stress response element promoter is activated. Patient lymphocytes show the same dysregulation, with ATF6-alpha up and HRD1 down. A chronically engaged unfolded protein response is not a louder version of a normal signal; it is an alarm that never stops, and the building is eventually evacuated for good.

ATF6-mediated unfolded protein response GO:0036500 ↑ INCREASED ATF6-alpha ubiquitination and proteasomal degradation GO:0016567 ↓ DECREASED

Experimental models

CRISPR-corrected patient iPSC-derived beta cells IPSC DERIVED MODEL Genetic correction decreased expression of genes associated with endoplasmic reticulum stress in patient-derived beta cells.

Downstream

Beta Cell Apoptosis Chronic unresolvable endoplasmic reticulum stress drives beta cell death.

Retinal Ganglion Cell and CNS Neuron Degeneration The same chronic stress response drives apoptosis in long-projection neurons.

Show evidence (2 references)

PMID:20160352 SUPPORT In Vitro

"Moreover, WFS1 stabilized the E3 ubiquitin ligase HRD1, brought ATF6alpha to the proteasome, and enhanced its ubiquitination and proteasome-mediated degradation, leading to suppression of ER stress signaling."

Defines the molecular mechanism by which wolframin restrains the ATF6 arm of the unfolded protein response.

PMID:20160352 SUPPORT Human Clinical

"lymphocytes from patients with Wolfram syndrome exhibited dysregulated ER stress signaling through upregulation of ATF6alpha and downregulation of HRD1."

Restricts the clinical evidence item to the patient-lymphocyte result; the mouse beta-cell observation in the same source sentence is not typed as human evidence here.

ER-Mitochondria Contact and Calcium Transfer Dysregulation

Wolframin forms a complex with neuronal calcium sensor 1 (NCS1) and the inositol 1,4,5-trisphosphate receptor to move calcium from the endoplasmic reticulum into mitochondria at mitochondria-associated membranes. In WFS1-null patient fibroblasts, NCS1 abundance falls, endoplasmic reticulum to mitochondria contacts and calcium exchange fall. CISD2 deficiency converges on the same compartment: isogenic CISD2-knockout human cortical neurons lose contact sites and calcium transfer, whereas one patient CISD2 missense variant increased both in fibroblasts. The node therefore records dysregulation, not a universal direction of effect across both molecular subtypes.

endoplasmic reticulum calcium ion homeostasis GO:0032469 ↕ DYSREGULATED

mitochondria-associated endoplasmic reticulum membrane GO:0044233

Experimental models

CISD2-knockout human iPSC-derived cortical neurons IPSC DERIVED MODEL CISD2-knockout neurons lose endoplasmic-reticulum to mitochondria contact sites and show severe loss of glutamate-evoked cytosolic calcium responses and mitochondrial calcium uptake.

Downstream

Mitochondrial Dysfunction Reduced calcium delivery to mitochondria impairs their function and dynamics.

Cytosolic Calcium Dysregulation Calcium that is not retained in the endoplasmic reticulum or handed to mitochondria raises cytosolic calcium.

Show evidence (5 references)

PMID:30352948 SUPPORT In Vitro

"Here, we showed that WFS1 formed a complex with neuronal calcium sensor 1 (NCS1) and inositol 1,4,5-trisphosphate receptor (IP3R) to promote Ca2+ transfer between the ER and mitochondria."

Establishes the physical complex through which wolframin supports organelle calcium transfer.

PMID:30352948 SUPPORT In Vitro

"In addition, we found that NCS1 abundance was reduced in WFS1-null patient fibroblasts, which showed reduced ER-mitochondria interactions and Ca2+ exchange."

Demonstrates the defect in patient-derived cells rather than only in engineered knockdowns.

PMID:17846994 SUPPORT In Vitro

"Lymphoblastoid cells from affected individuals show a significantly greater rise in intracellular calcium when stimulated with thapsigargin, compared with controls, although no difference was observed in resting concentrations of intracellular calcium."

Shows that the CISD2 route into this node also produces abnormal calcium handling. PARTIAL because the abnormality is a stimulated response in WS2 lymphoblastoid cells, not the same measured ER-mitochondria transfer defect demonstrated for WFS1.

+ 2 more references

Mitochondrial Dysfunction

Disturbed calcium exchange at endoplasmic-reticulum to mitochondria contact sites disrupts mitochondrial dynamics and bioenergetics. WFS1 knockdown in neurons inhibits mitochondrial fusion, alters trafficking, and augments mitophagy. CISD2-knockout human cortical neurons show reduced oxygen consumption, ATP production, and mitochondrial membrane-potential maintenance. These subtype-specific experiments converge on one atomic mitochondrial dysfunction node.

neuron CL:0000540

mitochondrion organization GO:0007005 ↕ DYSREGULATED

Downstream

Impaired Neuronal Development WFS1-associated mitochondrial dynamics defects delay neuronal development.

Retinal Ganglion Cell and CNS Neuron Degeneration Severe mitochondrial failure lowers stress resilience in CISD2-deficient neurons and contributes to neuronal loss.

Show evidence (3 references)

PMID:27434582 SUPPORT In Vitro

"We show that down-regulation of WFS1 in neurons leads to dramatic changes in mitochondrial dynamics (inhibited mitochondrial fusion, altered mitochondrial trafficking, and augmented mitophagy), delaying neuronal development."

Documents the specific mitochondrial-dynamics abnormalities caused by WFS1 deficiency.

PMID:27434582 SUPPORT In Vitro

"Importantly, ER stress, impaired Ca2+ homeostasis, altered mitochondrial dynamics, and delayed neuronal development are causatively related events because interventions at all these levels improved the downstream processes."

Establishes the causal ordering of stress, calcium, mitochondrial, and developmental defects by intervention at each level.

PMID:41299767 SUPPORT In Vitro

"Correlating with the profound changes in cellular Ca2+ handling, mitochondrial function (oxygen consumption rate, ATP production, mitochondrial potential maintenance) declined severely, while autophagic flux was increased."

Directly measures severe mitochondrial bioenergetic dysfunction after CISD2 loss in human iPSC-derived cortical neurons.

Impaired Neuronal Development

WFS1 down-regulation in neurons delays development downstream of endoplasmic-reticulum stress, calcium dyshomeostasis, and disturbed mitochondrial dynamics. Interventions at each upstream level improve the downstream steps, supporting a causal developmental branch rather than an imaging correlation alone.

neuron CL:0000540

neuron development GO:0048666 ↓ DECREASED

Downstream

Brainstem and Cerebellar Volume Loss Stalled neuronal and white-matter development contributes to early regional brain-volume deficits.

Show evidence (2 references)

PMID:27434582 SUPPORT In Vitro

Directly reports delayed neuronal development after WFS1 down-regulation.

PMID:27434582 SUPPORT In Vitro

Intervention at each upstream level supports the causal ordering of the developmental defect.

Cytosolic Calcium Dysregulation

WFS1-knockout insulinoma cells have impaired intracellular calcium homeostasis and Akt signaling, with reduced viability and glucose-stimulated insulin secretion. Re-expressing WFS1, overexpressing NCS1, or treating with a calpain inhibitor or ibudilast reverses these deficits. Because the quoted experiments do not directly quantify calpain activation, this node records only the demonstrated calcium dysregulation.

pancreatic beta cell CL:0000169

Downstream

Beta Cell Apoptosis Calcium dyshomeostasis reduces beta-cell viability.

Insulin Deficiency Calcium dyshomeostasis reduces glucose-stimulated insulin secretion.

Show evidence (2 references)

PMID:32632005 SUPPORT In Vitro

"Knockout (KO) of WFS1 in rat insulinoma (INS1) cells impaired calcium homeostasis and protein kinase B/Akt signaling and, subsequently, decreased cell viability and glucose-stimulated insulin secretion."

Links WFS1 loss to calcium dyshomeostasis and to the two beta cell functional readouts that matter clinically.

PMID:32632005 SUPPORT In Vitro

"Targeting calcium homeostasis with reexpression of WFS1, overexpression of WFS1's interacting partner neuronal calcium sensor-1 (NCS1), or treatment with calpain inhibitor and ibudilast reversed deficits observed in WFS1-KO cells."

Four independent rescues of the same node establish calcium dyshomeostasis as causally upstream of the beta cell deficits.

Beta Cell Apoptosis

Chronic unresolvable endoplasmic reticulum stress and calcium dyshomeostasis converge on intrinsic apoptosis in pancreatic beta cells. The loss is non-autoimmune and progressive. This node is restricted to demonstrated cell death; the downstream hormone deficit is represented separately so that replacement insulin does not appear to reverse apoptosis.

pancreatic beta cell CL:0000169

intrinsic apoptotic signaling in response to ER stress GO:0070059 ↑ INCREASED

Downstream

Insulin Deficiency Progressive non-autoimmune beta-cell loss reduces endogenous insulin supply.

Show evidence (1 reference)

PMID:20160352 SUPPORT In Vitro

"Wolfram syndrome is an autosomal-recessive disorder characterized by insulin-dependent diabetes mellitus, caused by nonautoimmune loss of beta cells, and neurological dysfunctions."

States that the diabetes of Wolfram syndrome arises from non-autoimmune beta cell loss.

Insulin Deficiency

Endogenous insulin supply falls through two related but non-identical routes. Progressive non-autoimmune beta-cell loss dominates WFS1, whereas CISD2 loss in beta cells also impairs beta-granule synthesis, calcium-mediated secretory signaling, and glucose-stimulated insulin secretion. The hormone deficit is the immediate mechanism producing diabetes mellitus and the mechanism restored by exogenous insulin.

pancreatic beta cell CL:0000169

insulin secretion GO:0030073 ↓ DECREASED

Experimental models

CRISPR-corrected patient iPSC-derived beta cells IPSC DERIVED MODEL Correcting the WFS1 variant restored robust dynamic insulin secretion in vitro. Transplantation of the corrected human beta cells separately reversed streptozotocin-induced diabetes in mice.

Animal models

Beta-cell-specific Cisd2 knockout mouse Mus musculus recapitulates Beta-cell-restricted Cisd2 loss impairs both phases of glucose-stimulated insulin secretion and disrupts systemic glucose homeostasis without changing insulin sensitivity.

Downstream

Diabetes Mellitus Insufficient endogenous insulin produces insulin-requiring diabetes.

Show evidence (2 references)

PMID:7490992 SUPPORT Human Clinical

"Non-autoimmune, insulin-deficient diabetes mellitus presented at a median age of 6 years, followed by optic atrophy (11 years)."

Provides the median onset ages and confirms the insulin-deficient, non-autoimmune character in a national cohort.

PMID:40189101 SUPPORT In Vitro

"Cisd2 deficiency leads to impairment of glucose-induced extracellular Ca2+ influx, which compromises Ca2+-mediated insulin secretory signaling, causing mitochondrial dysfunction and, thereby impairing insulin secretion in the MIN6-Cisd2KO β-cells."

Defines the calcium-dependent insulin-secretory failure caused by CISD2 loss in a beta-cell model.

Retinal Ganglion Cell and CNS Neuron Degeneration

Cell-intrinsic stress, calcium-transfer defects, and mitochondrial dysfunction reduce the survival of retinal ganglion cells and long-projection central neurons. Retinal ganglion cell loss thins the retinal nerve fiber layer and produces the bilateral progressive optic atrophy that, paired with early diabetes, defines the syndrome clinically. WFS1 evidence directly links endoplasmic-reticulum stress to cell death; CISD2-knockout human cortical neurons show markedly reduced resilience to an apoptosis inducer.

retinal ganglion cell CL:0000740

neuron apoptotic process GO:0051402 ↑ INCREASED

Animal models

Wfs1 exon-8 knockout mouse Mus musculus recapitulates The knockout reproduces progressive visual-acuity loss, optic-disc pallor, retinal thinning, and severe optic-nerve axon damage; rescue by retinal delivery of human WFS1 strengthens the causal interpretation.

Downstream

Optic Atrophy Loss of retinal ganglion cells produces progressive bilateral optic atrophy.

Brainstem and Cerebellar Volume Loss Degeneration of long-projection central neurons contributes to brainstem and cerebellar tissue loss.

Show evidence (2 references)

PMID:22792385 SUPPORT Human Clinical

"WFS is caused by mutations in the WFS1 gene, which lead to endoplasmic reticulum (ER) stress-mediated cell death."

Attributes the neuronal loss of Wolfram syndrome to endoplasmic reticulum stress-mediated cell death.

PMID:41299767 SUPPORT In Vitro

"Overall, these deficiencies further impact the resilience of Cisd2-deficient cortical neurons to cell stress as Cisd2-KO neurons were highly sensitive to staurosporine, an inducer of apoptosis."

Links CISD2 loss to reduced survival under apoptotic stress in human iPSC-derived cortical neurons.

Hypothalamic Magnocellular Neuron Loss

Human neuropathology in WS1 shows gliosis and severe loss of magnocellular neurons in the supraoptic and paraventricular hypothalamic nuclei. Loss of these vasopressin-producing neurons supplies the tissue-level link between the molecular WFS1 defect and central diabetes insipidus; the upstream molecular steps that create this selective vulnerability are not yet resolved.

neuron CL:0000540

hypothalamus UBERON:0001898

Downstream

Diabetes Insipidus Loss of hypothalamic magnocellular neurons depletes central vasopressin output and produces central diabetes insipidus.

Show evidence (1 reference)

PMID:39202345 SUPPORT Human Clinical

"In some WS1 cases, the hypothalamus exhibited gliosis and a severe loss of magnocellular neurons in the supraoptic and paraventricular nuclei"

A recent review of human postmortem findings directly localizes the magnocellular-neuron loss in WS1.

Cochlear and Auditory Pathway Degeneration

Human WS1 neuropathology shows a continuous pattern of auditory-system injury: loss of the organ of Corti in basal cochlear turns, cochlear-nerve fibers, and neurons in the cochlear nuclei and inferior colliculus. This regional lesion connects WFS1 deficiency to the progressive sensorineural hearing phenotype without assuming that every affected person has injury at every listed site.

cochlea UBERON:0001844

Downstream

Sensorineural Hearing Impairment Degeneration of the organ of Corti, cochlear nerve, and central auditory nuclei impairs auditory signal transduction and transmission.

Show evidence (1 reference)

PMID:39202345 SUPPORT Human Clinical

"The auditory pathways are characterized by the loss of the organ of Corti in the basal turns of the cochlea, as well as the loss of fibers in the cochlear nerve and neurons in the cochlear nuclei and inferior colliculus"

A recent review of human neuropathology directly describes the peripheral and central auditory lesions in WS1.

Lower Urinary Tract Neural Dysfunction

Neurologic and autonomic involvement in WS1 disrupts lower-urinary-tract control. Urodynamic studies show both hypocontractile detrusor and detrusor-sphincter dyssynergia, explaining how the neural disease produces neurogenic bladder and, secondarily, upper-tract dilatation.

urinary bladder UBERON:0001255

Downstream

Neurogenic Bladder Impaired detrusor contraction or detrusor-sphincter coordination produces the clinically recognized neurogenic bladder.

Hydronephrosis Chronic bladder dysfunction can propagate pressure and urinary stasis to the upper urinary tract, producing ureterohydronephrosis.

Show evidence (2 references)

PMID:38465704 SUPPORT Human Clinical

"two of them had hypocontractile detrusor and another had sphincter-detrusor dyssynergia."

Prospective urodynamic testing directly identifies the detrusor and sphincter abnormalities represented by this intermediate node.

PMID:39527371 SUPPORT Human Clinical

"These include ureterohydronephrosis due to bladder dysfunction, as confirmed by urodynamic testing, and autonomic neuropathy."

Expert consensus links urodynamically confirmed bladder dysfunction and autonomic neuropathy to upper-tract dilatation.

Brainstem and Cerebellar Volume Loss

Volume loss centers on the brainstem, ventral pons, and cerebellum, and it is already measurable at the earliest clinical presentation, in the youngest patients with the mildest symptoms. Longitudinal morphometry separates two processes that clinical intuition tends to blur: controls gained white matter volume where the Wolfram group was flat in the optic radiations or shrinking in the brainstem and ventral pons, so there is failed developmental growth as well as frank degeneration. That distinction is not academic. Because part of the deficit is growth that never happened, a disease-modifying therapy plausibly has to start before or around the time diabetes is diagnosed to capture the full benefit. Progressive bulbar dysfunction and central apnea from this territory are what ultimately kill.

neuron CL:0000540

brainstem UBERON:0002298

Downstream

Brain Atrophy Regional volume loss is part of a broader pattern of brain atrophy.

Myoclonus Myoclonus accompanies cerebellar ataxia in the neurological phase.

Ataxia Cerebellar and brainstem tissue loss produces gait ataxia.

Dysarthria Bulbar involvement produces dysarthria.

Dysphagia Bulbar involvement produces dysphagia.

Central Apnea Brainstem degeneration can disrupt central respiratory drive.

Show evidence (4 references)

PMID:22792385 SUPPORT Human Clinical

"Compared to healthy and type 1 diabetic control groups, the WFS group had smaller intracranial volume and preferentially affected gray matter volume and white matter microstructural integrity in the brainstem, cerebellum and optic radiations."

Localizes the structural abnormality to brainstem, cerebellum, and optic radiations against both healthy and diabetic controls.

PMID:22792385 SUPPORT Human Clinical

"Abnormalities were detected in even the youngest patients with mildest symptoms, and some measures did not follow the typical age-dependent developmental trajectory."

Establishes that the abnormality is present at the earliest clinical stage and departs from a normal developmental trajectory.

PMID:30979932 SUPPORT Human Clinical

"Controls had uniformly increasing volume in white matter, whereas the Wolfram group had stable (optic radiations) or decreasing (brainstem, ventral pons) white matter volumes."

Longitudinal comparison separating failed white-matter growth from frank degeneration.

+ 1 more reference

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Blood 1

Abnormal Bleeding HP:0001892

Show evidence (1 reference)

PMID:28335035 SUPPORT Human Clinical

"The defining diagnostic criteria for WFS2 also consist of optic atrophy and diabetes mellitus, but unlike WFS1, this phenotypic subgroup has been associated with peptic ulcer disease and an increased bleeding tendency."

Directly identifies increased bleeding tendency as a WFS2-associated discriminator.

Digestive 2

Dysphagia HP:0002015

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:39527371 SUPPORT Human Clinical

"WFS is also associated with central nervous system abnormalities like anosmia, ataxia, seizures, nystagmus, gaze palsies, dysarthria, dysphagia, psychiatric disturbances, cognitive impairment, and others."

Current expert consensus explicitly includes dysphagia among the central nervous system manifestations.

Peptic Ulcer HP:0004398

Show evidence (1 reference)

PMID:28335035 SUPPORT Human Clinical

Directly identifies peptic ulcer disease as a WFS2-associated discriminator.

Ear 1

Sensorineural Hearing Impairment FREQUENT HP:0000407

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

"Cranial diabetes insipidus occurred in 33 patients (73%) with sensorineural deafness (28, 62%) in the second decade; renal-tract abnormalities (26, 58%) presented in the third decade followed by neurological complications"

Sensorineural deafness in 62% of 45 patients, within the FREQUENT band.

Endocrine 2

Diabetes Mellitus VERY_FREQUENT HP:0000819

Course: PROGRESSIVE

Show evidence (2 references)

PMID:7490992 SUPPORT Human Clinical

"Non-autoimmune, insulin-deficient diabetes mellitus presented at a median age of 6 years, followed by optic atrophy (11 years)."

Establishes diabetes mellitus as the first manifestation with a median onset of 6 years in a national cohort.

PMID:20301750 SUPPORT Human Clinical

"Classic WFS1-SD, a progressive neurodegenerative disorder, is characterized by onset of diabetes mellitus and optic atrophy before age 16 years."

GeneReviews states diabetes mellitus before age 16 as a defining feature of classic disease, supporting a VERY_FREQUENT band.

Diabetes Insipidus FREQUENT HP:0000873

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

Cranial diabetes insipidus in 73% of 45 patients, within the FREQUENT band of 30 to 79%.

Eye 3

Optic Atrophy VERY_FREQUENT HP:0000648

Course: PROGRESSIVE

Show evidence (3 references)

PMID:7490992 SUPPORT Human Clinical

"Juvenile-onset diabetes mellitus and optic atrophy are the best available diagnostic criteria for Wolfram syndrome, the differential diagnosis of which includes other causes of neurodegeneration."

Establishes optic atrophy alongside juvenile diabetes as the diagnostic criterion pair.

PMID:20301750 SUPPORT Human Clinical

"Classic WFS1-SD, a progressive neurodegenerative disorder, is characterized by onset of diabetes mellitus and optic atrophy before age 16 years."

GeneReviews states optic atrophy before age 16 as a defining feature of classic disease.

PMID:41870390 SUPPORT Human Clinical

"Thirty-six patients (22 women, 14 men; median age 20 years) were identified. Median mutation severity score was 3.5. Vision loss occurred in 31 patients; in 3 patients it was the only major symptom, in 5 patients it preceded DM, and in 6 patients it occurred without DM."

A recent genetically confirmed WS1 cohort documents vision loss in 31 of 36 patients and shows that it can precede diabetes.

Nystagmus OCCASIONAL HP:0000639

Show evidence (1 reference)

PMID:23981289 SUPPORT Human Clinical

"Abnormalities in visual acuity and color vision were present in 17 (94%). Abnormal pupillary response, nystagmus, and cataracts were present in 11 (61%), five (28%), and five (28%), respectively."

Nystagmus occurred in 5 of 18 participants (28%), within the OCCASIONAL band.

Cataract OCCASIONAL HP:0000518

Show evidence (1 reference)

PMID:23981289 SUPPORT Human Clinical

"Abnormalities in visual acuity and color vision were present in 17 (94%). Abnormal pupillary response, nystagmus, and cataracts were present in 11 (61%), five (28%), and five (28%), respectively."

Cataracts occurred in 5 of 18 participants (28%), within the OCCASIONAL band.

Genitourinary 1

Neurogenic Bladder FREQUENT HP:0000011

Course: PROGRESSIVE

Show evidence (2 references)

PMID:29728875 SUPPORT Human Clinical

"The remaining criteria were present with a variable frequency: 77% had diabetes insipidus, 66.7% auditory alterations, 77.8% neurogenic bladder, 61.1% neurological involvement, and 27.8% hypogonadism."

Neurogenic bladder itself occurred in 77.8% of the cohort, within the FREQUENT band; this replaces an indirect grouped renal-tract statistic.

PMID:38465704 SUPPORT Human Clinical

"Patients with hypocontractile bladder were taught clean intermittent catheterization and the use of overnight drain."

Directly documents clean intermittent catheterization for urodynamically confirmed hypocontractile bladder in a prospective case series.

Nervous System 10

Tremor HP:0001337

Show evidence (1 reference)

PMID:23981289 SUPPORT Human Clinical

"Increased tone lower extremities; intention tremor"

Direct neurologic examination documented intention tremor in an affected participant; the study text does not support a population frequency band.

Peripheral Neuropathy HP:0009830

Show evidence (1 reference)

PMID:9817917 SUPPORT Human Clinical

"Wolfram syndrome is an autosomal recessive disorder characterized by juvenile diabetes mellitus, diabetes insipidus, optic atrophy and a number of neurological symptoms including deafness, ataxia and peripheral neuropathy."

The WFS1 gene-identification cohort explicitly includes peripheral neuropathy in the neurologic phenotype.

Cognitive Impairment HP:0100543

Show evidence (1 reference)

PMID:21446023 SUPPORT Human Clinical

"Cognitive impairment, which was not frequent in previous reports, was observed in 32% of patients with neurologic signs."

Directly quantifies cognitive impairment within the neurologically affected subgroup while precluding a whole-cohort frequency inference.

Seizure HP:0001250

Show evidence (1 reference)

PMID:21446023 SUPPORT Human Clinical

"Like epilepsy, it was mainly found in patients who developed neurologic signs before 15 years of age."

Links epilepsy to the early-neurologic-onset subgroup in the 59-patient neurologic cohort.

Ataxia HP:0001251

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

Places ataxia among the fourth-decade neurological complications. The 62% figure applies to neurological complications as a group, so this entry does not assign an individual ataxia frequency.

Myoclonus HP:0001336

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

"renal-tract abnormalities (26, 58%) presented in the third decade followed by neurological complications (cerebellar ataxia, myoclonus [28, 62%]) in the fourth decade."

Names myoclonus among the fourth-decade neurological complications. The 62% figure applies to neurological complications as a group, so this entry does not assign an individual myoclonus frequency.

Dysarthria HP:0001260

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:39527371 SUPPORT Human Clinical

Current expert consensus explicitly includes dysarthria among the central nervous system manifestations.

Depression HP:0000716

Show evidence (2 references)

PMID:22792385 SUPPORT Human Clinical

"Compared to normative data, the WFS group had intact cognition, significant anxiety and depression, and gait abnormalities."

Documents significant anxiety and depression against normative data, with cognition intact at this stage.

PMID:12707947 SUPPORT Human Clinical

"There is evidence suggesting that subjects affected with the Wolfram syndrome (WFS) and normal carriers present an increased risk of psychiatric disorders, particularly depression and suicidal behavior."

Records the elevated psychiatric and suicidality risk in Wolfram syndrome. PARTIAL because this study's own measurements were made in a general suicide-victim cohort genotyped at WFS1 rather than in patients with Wolfram syndrome, so it substantiates a role for WFS1 rather than a rate in this disease.

Anxiety FREQUENT HP:0000739

Show evidence (1 reference)

PMID:39202345 SUPPORT Human Clinical

"Some authors found that 77% of WS1 patients had anxiety as their prevalent symptom."

The review reports anxiety in 77% of WS1 patients, within the FREQUENT band; the secondary-source context precludes treating 77% as a pooled prevalence.

Obstructive Sleep Apnea OCCASIONAL HP:0002870

Show evidence (1 reference)

PMID:39202345 SUPPORT Human Clinical

"Adults and children with WS1 had significantly higher OSA rates than the general population (29.4% vs. 2–7% for adults, and 100% vs. 1–5% for children)."

The adult WS1 rate of 29.4% supports OCCASIONAL; the distinct pediatric estimate is retained in the explanation rather than conflated into one disease-wide percentage.

Growth 1

Growth Delay HP:0001510

Show evidence (1 reference)

PMID:39527371 SUPPORT Human Clinical

"Some individuals with WFS experience growth retardation, although most achieve an adult height within the normal range. Cases of growth hormone deficiency have been reported, highlighting another aspect of the syndrome’s complexity."

Current expert consensus directly supports growth retardation while noting normal adult height in most patients.

Other 8

Abnormality of the Sense of Smell FREQUENT HP:0004408

Show evidence (1 reference)

PMID:23981289 SUPPORT Human Clinical

"Seventeen (94%) had optic disc pallor and defects in color vision, 14 (78%) had hearing loss and 13 (72%) had olfactory defects, eight (44%) had impaired vibration sensation."

Olfactory defects occurred in 13 of 18 participants (72%), within the FREQUENT band.

Impaired Vibratory Sensation FREQUENT HP:0002495

Show evidence (1 reference)

PMID:23981289 SUPPORT Human Clinical

"Seventeen (94%) had optic disc pallor and defects in color vision, 14 (78%) had hearing loss and 13 (72%) had olfactory defects, eight (44%) had impaired vibration sensation."

Impaired vibration sensation occurred in 8 of 18 participants (44%), within the FREQUENT band.

Hyporeflexia FREQUENT HP:0001265

Show evidence (1 reference)

PMID:29728875 SUPPORT Human Clinical

"A 16.7% of the patients had positive albuminuria (urinary albumin/creatinine ratio > 30 mg/g) and 72.2% had hyporreflexia."

Hyporeflexia was present in 72.2% of this molecularly studied cohort, within the FREQUENT band.

Hydronephrosis HP:0000126

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

The cohort reports renal-tract abnormalities as a category. PARTIAL because hydronephrosis specifically is not separately enumerated, so no frequency band is assigned here.

Gastrointestinal Dysmotility OCCASIONAL HP:0002579

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

"Other abnormalities included gastrointestinal dysmotility in 11 (24%), and primary gonadal atrophy in seven of ten males investigated."

Gastrointestinal dysmotility occurred in 11 of 45 participants (24%), within the OCCASIONAL band.

Central Apnea HP:0002871

Course: PROGRESSIVE

Show evidence (2 references)

PMID:39527371 SUPPORT Human Clinical

"Neurological and autonomic disorders include central apnea, ataxia, dysphagia, areflexia, epilepsy, decreased ability to taste and detect odors, headaches, orthostatic hypotension, hyperpyrexia, hypothermia, constipation, gastroparesis."

Current expert consensus explicitly identifies central apnea as a neurologic and autonomic manifestation.

PMID:7490992 SUPPORT Human Clinical

"Median age at death (commonly central respiratory failure with brain-stem atrophy) was 30 years (range 25-49)."

Links loss of central respiratory drive to brainstem atrophy and mortality in the national cohort.

Brain Atrophy HP:0012444

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:22792385 SUPPORT Human Clinical

"These results establish that WFS is associated with smaller intracranial volume with specific abnormalities in the brainstem and cerebellum, even at the earliest stage of clinical symptoms."

Documents reduced intracranial volume with regional brainstem and cerebellar abnormality at the earliest clinical stage.

Testicular Atrophy FREQUENT HP:0000029

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

"Other abnormalities included gastrointestinal dysmotility in 11 (24%), and primary gonadal atrophy in seven of ten males investigated."

Primary gonadal atrophy in 7 of 10 males investigated (70%), within the FREQUENT band of 30 to 79%.

🧬

Genetic Associations

WFS1 Biallelic Loss of Function

Gene: WFS1 hgnc:12762 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (3 references)

PMID:9771706 SUPPORT Human Clinical

Establishes WFS1 variants as causative in all affected individuals across six families.

PMID:23429432 SUPPORT Human Clinical

"More than 200 different variations in WFS1 have been described in patients with Wolfram syndrome, which complicates the establishment of clear genotype-phenotype correlation."

Documents the allelic heterogeneity that makes genotype and phenotype correlation difficult.

PMID:23429432 SUPPORT Human Clinical

"(i) 15% of published patients do not fulfill the current -inclusion criterion; (ii) genotypic prevalence differences may exist among countries; (iii) diabetes mellitus and optic atrophy might not be the first two clinical features in some patients; (iv) mutations are nonuniformly distributed in..."

Meta-analysis of 412 patients reporting that onset age and progression rate may depend on genotypic class, and that the canonical presentation order is not universal.

CISD2 Biallelic Loss of Function

Gene: CISD2 hgnc:24212 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:17846994 SUPPORT Human Clinical

"A single missense mutation was identified in a novel, highly conserved zinc-finger gene, ZCD2, in three consanguineous families of Jordanian descent with Wolfram syndrome (WFS)."

The gene-identification study for Wolfram syndrome 2.

PMID:17846994 SUPPORT Human Clinical

"The mutation was found to disrupt messenger RNA splicing by eliminating exon 2, and it results in the introduction of a premature stop codon."

Establishes that the functional consequence is a splicing defect producing a premature stop, not a missense effect.

💊

Medical Actions

Insulin Therapy

Action: Pharmacotherapy NCIT:C15986

Insulin replacement, by multiple daily injections or pump, with continuous glucose monitoring. The diabetes is insulin-deficient and non-autoimmune, so management follows type 1 diabetes practice while the underlying beta cell loss is mechanistically different. Insulin replaces the missing hormone and does nothing to slow beta cell loss.

Mechanism Target:

RESTORES Insulin Deficiency — Exogenous insulin restores the hormone that surviving beta cells can no longer supply, without acting on the cell loss itself.

Show evidence (1 reference)

PMID:39527371 SUPPORT Human Clinical

"Nearly all diagnosed individuals require insulin therapy to manage their condition."

Current expert consensus directly states that nearly all diagnosed individuals require insulin therapy.

Desmopressin for Central Diabetes Insipidus

Action: Pharmacotherapy NCIT:C15986

In WS1, desmopressin replaces vasopressin lost with degeneration of the hypothalamo-neurohypophyseal axis. In a prospective four-patient case series, three children with persistent polyuria and polydipsia despite optimized glycemic control were diagnosed with diabetes insipidus and treated with desmopressin.

Show evidence (1 reference)

PMID:38465704 SUPPORT Human Clinical

"Three children had persistent polyuria and polydipsia despite having optimum glycemic control; hence were diagnosed to have DI and treated with desmopressin."

Directly documents desmopressin treatment of central diabetes insipidus in a prospective Wolfram syndrome case series.

Multidisciplinary Supportive Care

Action: Supportive Care NCIT:C15747

There is no cure. Care is supportive and multidisciplinary, spanning diabetes care, endocrinology, ophthalmology and low vision, audiology and cochlear implantation, speech and language therapy, neurology, pulmonology, psychiatry, urology, gastroenterology, social work, and medical genetics, with regular surveillance for emerging manifestations. Urodynamic assessment with clean intermittent catheterization for hypocontractile bladder and proactive psychiatric and suicide-risk assessment are important components.

Show evidence (3 references)

PMID:20301750 SUPPORT Human Clinical

"There is no cure for WFS1-SD."

States plainly that no curative therapy exists, which is why care is supportive.

PMID:20301750 SUPPORT Human Clinical

"Surveillance: For both classic and nonclassic WFS1-SD, regular monitoring of existing manifestations, the response of an individual to supportive care, and the emergence of new manifestations is recommended."

Establishes regular surveillance as the recommended management framework.

PMID:38465704 SUPPORT Human Clinical

"Patients with hypocontractile bladder were taught clean intermittent catheterization and the use of overnight drain."

Provides direct clinical evidence for catheter-based management of hypocontractile bladder.

Genetic Counseling and Cascade Testing

Action: Genetic Counseling NCIT:C15240

Autosomal recessive counseling with a 25% recurrence risk per pregnancy for carrier couples, plus cascade testing of siblings, which is the population in whom early diagnosis is actually achievable. Prenatal and preimplantation testing are possible once the familial variants are known. Counseling arithmetic differs completely if the family variant belongs to the dominant WFS1 allelic series, and misclassifying which series a family is in is a real counseling error.

Show evidence (2 references)

PMID:20301750 SUPPORT Human Clinical

"If both parents are known to be heterozygous for a WFS1 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of inheriting neither of the familial pathogenic variants."

Gives the recurrence risk figures that drive counseling.

PMID:20301750 SUPPORT Human Clinical

"Evaluation of relatives at risk: It is appropriate to clarify the genetic status of apparently asymptomatic at-risk relatives in order to identify as early as possible those who would benefit from prompt initiation of treatment for the earliest manifestations of WFS1-SD: diabetes mellitus, optic..."

Supports cascade testing of at-risk relatives as the route to early intervention.

Dantrolene Sodium

Action: Pharmacotherapy NCIT:C15986

A ryanodine-receptor blocker trialed on the endoplasmic-reticulum-calcium stabilizer rationale, and the first clinical trial ever conducted in Wolfram syndrome. It was safe and well tolerated, and it did not work: beta cell function was not significantly improved overall, and neither visual acuity nor neurological function improved at six months. Recorded here because a negative result in a disease with no therapy is information, not an absence of it.

Mechanism Target:

INHIBITS Cytosolic Calcium Dysregulation — Dantrolene inhibits ryanodine-receptor-mediated endoplasmic reticulum calcium efflux, the intended point of action on this node. The pharmacology is unambiguous; the clinical trial nonetheless showed no benefit.

Show evidence (2 references)

PMID:34185708 REFUTE Human Clinical

"Dantrolene sodium was well tolerated by Wolfram syndrome patients. Overall, β cell functions were not significantly improved, but there was a significant correlation between baseline β cell functions and change in β cell responsiveness (R2, P = 0.004) after 6-month dantrolene therapy."

Reports tolerability but no significant overall improvement in beta cell function, refuting an efficacy claim.

PMID:34185708 REFUTE Human Clinical

"Visual acuity and neurological functions were not improved by 6-month dantrolene sodium."

Directly refutes benefit on the visual and neurological endpoints.

Sodium Phenylbutyrate and Taurursodiol

Action: Pharmacotherapy NCIT:C15986

An oral combination of a chemical chaperone and an endoplasmic-reticulum-stress and apoptosis modulator, acting on the pathway wolframin normally regulates. The HELIOS trial reported improved or stabilized pancreatic function, vision, and symptom burden at 24 and 48 weeks: stimulated C-peptide (the primary endpoint) and the glycemic secondary endpoints improved from baseline, visual acuity trended toward stabilization, and every assessable participant was a responder on both global-impression scales. Tolerability was acceptable — adverse events in eleven of twelve participants, all mild or moderate and mostly gastrointestinal, with dose interruption or reduction in three each but no discontinuations, serious events, or deaths. The design ceiling has to travel with the result: single-center, single-arm, open-label, twelve participants, no placebo. Graded PARTIAL for that reason, and the objective endpoints are curated separately from the unblinded global-impression scales because the latter are the ones open-label expectancy most easily inflates.

Mechanism Target:

MODULATES Unrestrained ER Stress Signaling Through ATF6-alpha — Phenylbutyrate acts as a chemical chaperone and taurursodiol modulates endoplasmic reticulum stress and apoptosis, targeting the pathway wolframin normally restrains. MODULATES rather than INHIBITS because the human evidence is a single-arm open-label trial that cannot establish the direction of effect on this node.

MODULATES Mitochondrial Dysfunction — The combination is described as targeting dysfunctional mitochondrial pathways alongside the endoplasmic-reticulum arm, taurursodiol being the component associated with mitochondrial effects. This link records the second half of the drug's stated mechanism, which the entry previously left unattached. MODULATES for the same reason as the ER node: no trial readout measures mitochondrial function.

Show evidence (1 reference)

PMID:42138079 SUPPORT Human Clinical

"An investigational oral combination of sodium phenylbutyrate and taurursodiol (PB&TURSO) targets dysfunctional ER and mitochondrial pathways to reduce pancreatic β cell and neuronal death"

Names the mitochondrial arm of the mechanism. PARTIAL because this is the trial report's mechanistic framing citing prior work, not a measurement made in this trial.

INHIBITS Beta Cell Apoptosis — The stated purpose of acting on the ER and mitochondrial pathways is to reduce pancreatic beta cell death. INHIBITS is used here, unlike the two upstream nodes, because the trial's primary endpoint is a direct functional readout of surviving beta cell mass — stimulated C-peptide — and it improved from baseline at both 24 and 48 weeks. The uncontrolled design still means this is a within-participant change, not a demonstrated causal effect. One caveat belongs on the direction itself: reduced apoptosis predicts arrested decline, whereas C-peptide *improving* from baseline is at least as consistent with recovered secretory function in beta cells that were still alive. The INHIBITS direction therefore rests on the drug's stated mechanism, which names cell death explicitly, with the C-peptide result as functional corroboration rather than as a measurement of apoptosis.

Show evidence (2 references)

PMID:42138079 SUPPORT Human Clinical

"An investigational oral combination of sodium phenylbutyrate and taurursodiol (PB&TURSO) targets dysfunctional ER and mitochondrial pathways to reduce pancreatic β cell and neuronal death"

The only statement in the source that names beta cell death, and therefore what the INHIBITS direction is evidenced on. PARTIAL because it is the trial report's mechanistic framing citing prior work, not a measurement made here.

PMID:42138079 SUPPORT Human Clinical

"The primary efficacy endpoint — C-peptide response at 120 minutes during a mixed-meal tolerance test (MMTT) — showed overall improvement from baseline at weeks 24 and 48."

Functional corroboration: the primary endpoint indexes residual beta cell mass. It does not measure apoptosis, and is PARTIAL for the further reason that a single-arm open-label design cannot separate treatment effect from natural variation.

MODULATES Retinal Ganglion Cell and CNS Neuron Degeneration — The same mechanism sentence names reduction of neuronal death as an intended effect, and the trial's visual-acuity readout is the clinical correlate of this node. Visual acuity trended toward stabilization rather than improving, and the authors themselves note that natural history includes periods of stability — so this link is deliberately MODULATES with a stabilization claim only.

Show evidence (1 reference)

PMID:42138079 SUPPORT Human Clinical

"Best-corrected visual acuity trended toward stabilization over 48 weeks in both analysis sets (Figure 1E), consistent with periods of stability in natural history cohorts."

Records stabilization rather than improvement, and carries the authors' own natural-history caveat that makes this the weakest of the four links.

Show evidence (7 references)

PMID:42138079 SUPPORT Human Clinical

"PB&TURSO was associated with improved or stabilized pancreatic function, vision, and overall symptom burden in individuals with Wolfram syndrome, a rare and progressive degenerative disease."

Reports the positive result. PARTIAL because the trial is single-arm and open-label with twelve participants, which cannot establish disease modification.

PMID:42138079 SUPPORT Human Clinical

"We report 24- and 48-week results from the ongoing HELIOS trial (ClinicalTrials.gov NCT05676034), a single-center, single-arm, open-label, phase II trial of PB&TURSO."

Documents the trial design, which is the basis for the PARTIAL grading of the efficacy claim above.

PMID:42138079 SUPPORT Human Clinical

"Secondary measures including HbA1c and time in target glucose range improved from baseline at weeks 24 and 48 (Figure 1, C and D)."

Objective glycemic secondary endpoints, recorded separately from the subjective global-impression measures because they are the outcomes least vulnerable to the open-label design.

+ 4 more references

GLP-1 Receptor Agonists

Action: Pharmacotherapy NCIT:C15986

A strong preclinical package has not yet translated into demonstrated clinical benefit. Dulaglutide, exenatide, and related agents improve beta-cell and neuronal readouts in WFS1-deficient models. In the largest human evaluation, 30 of 84 registry participants had received a GLP-1 receptor agonist, but paired retrospective analyses found no glycemic or visual benefit over one to two years and gastrointestinal adverse effects were common. The uncontrolled, clinically selected sample makes that result preliminary rather than a definitive efficacy test.

Mechanism Target:

INHIBITS Beta Cell Apoptosis — GLP-1 receptor agonism improves beta cell function and prevents apoptosis in WFS1-deficient human beta cell models. The evidence is preclinical.

Show evidence (4 references)

PMID:36995380 SUPPORT Model Organism

"the long-lasting GLP-1R agonist dulaglutide reverses impaired glucose tolerance in WFS1-deficient mice"

Isolates the intact-mouse metabolic result from the human in-vitro findings reported in the same source sentence.

PMID:36995380 SUPPORT In Vitro

"exenatide and dulaglutide improve beta cell function and prevent apoptosis in different human WFS1-deficient models including iPSC-derived beta cells from people with Wolfram syndrome."

Isolates the human WFS1-deficient beta-cell-model result without implying that these patient-derived cells constitute clinical treatment evidence.

PMID:36995380 SUPPORT In Vitro

"Exenatide improved mitochondrial function, reduced oxidative stress and prevented apoptosis in Wolfram syndrome iPSC-derived neural precursors and cerebellar neurons."

Extends the preclinical benefit to the neuronal arm of the disease.

+ 1 more reference

🔬

Biochemical Markers

Elevated Serum Neurofilament Light Chain (INCREASED)

Context: Serum neurofilament light chain, a marker of neuroaxonal damage, is elevated in Wolfram syndrome relative to parents, unaffected siblings, and individuals with and without newly diagnosed type 1 diabetes, whereas glial fibrillary acidic protein is not. The specificity is informative about the biology, since it points to axonal injury rather than reactive astrogliosis. Its utility as a progression marker is limited, however, because levels did not change over time and did not correlate reliably with clinical or neuroimaging severity.

Show evidence (2 references)

PMID:41929703 SUPPORT Human Clinical

"NfL levels were higher in the Wolfram group relative to all control groups (p < 0.001, η p 2 = 0.51) after adjusting for age and sex, whereas GFAP levels were not different between any of the groups."

Establishes elevated serum neurofilament light chain with unchanged glial fibrillary acidic protein.

PMID:41929703 SUPPORT Human Clinical

"Within the Wolfram group, neither NfL nor GFAP levels changed over time, and NfL levels did not correlate reliably with any measures of clinical disease severity or neurodegeneration (p > 0.05 after excluding outliers)."

Qualifies the marker: elevated but not tracking progression, so it is a state marker rather than a monitoring biomarker.

🔬

Diagnosis

Clinical Diagnostic Criteria

Insulin-requiring diabetes mellitus plus optic atrophy, both with onset before age 16 and no alternative explanation, is the operative clinical rule. The diabetes workup is what separates this from type 1 diabetes: islet autoantibodies are negative, there is no HLA-DR3 or DR4 risk association, and C-peptide is preserved longer.

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

"Juvenile-onset diabetes mellitus and optic atrophy are the best available diagnostic criteria for Wolfram syndrome, the differential diagnosis of which includes other causes of neurodegeneration."

States the clinical criterion pair and flags the neurodegenerative differential.

Molecular Genetic Testing

Sequencing of WFS1 is the diagnostic gold standard when the picture is classic, with multigene panels for partial presentations and exome or genome sequencing for atypical cases, which is also how CISD2 cases are found. Chromosomal microarray, karyotype, and repeat-expansion testing have no role; mitochondrial DNA testing is indicated only to exclude mimics. The current Italian expert consensus explicitly recommends folding genetic testing into the diagnostic protocol rather than treating it as confirmatory afterthought.

Show evidence (2 references)

PMID:20301750 SUPPORT Human Clinical

"The diagnosis is established in a proband with suggestive findings and biallelic pathogenic (or likely pathogenic) variants in WFS1 identified by molecular genetic testing."

GeneReviews states that molecular identification of biallelic WFS1 variants establishes the diagnosis.

PMID:39527371 SUPPORT Human Clinical

"The consensus recommends the revision of diagnostic protocols to include genetic testing and comprehensive multidisciplinary evaluations to ensure accurate diagnosis of WFS, advocates for personalized management plans tailored to the unique needs of each patient, with an emphasis on exploring..."

Current expert consensus recommending genetic testing within the diagnostic protocol.

Brain MRI

MRI shows an absent posterior pituitary bright spot on T1, the hallmark of central diabetes insipidus, together with brainstem, ventral pontine, and cerebellar atrophy and thinning of the optic nerves, chiasm, and tracts. Volume abnormalities are detectable at the earliest clinical stage, which makes serial imaging the leading candidate progression measure for trials.

Show evidence (1 reference)

PMID:22792385 SUPPORT Human Clinical

"These results establish that WFS is associated with smaller intracranial volume with specific abnormalities in the brainstem and cerebellum, even at the earliest stage of clinical symptoms."

Supports MRI detection of the characteristic regional abnormalities from the earliest clinical stage.

Optical Coherence Tomography

Optical coherence tomography quantifies retinal nerve fiber layer and ganglion cell complex thinning. Together with best-corrected visual acuity, these structural measures support longitudinal monitoring of optic neuropathy; their prognostic role remains promising rather than fully validated.

Show evidence (1 reference)

PMID:41870390 SUPPORT Human Clinical

"BCVA correlated inversely with RNFL thickness ( P = 0.0017, R 2 = 0.14), GCC thickness ( P = 0.0018, R 2 = 0.29), and mutation severity score ( P = 0.031, R 2 = 0.14)."

Correlations in a retrospective WS1 cohort support OCT measures as monitoring biomarkers, but do not yet validate them as surrogate endpoints.

📈

Progression

First decade - diabetes and optic atrophy

WS1

Insulin-requiring non-autoimmune diabetes mellitus at a median of 6 years, followed by optic atrophy at a median of 11 years. Brainstem and cerebellar volume abnormalities are already measurable at this stage, before the corresponding symptoms appear.

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

"Non-autoimmune, insulin-deficient diabetes mellitus presented at a median age of 6 years, followed by optic atrophy (11 years)."

Gives the median onset ages of the two defining features.

Second decade - diabetes insipidus and deafness

WS1

Cranial diabetes insipidus and sensorineural deafness appear in the second decade, in 73% and 62% of the UK cohort respectively.

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

Gives the decade-by-decade order and frequencies of the later features.

Third and fourth decades - urological and neurological

WS1

Renal-tract abnormalities in the third decade (58%), then neurological complications including cerebellar ataxia and myoclonus in the fourth decade (62%). Death, most often from central respiratory failure with brainstem atrophy, occurred at a median age of 30 years with a range of 25 to 49 in the UK cohort.

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

"Median age at death (commonly central respiratory failure with brain-stem atrophy) was 30 years (range 25-49)."

Gives median age and cause of death in the UK national cohort.

📊

Prevalence

United Kingdom

Point Prevalence 0.13 per 100,000 1–9 per 1,000,000

One per 770,000 from a UK nationwide cross-sectional case-finding study identifying 45 patients. Carrier frequency about 1 in 354.

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

"We identified 45 patients with Wolfram syndrome--a prevalence of one per 770,000."

Gives the UK nationwide prevalence estimate.

Messina district, north-eastern Sicily

Point Prevalence 1.84 per 100,000 1–9 per 100,000

One in 54,478 in the Messina district of Sicily against one in 1,351,000 for Italy nationally and one in 770,000 for the UK. The roughly 25-fold spread between a consanguineous or founder population and a national estimate is a finding about population structure, not measurement noise, so a prevalence figure for this disease should never be quoted without the population attached.

Show evidence (1 reference)

PMID:39527371 SUPPORT Human Clinical

"More recently, the estimated prevalence was 1 in 54.478 in the Messina district of north-eastern Sicily, 1 in 805.000 in Northern India, and 1 in 1.351.000 in Italy [7–9]."

Gives the Sicilian, Northern Indian, and Italian national prevalence estimates side by side, which is what makes the spread visible.

⚖️

Clinical Burden

High

By the third decade a typical WS1 patient carries insulin-dependent diabetes, legal blindness, significant hearing loss, incontinence, and progressive gait and speech impairment at the same time, and these do not merely add: losing vision and hearing together removes both compensatory channels at once. Median age at death was 30 years in the UK national cohort, usually from central respiratory failure with brainstem atrophy, and suicide is a documented additional cause. No approved disease-modifying therapy exists anywhere.

Show evidence (2 references)

PMID:7490992 SUPPORT Human Clinical

"The natural history of Wolfram syndrome suggests that most patients will eventually develop most complications of this progressive, neurodegenerative disorder."

Establishes the cumulative, multi-domain nature of the disability.

PMID:39202345 SUPPORT Human Clinical

"The rapid clinical course of WS1 results in death by the age of 30. Severe brain atrophy leads to central respiratory failure, which is the main cause of death in WS1 patients."

States the age at death and the dominant mechanism of mortality.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Wolfram Syndrome:

Type 1 Diabetes Mellitus

Overlapping Features The commonest misdiagnosis, and the reason Wolfram syndrome is typically identified years late. Distinguished by autoimmunity: islet autoantibodies are positive in type 1 diabetes and negative here, HLA risk haplotypes are present there and absent here, and C-peptide falls faster. Genetic testing of every child with autoantibody-negative, non-HLA-associated insulin-dependent diabetes is the highest-yield case-finding intervention available.

Distinguishing Features

Islet autoantibodies positive in type 1 diabetes, negative in Wolfram syndrome
HLA-DR3 and DR4 risk haplotypes present in type 1 diabetes only
Optic atrophy, diabetes insipidus, and deafness do not occur in isolated type 1 diabetes

Show evidence (1 reference)

PMID:20160352 SUPPORT In Vitro

"Wolfram syndrome is an autosomal-recessive disorder characterized by insulin-dependent diabetes mellitus, caused by nonautoimmune loss of beta cells, and neurological dysfunctions."

The non-autoimmune basis of the beta cell loss is what separates this from type 1 diabetes.

Mitochondrial Diabetes and Deafness

Overlapping Features Maternally inherited diabetes and deafness from the m.3243A>G variant overlaps clinically and was historically confused with Wolfram syndrome. Distinguished by maternal inheritance, the mitochondrial tRNA-Leu 3243 variant, and the absence of the autosomal recessive family pattern.

Distinguishing Features

Maternal inheritance pattern rather than autosomal recessive
Mitochondrial tRNA-Leu 3243 variant present
Optic atrophy is not the typical visual lesion

Show evidence (1 reference)

PMID:7490992 SUPPORT Human Clinical

Explicitly excludes the mitochondrial mimic on both inheritance pattern and genotype.

Nonclassic (Dominant) WFS1 Spectrum Disorder

Overlapping Features Heterozygous WFS1 variants cause a distinct, dominantly inherited spectrum: DFNA6/14/38 low-frequency sensorineural hearing loss, Wolfram-like syndrome with adult-onset diabetes plus hearing loss and juvenile optic atrophy, and a de novo neonatal diabetes with congenital deafness and cataracts. The inheritance, the audiogram shape (low-frequency dominant versus high-frequency recessive), and the molecular mechanism (dominant-negative versus null) all differ. This entry deliberately covers only the recessive disease; the dominant spectrum belongs in separate entries.

Distinguishing Features

Single heterozygous WFS1 variant with dominant transmission
Low-frequency rather than high-frequency sensorineural hearing loss
Milder or partial phenotype without the full DIDMOAD sequence

Show evidence (1 reference)

PMID:20301750 SUPPORT Human Clinical

"Nonclassic WFS1-SD. The diagnosis is established in a proband with suggestive findings and a heterozygous pathogenic (or likely pathogenic) variant identified by molecular genetic testing."

GeneReviews formalizes the heterozygous, nonclassic spectrum as a separate diagnostic category from classic biallelic disease.

📊

Related Datasets

Single Cell Sequencing Analysis for Wolfram Syndrome (WS4) Unedited and Corrected Stem Cell-Derived Beta Cells geo:GSE139535

Single-cell transcriptomic comparison of unedited Wolfram patient stem-cell-derived beta cells and CRISPR-corrected isogenic beta cells, directly linked to the genetic-rescue experimental model in this entry.

human SINGLE CELL RNA SEQ n=2

PMID:32846125

Accession, title, organism, sequencing type, and two GEO samples were verified against NCBI GEO on 2026-08-19. GEO metadata links this accession to PMID:32846125, the stem-cell-derived islet maturation study. The disease-specific CRISPR-correction report (PMID:32321868) describes the WS4corr model but is not the publication assigned to this GEO record.

🔬

Clinical Trials

NCT02829268 PHASE_II COMPLETED

Open-label phase Ib/IIa trial of dantrolene sodium, the first clinical trial ever conducted in Wolfram syndrome. Safety and tolerability were the primary objective, with beta cell function, visual acuity, and neurological function as secondary. Published as PMID:34185708. Dantrolene was well tolerated and did not improve beta cell function, visual acuity, or neurological function.

Target Phenotypes: Diabetes mellitus HP:0000819 Optic atrophy HP:0000648

Show evidence (2 references)

clinicaltrials:NCT02829268 SUPPORT Human Clinical

"The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome."

Registry record establishing the trial and its primary objective.

PMID:34185708 REFUTE Human Clinical

"Visual acuity and neurological functions were not improved by 6-month dantrolene sodium."

The published result, which was negative on the efficacy endpoints.

NCT05676034 PHASE_II ACTIVE_NOT_RECRUITING

HELIOS, a single-center, single-arm, open-label phase II trial of AMX0035 (sodium phenylbutyrate and taurursodiol) in twelve adults with Wolfram syndrome. Reported improved or stabilized pancreatic function, vision, and symptom burden at 24 and 48 weeks (PMID:42138079). The uncontrolled design is the reason the entry grades that result PARTIAL.

Target Phenotypes: Diabetes mellitus HP:0000819 Optic atrophy HP:0000648

Show evidence (1 reference)

clinicaltrials:NCT05676034 SUPPORT Human Clinical

"This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome."

Registry record establishing the open-label single-arm design that qualifies the reported result.

NCT03717909 PHASE_II COMPLETED

TREATWOLFRAM, a randomized double-blind placebo-controlled trial of sodium valproate across six international centers, and the most rigorous study the field has run. Recruitment was stopped in November 2022 with 63 of a planned 70 patients enrolled. The trial is reported to have missed its primary endpoint on the rate of visual acuity loss, but only the protocol paper (PMID:40010822) is indexed in PubMed at the time of curation, so that result is recorded in the entry notes rather than as evidence, and valproate is deliberately absent from treatments.

Target Phenotypes: Optic atrophy HP:0000648

Show evidence (1 reference)

clinicaltrials:NCT03717909 SUPPORT Human Clinical

"70 paediatric and adult patients were initially planned to be randomised 2:1 to receive either sodium valproate or placebo at 6 international centres. 63 patients were recruited when a decision was made to stop the study recruitment in November 2022."

Registry record establishing the randomized placebo-controlled design and the actual enrollment, which is the design context for the reported but unpublished negative result.

NCT02882477 PHASE_III UNKNOWN

A combined phase II/III single-group study in genetically diagnosed WFS2 that offered deferiprone plus acetylcysteine, with incretin-based therapy added for participants with diabetes. The registry status is UNKNOWN as of 2026-08-19, and no peer-reviewed efficacy result was identified; this is a trial record, not a treatment recommendation.

Target Phenotypes: Diabetes mellitus HP:0000819 Abnormal bleeding HP:0001892

Show evidence (1 reference)

clinicaltrials:NCT02882477 SUPPORT Human Clinical

"Patients who are genetically diagnosed with the recently reported and rare Wolfram syndrome type 2 ( WFS2) and have the degenerative and symptomatic disease including signs such as diabetes, platelet aggregation defect or visual problems will be asked to participate in this study."

Establishes that the study is specifically WFS2 and targets diabetes, bleeding-related platelet dysfunction, and visual disease.

NCT04940572 PHASE_II UNKNOWN

AUDIOWOLF, a nonrandomized open-label phase II study of three years of sodium valproate in participants with biallelic WFS1 disease and sensorineural hearing loss. The registry status is UNKNOWN as of 2026-08-19, and no peer-reviewed efficacy result was identified.

Target Phenotypes: Sensorineural hearing impairment HP:0000407

Show evidence (1 reference)

clinicaltrials:NCT04940572 SUPPORT Human Clinical

"Open label, phase II study non randomized single group assignment of 20 evaluable patients 13 years and older, over 37,5 kg body-weight, with sensorineural hearing loss of at least 20 dB at 8 kHz in high frequency average (HFA), and with documented genetic mutations in the WFS1 gene and with at..."

Establishes the WFS1 genotype requirement, hearing-loss endpoint population, and uncontrolled phase II design.

NCT05659368 PHASE_II UNKNOWN

A prospective nonrandomized single-group phase II trial of tirzepatide in WFS1, designed to assess endogenous insulin production and glycemic lability. The registry status is UNKNOWN as of 2026-08-19, and no efficacy result was identified; the study does not establish tirzepatide as treatment.

Target Phenotypes: Diabetes mellitus HP:0000819

Show evidence (1 reference)

clinicaltrials:NCT05659368 SUPPORT Human Clinical

"It will be a prospective phase 2, non-randomized, single group assignment, intervention trial to determine the efficacy of tirzepatide (GIP/GLP-1 receptor agonist) in increasing endogenous insulin production and correcting glycemic lability in patients with Wolfram syndrome type 1 (WS1)."

Directly states the WFS1 scope, phase, design, intervention, and intended metabolic endpoints.

NCT02841553 NOT_APPLICABLE RECRUITING

The international registry and natural-history study for Wolfram syndrome and WFS1-related disorders. ClinicalTrials.gov listed it as recruiting with an estimated enrollment of 5,000 on 2026-08-19. It supplies longitudinal clinical and genetic data rather than testing a therapeutic intervention.

Target Phenotypes: Diabetes mellitus HP:0000819 Optic atrophy HP:0000648

Show evidence (1 reference)

clinicaltrials:NCT02841553 SUPPORT Human Clinical

"Aim 1. Establish and maintain a registry of patients with Wolfram syndrome. An Internet based registry will be employed to enroll participants with the clinical diagnosis of Wolfram syndrome (insulin dependent DM and bilateral OA). Clinical information regarding age of diagnosis and progression..."

Establishes the registry, enrollment phenotype, and natural-history purpose.

🧫

Experimental Models

CRISPR-corrected patient iPSC-derived beta cells IPSC_DERIVED_MODEL

CRISPR-Cas9 correction of a pathogenic WFS1 variant in induced pluripotent stem cells from a patient with Wolfram syndrome, differentiated to stem-cell-derived beta cells. This is the most concrete route to replacing beta cells rather than protecting them, and it demonstrates that the beta cell defect is reversible at the genetic level.

Publication

PMID:32321868

Pathograph links

Insulin Deficiency rescues fidelity: moderate Correcting the WFS1 variant restored robust dynamic insulin secretion in vitro. Transplantation of the corrected human beta cells separately reversed streptozotocin-induced diabetes in mice.

Limitations: Transplantation was into mice with streptozocin-induced diabetes rather than into patients, so the therapeutic claim is preclinical and the diabetes reversed was chemically induced rather than WFS1-driven. The model addresses only the beta cell arm and says nothing about the neurodegenerative arm, which is what determines survival.

Readouts

Glucose-responsive insulin secretion in corrected beta cells

Direction: RESTORED

Interpretation: Dynamic insulin secretion in response to glucose is the direct in-vitro functional readout for relief of the insulin-deficiency node.

Show evidence (1 reference)

PMID:32321868 SUPPORT In Vitro

"corrected WS SC-β cells performed robust dynamic insulin secretion in vitro in response to glucose"

Isolates the human beta-cell in-vitro secretion result from the mouse transplantation result reported in the same source sentence.

Diabetes after corrected beta-cell transplantation

Direction: RESTORED

Interpretation: Reversal of streptozotocin-induced diabetes is an intact-animal functional readout of insulin delivery by the transplanted corrected cells.

Show evidence (1 reference)

PMID:32321868 SUPPORT Model Organism

"reversed preexisting streptozocin-induced diabetes after transplantation into mice."

Restricts this evidence item to the in-vivo recipient result and does not present it as a human therapeutic outcome.

Show evidence (2 references)

PMID:32321868 SUPPORT In Vitro

"corrected WS SC-β cells performed robust dynamic insulin secretion in vitro in response to glucose"

Directly supports restoration of insulin secretion in the corrected human beta-cell model.

+ 1 more reference

Unrestrained ER Stress Signaling Through ATF6-alpha rescues fidelity: moderate Genetic correction decreased expression of genes associated with endoplasmic reticulum stress in patient-derived beta cells.

Limitations: The transcriptomic readout is an ER-stress-associated gene set rather than a direct ATF6-alpha or HRD1 assay, so it supports relief of this graph branch without proving that every molecular step in the node was normalized.

Readouts

Endoplasmic reticulum stress gene expression in corrected beta cells

Direction: DECREASED

Interpretation: Reduced expression of ER-stress-associated genes after isogenic correction is the measured molecular correlate of relief of the ER-stress node.

Show evidence (1 reference)

PMID:32321868 SUPPORT In Vitro

"Single-cell transcriptomics showed that corrected SC-β cells displayed increased insulin and decreased expression of genes associated with endoplasmic reticulum stress."

Reports the measured reduction in ER-stress-associated gene expression after correction in the human beta-cell model.

Show evidence (1 reference)

PMID:32321868 SUPPORT In Vitro

"Single-cell transcriptomics showed that corrected SC-β cells displayed increased insulin and decreased expression of genes associated with endoplasmic reticulum stress."

Supports the distinct ER-stress rescue assertion without conflating it with the insulin-secretion or mouse-transplantation readouts.

CISD2-knockout human iPSC-derived cortical neurons IPSC_DERIVED_MODEL

Isogenic CRISPR-Cas9 CISD2-knockout human induced pluripotent stem cells differentiated into cortical neurons. The model isolates complete CISD2 loss and directly measures organelle contacts, calcium responses, mitochondrial bioenergetics, autophagic flux, and stress-induced apoptosis.

Publication

PMID:41299767

Pathograph links

ER-Mitochondria Contact and Calcium Transfer Dysregulation recapitulates fidelity: moderate CISD2-knockout neurons lose endoplasmic-reticulum to mitochondria contact sites and show severe loss of glutamate-evoked cytosolic calcium responses and mitochondrial calcium uptake.

Limitations: Complete engineered knockout may not reproduce every patient missense variant; one patient-derived fibroblast model showed increased rather than decreased contact-site abundance.

Show evidence (1 reference)

PMID:41299767 SUPPORT In Vitro

"However, studying the impact of Cisd2 deficiency in human induced pluripotent stem cell -derived cortical neurons revealed a severe loss of glutamate-evoked Ca2+ responses in cytosol and associated uptake in mitochondria due to loss of ER-mitochondria contact sites."

Directly reports the contact-site and calcium-transfer phenotype in the disease-relevant human neuronal model.

🐁

Animal Models

Wfs1 exon-8 knockout mouse

The Estonian Wfs1 exon-8 knockout mouse develops progressive visual-acuity loss, optic-disc pallor, and severe optic-nerve damage. Intravitreal AAV2 delivery of human WFS1 provides a direct rescue experiment for the retinal ganglion-cell branch.

Species

Mus musculus

Genotype

Wfs1 exon-8 knockout

Genes

Wfs1 MGI:1328355

Publication

PMID:41998758

Pathograph links

Retinal Ganglion Cell and CNS Neuron Degeneration recapitulates fidelity: moderate The knockout reproduces progressive visual-acuity loss, optic-disc pallor, retinal thinning, and severe optic-nerve axon damage; rescue by retinal delivery of human WFS1 strengthens the causal interpretation.

Limitations: This link is restricted to the retinal and optic-nerve branch. The model did not show significant retinal-ganglion-cell soma loss at the studied age and does not establish fidelity for the broader human CNS phenotype.

Readouts

Visual-acuity loss and optic-nerve damage

Direction: INCREASED

Interpretation: Progressive visual loss, pallor, and optic-nerve damage are functional and structural readouts of the modeled retinal neurodegeneration.

Show evidence (1 reference)

PMID:41998758 SUPPORT Model Organism

"the Wfs1 knockout mice produced by the Estonian group, in which exon 8 of the Wfs1 gene was disrupted, exhibit a progressive loss of visual acuity, optic disc pallor and severe optic nerve damage."

Directly states the genotype and the functional and structural retinal phenotypes represented by this model link.

Show evidence (1 reference)

PMID:41998758 SUPPORT Model Organism

"the Wfs1 knockout mice produced by the Estonian group, in which exon 8 of the Wfs1 gene was disrupted, exhibit a progressive loss of visual acuity, optic disc pallor and severe optic nerve damage."

Establishes that the mouse recapitulates the optic-neuropathy branch.

Show evidence (1 reference)

PMID:41998758 SUPPORT Model Organism

"Our results provide the first evidence that intravitreal injection of human WFS1 has significant neuroprotective effects on retinal ganglion cells and their axons and slows the loss of visual acuity."

AAV2-WFS1 rescue of retinal ganglion-cell structure and visual function provides causal model support for the optic-neuropathy branch.

Beta-cell-specific Cisd2 knockout mouse

Ins1-Cre-mediated beta-cell Cisd2 knockout mice develop glucose intolerance with impaired first- and second-phase glucose-stimulated insulin secretion but unchanged insulin sensitivity, modeling the WFS2 beta-cell secretory defect.

Species

Mus musculus

Genotype

Beta-cell-specific Cisd2 knockout

Genes

Cisd2 MGI:1914256

Publication

PMID:40189101

Pathograph links

Insulin Deficiency recapitulates fidelity: moderate Beta-cell-restricted Cisd2 loss impairs both phases of glucose-stimulated insulin secretion and disrupts systemic glucose homeostasis without changing insulin sensitivity.

Limitations: A beta-cell-specific knockout isolates the secretory arm of WFS2 and does not model optic atrophy, hearing impairment, ulceration, bleeding, or the effects of specific human CISD2 alleles.

Readouts

Biphasic glucose-stimulated insulin secretion

Direction: DECREASED

Interpretation: Defects in both phases of glucose-stimulated insulin secretion are the direct intact-animal readout for the insulin-deficiency node.

Show evidence (1 reference)

PMID:40189101 SUPPORT Model Organism

"our results reveal that there are defects during both phases of GSIS in the Cisd2 βKO mice"

Directly reports impaired first- and second-phase insulin secretion in the beta-cell-specific knockout mouse.

Show evidence (1 reference)

PMID:40189101 SUPPORT Model Organism

Establishes the in-vivo secretory defect and systemic glucose consequence represented by the model link.

Show evidence (1 reference)

PMID:40189101 SUPPORT Model Organism

"Firstly, β-cell specific Cisd2KO in mice disrupts systemic glucose homeostasis via impairing β-granules synthesis and insulin secretion; hypertrophy of the β-islets and the presence of a loss of identity that affects certain β-cells."

Directly demonstrates impaired insulin synthesis and secretion after beta-cell-specific Cisd2 loss in vivo.

{ }

Source YAML

click to show

name: Wolfram Syndrome
creation_date: "2026-08-15T00:00:00Z"
category: Mendelian
parents:
- Neurodegenerative Disease
- Monogenic Diabetes
disease_term:
  preferred_term: Wolfram Syndrome
  term:
    id: MONDO:0018105
    label: Wolfram syndrome
synonyms:
- DIDMOAD
- DIDMOAD syndrome
- diabetes insipidus, diabetes mellitus, optic atrophy and deafness syndrome
description: >-
  Wolfram syndrome is an autosomal recessive neurodegenerative disorder caused by
  failure of either of two endoplasmic-reticulum and organelle-contact proteins.
  The cells that suffer most are insulin-secreting pancreatic beta cells and
  long-projection neurons. Biallelic loss-of-function variants in
  WFS1 account for the large majority of cases; biallelic CISD2 variants cause the
  rarer Wolfram syndrome 2. Wolframin normally restrains the unfolded protein
  response by stabilizing the E3 ubiquitin ligase HRD1 and routing ATF6-alpha to
  the proteasome, maintains endoplasmic reticulum calcium stores, and supports
  endoplasmic-reticulum to mitochondria contact sites. CISD2 loss reaches the same
  calcium-transfer and mitochondrial compartment through a distinct route. These
  defects converge on beta-cell dysfunction or loss and neuronal injury. In WS1,
  this typically reads out as the DIDMOAD sequence: insulin-requiring
  autoantibody-negative diabetes mellitus in the first decade, then optic atrophy,
  then sensorineural hearing loss and central diabetes insipidus, then neurogenic
  bladder and brainstem or cerebellar dysfunction. WS2 shares diabetes mellitus,
  optic atrophy, and hearing impairment but usually lacks diabetes insipidus and
  instead adds upper intestinal ulceration and a bleeding tendency. In the
  historical, predominantly WS1 natural-history cohort, death occurred at a median
  age around 30 years and was usually from central respiratory failure with
  brainstem atrophy. Brain volume abnormalities are already measurable at the
  earliest clinical presentation, so part of the deficit is failed development
  rather than degeneration alone. There is no approved disease-modifying therapy.
has_subtypes:
- name: WS1
  display_name: Wolfram syndrome 1 (WFS1-related)
  subtype_term:
    preferred_term: Wolfram syndrome 1
    term:
      id: MONDO:0009101
      label: Wolfram syndrome 1
  description: >-
    The classic and by far the commoner form, caused by biallelic WFS1 variants,
    accounting for roughly 90% of cases. Diabetes mellitus and optic atrophy before
    age 16 are the defining pair; diabetes insipidus, sensorineural deafness,
    neurogenic bladder, and brainstem or cerebellar neurodegeneration follow.
  genes:
  - preferred_term: WFS1
    term:
      id: hgnc:12762
      label: WFS1
  evidence:
  - reference: PMID:39202345
    reference_title: "Wolfram Syndrome 1: A Neuropsychiatric Perspective on a Rare Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in the WFS1 gene, located on chromosome 4p16, account for approximately 90% of WS1 cases."
    explanation: >-
      Quantifies the share of Wolfram syndrome attributable to WFS1 variants.
- name: WS2
  display_name: Wolfram syndrome 2 (CISD2-related)
  subtype_term:
    preferred_term: Wolfram syndrome 2
    term:
      id: MONDO:0011502
      label: Wolfram syndrome 2
  description: >-
    A rarer form caused by biallelic variants in CISD2, which encodes ERIS, a small
    protein of the mitochondria-associated endoplasmic reticulum membrane. ERIS
    localizes to the same organelle as wolframin but does not interact with it
    directly, so the two genes converge on the same compartment by separate routes.
    Clinically WS2 typically lacks diabetes insipidus and adds upper intestinal
    ulceration and a bleeding tendency.
  genes:
  - preferred_term: CISD2
    term:
      id: hgnc:24212
      label: CISD2
  evidence:
  - reference: PMID:39527371
    reference_title: SID/SIEDP expert consensus on optimizing clinical strategies for early detection and management of wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additionally, a second gene, CISD2, located on chromosome 4q22, has been identified in individuals with WFS type 2 (WFS2), which leads to early onset optic atrophy, diabetes mellitus, deafness, bleeding tendency and upper intestinal ulcers, a shortened lifespan, but notably not diabetes insipidus."
    explanation: >-
      Defines the CISD2-related subtype and its clinical discriminators, including
      the characteristic absence of diabetes insipidus.
pathophysiology:
- name: Loss of Wolframin at the Endoplasmic Reticulum Membrane
  biological_scale: MOLECULAR
  subtypes:
  - WS1
  description: >-
    Biallelic loss-of-function variants in WFS1 remove wolframin, a multipass
    transmembrane glycoprotein of the endoplasmic reticulum. Wolframin holds three
    jobs at once: it negatively regulates the unfolded protein response, it
    maintains endoplasmic reticulum calcium stores, and it supports the contact
    sites where the endoplasmic reticulum meets mitochondria. Nothing downstream in
    this entry is a separate insult; every later node is one of those three jobs
    going unattended.
  genes:
  - preferred_term: WFS1
    term:
      id: hgnc:12762
      label: WFS1
  cellular_components:
  - preferred_term: endoplasmic reticulum membrane
    term:
      id: GO:0005789
      label: endoplasmic reticulum membrane
  downstream:
  - target: Unrestrained ER Stress Signaling Through ATF6-alpha
    description: >-
      Loss of the wolframin brake releases ATF6-alpha and the unfolded protein
      response.
    causal_link_type: DIRECT
  - target: ER-Mitochondria Contact and Calcium Transfer Dysregulation
    description: >-
      Loss of wolframin removes its contribution to endoplasmic reticulum calcium
      handling and to the NCS1-IP3R complex at contact sites.
    causal_link_type: DIRECT
  - target: Hypothalamic Magnocellular Neuron Loss
    description: >-
      In WS1, wolframin deficiency is associated with selective degeneration of
      vasopressin-producing magnocellular neurons in the supraoptic and
      paraventricular hypothalamic nuclei.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39202345
      reference_title: "Wolfram Syndrome 1: A Neuropsychiatric Perspective on a Rare Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In some WS1 cases, the hypothalamus exhibited gliosis and a severe loss of magnocellular neurons in the supraoptic and paraventricular nuclei"
      explanation: >-
        A recent review of human neuropathology localizes the neuronal loss that
        provides the anatomical bridge from WFS1 deficiency to central diabetes
        insipidus; the molecular intermediates remain unresolved.
  - target: Cochlear and Auditory Pathway Degeneration
    description: >-
      In WS1, wolframin deficiency is associated with degeneration from the organ
      of Corti through the cochlear nerve and central auditory nuclei.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39202345
      reference_title: "Wolfram Syndrome 1: A Neuropsychiatric Perspective on a Rare Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The auditory pathways are characterized by the loss of the organ of Corti in the basal turns of the cochlea, as well as the loss of fibers in the cochlear nerve and neurons in the cochlear nuclei and inferior colliculus"
      explanation: >-
        Human neuropathology supplies the anatomical bridge to hearing impairment,
        while the steps between WFS1 loss and region-selective injury remain
        uncertain.
  - target: Lower Urinary Tract Neural Dysfunction
    description: >-
      In WS1, neurologic and autonomic involvement can disrupt detrusor and
      sphincter control, producing the characteristic bladder phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39527371
      reference_title: SID/SIEDP expert consensus on optimizing clinical strategies for early detection and management of wolfram syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These include ureterohydronephrosis due to bladder dysfunction, as confirmed by urodynamic testing, and autonomic neuropathy."
      explanation: >-
        Clinical and urodynamic observations connect urinary tract dysfunction
        with autonomic neuropathy, but do not resolve the intervening neural lesion.
  evidence:
  - reference: PMID:9771706
    reference_title: A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in a novel gene (WFS1) encoding a putative transmembrane protein were found in all affected individuals in six WFS families, and these mutations were associated with the disease phenotype."
    explanation: >-
      The gene-identification study establishing WFS1 variants as the cause of
      Wolfram syndrome.
  - reference: PMID:9771706
    reference_title: A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "WFS1 appears to function in survival of islet beta-cells and neurons."
    explanation: >-
      Identifies the two cell populations whose survival depends on wolframin,
      which is the whole shape of the clinical phenotype.
- name: Loss of CISD2 at Organelle Contact Membranes
  biological_scale: MOLECULAR
  subtypes:
  - WS2
  description: >-
    Biallelic loss-of-function variants remove CISD2, an integral membrane protein
    present at the endoplasmic reticulum, mitochondrial outer membrane, and
    mitochondria-associated endoplasmic-reticulum membranes. Unlike wolframin,
    CISD2 does not interact with WFS1 directly. Its loss independently disrupts
    intracellular calcium handling, organelle contacts, mitochondrial function,
    and beta-cell insulin secretion.
  genes:
  - preferred_term: CISD2
    term:
      id: hgnc:24212
      label: CISD2
  cellular_components:
  - preferred_term: mitochondria-associated endoplasmic reticulum membrane
    term:
      id: GO:0044233
      label: mitochondria-associated endoplasmic reticulum membrane contact site
  downstream:
  - target: ER-Mitochondria Contact and Calcium Transfer Dysregulation
    description: >-
      CISD2 loss perturbs contact-site abundance and calcium transfer, with the
      measured direction depending on variant and model context.
    causal_link_type: DIRECT
  - target: Insulin Deficiency
    description: >-
      Beta-cell-specific Cisd2 loss impairs calcium-mediated insulin secretion.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:17846994
    reference_title: "A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The ZCD2-encoded protein, ERIS (endoplasmic reticulum intermembrane small protein), is also shown to localize to the endoplasmic reticulum but does not interact directly with Wolframin."
    explanation: >-
      Establishes the separate CISD2 route into the endoplasmic-reticulum
      compartment and its lack of direct interaction with wolframin.
  - reference: PMID:40189101
    reference_title: Wolfram syndrome 2 gene (CISD2) deficiency disrupts Ca(2+)-mediated insulin secretion in β-cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "β-cell specific Cisd2KO in mice disrupts systemic glucose homeostasis via impairing β-granules synthesis and insulin secretion; hypertrophy of the β-islets and the presence of a loss of identity that affects certain β-cells."
    explanation: >-
      Directly links beta-cell CISD2 loss to impaired insulin production and
      secretion in vivo.
- name: Unrestrained ER Stress Signaling Through ATF6-alpha
  biological_scale: MOLECULAR
  subtypes:
  - WS1
  description: >-
    Wolframin's mechanism of restraint is specific and now well defined. It
    stabilizes the E3 ubiquitin ligase HRD1, brings the transcription factor
    ATF6-alpha to the proteasome, and enhances its ubiquitination and degradation.
    Without wolframin, ATF6-alpha accumulates, its target genes are derepressed,
    and the endoplasmic reticulum stress response element promoter is activated.
    Patient lymphocytes show the same dysregulation, with ATF6-alpha up and HRD1
    down. A chronically engaged unfolded protein response is not a louder version
    of a normal signal; it is an alarm
    that never stops, and the building is eventually evacuated for good.
  biological_processes:
  - preferred_term: ATF6-mediated unfolded protein response
    term:
      id: GO:0036500
      label: ATF6-mediated unfolded protein response
    modifier: INCREASED
  - preferred_term: ATF6-alpha ubiquitination and proteasomal degradation
    term:
      id: GO:0016567
      label: protein ubiquitination
    modifier: DECREASED
  downstream:
  - target: Beta Cell Apoptosis
    description: >-
      Chronic unresolvable endoplasmic reticulum stress drives beta cell death.
    causal_link_type: DIRECT
  - target: Retinal Ganglion Cell and CNS Neuron Degeneration
    description: >-
      The same chronic stress response drives apoptosis in long-projection
      neurons.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:20160352
    reference_title: Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Moreover, WFS1 stabilized the E3 ubiquitin ligase HRD1, brought ATF6alpha to the proteasome, and enhanced its ubiquitination and proteasome-mediated degradation, leading to suppression of ER stress signaling."
    explanation: >-
      Defines the molecular mechanism by which wolframin restrains the ATF6 arm of
      the unfolded protein response.
  - reference: PMID:20160352
    reference_title: Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "lymphocytes from patients with Wolfram syndrome exhibited dysregulated ER stress signaling through upregulation of ATF6alpha and downregulation of HRD1."
    explanation: >-
      Restricts the clinical evidence item to the patient-lymphocyte result; the
      mouse beta-cell observation in the same source sentence is not typed as
      human evidence here.
- name: ER-Mitochondria Contact and Calcium Transfer Dysregulation
  biological_scale: CELLULAR
  subtypes:
  - WS1
  - WS2
  description: >-
    Wolframin forms a complex with neuronal calcium sensor 1 (NCS1) and the
    inositol 1,4,5-trisphosphate receptor to move calcium from the endoplasmic
    reticulum into mitochondria at mitochondria-associated membranes. In WFS1-null
    patient fibroblasts, NCS1 abundance falls, endoplasmic reticulum to
    mitochondria contacts and calcium exchange fall. CISD2 deficiency converges on
    the same compartment: isogenic CISD2-knockout human cortical neurons lose
    contact sites and calcium transfer, whereas one patient CISD2 missense variant
    increased both in fibroblasts. The node therefore records dysregulation, not a
    universal direction of effect across both molecular subtypes.
  biological_processes:
  - preferred_term: endoplasmic reticulum calcium ion homeostasis
    term:
      id: GO:0032469
      label: endoplasmic reticulum calcium ion homeostasis
    modifier: DYSREGULATED
  cellular_components:
  - preferred_term: mitochondria-associated endoplasmic reticulum membrane
    term:
      id: GO:0044233
      label: mitochondria-associated endoplasmic reticulum membrane contact site
  downstream:
  - target: Mitochondrial Dysfunction
    description: >-
      Reduced calcium delivery to mitochondria impairs their function and
      dynamics.
    causal_link_type: DIRECT
  - target: Cytosolic Calcium Dysregulation
    description: >-
      Calcium that is not retained in the endoplasmic reticulum or handed to
      mitochondria raises cytosolic calcium.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:30352948
    reference_title: ER-mitochondria cross-talk is regulated by the Ca(2+) sensor NCS1 and is impaired in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here, we showed that WFS1 formed a complex with neuronal calcium sensor 1 (NCS1) and inositol 1,4,5-trisphosphate receptor (IP3R) to promote Ca2+ transfer between the ER and mitochondria."
    explanation: >-
      Establishes the physical complex through which wolframin supports organelle
      calcium transfer.
  - reference: PMID:30352948
    reference_title: ER-mitochondria cross-talk is regulated by the Ca(2+) sensor NCS1 and is impaired in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In addition, we found that NCS1 abundance was reduced in WFS1-null patient fibroblasts, which showed reduced ER-mitochondria interactions and Ca2+ exchange."
    explanation: >-
      Demonstrates the defect in patient-derived cells rather than only in
      engineered knockdowns.
  - reference: PMID:17846994
    reference_title: "A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Lymphoblastoid cells from affected individuals show a significantly greater rise in intracellular calcium when stimulated with thapsigargin, compared with controls, although no difference was observed in resting concentrations of intracellular calcium."
    explanation: >-
      Shows that the CISD2 route into this node also produces abnormal calcium
      handling. PARTIAL because the abnormality is a stimulated response in WS2
      lymphoblastoid cells, not the same measured ER-mitochondria transfer defect
      demonstrated for WFS1.
  - reference: PMID:41299767
    reference_title: "CISD2 ensures adequate ER-mitochondrial coupling, critically supporting mitochondrial function in neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "However, studying the impact of Cisd2 deficiency in human induced pluripotent stem cell -derived cortical neurons revealed a severe loss of glutamate-evoked Ca2+ responses in cytosol and associated uptake in mitochondria due to loss of ER-mitochondria contact sites."
    explanation: >-
      Demonstrates reduced contact sites and calcium transfer in a disease-relevant
      human neuronal model of complete CISD2 loss.
  - reference: PMID:28335035
    reference_title: A novel CISD2 mutation associated with a classical Wolfram syndrome phenotype alters Ca2+ homeostasis and ER-mitochondria interactions.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "This Ca2+ dysregulation was associated with increased ER-mitochondria contact, a swollen ER lumen and a hyperfused mitochondrial network in the absence of overt ER stress."
    explanation: >-
      Shows the opposite contact-site direction in fibroblasts carrying a specific
      CISD2 missense variant, justifying a direction-neutral dysregulation node.
- name: Mitochondrial Dysfunction
  biological_scale: CELLULAR
  subtypes:
  - WS1
  - WS2
  description: >-
    Disturbed calcium exchange at endoplasmic-reticulum to mitochondria contact
    sites disrupts mitochondrial dynamics and bioenergetics. WFS1 knockdown in
    neurons inhibits mitochondrial fusion, alters trafficking, and augments
    mitophagy. CISD2-knockout human cortical neurons show reduced oxygen
    consumption, ATP production, and mitochondrial membrane-potential maintenance.
    These subtype-specific experiments converge on one atomic mitochondrial
    dysfunction node.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
    modifier: DYSREGULATED
  downstream:
  - target: Impaired Neuronal Development
    description: >-
      WFS1-associated mitochondrial dynamics defects delay neuronal development.
    causal_link_type: DIRECT
  - target: Retinal Ganglion Cell and CNS Neuron Degeneration
    description: >-
      Severe mitochondrial failure lowers stress resilience in CISD2-deficient
      neurons and contributes to neuronal loss.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:27434582
    reference_title: "Role of Mitochondrial Dynamics in Neuronal Development: Mechanism for Wolfram Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We show that down-regulation of WFS1 in neurons leads to dramatic changes in mitochondrial dynamics (inhibited mitochondrial fusion, altered mitochondrial trafficking, and augmented mitophagy), delaying neuronal development."
    explanation: >-
      Documents the specific mitochondrial-dynamics abnormalities caused by WFS1
      deficiency.
  - reference: PMID:27434582
    reference_title: "Role of Mitochondrial Dynamics in Neuronal Development: Mechanism for Wolfram Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Importantly, ER stress, impaired Ca2+ homeostasis, altered mitochondrial dynamics, and delayed neuronal development are causatively related events because interventions at all these levels improved the downstream processes."
    explanation: >-
      Establishes the causal ordering of stress, calcium, mitochondrial, and
      developmental defects by intervention at each level.
  - reference: PMID:41299767
    reference_title: "CISD2 ensures adequate ER-mitochondrial coupling, critically supporting mitochondrial function in neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Correlating with the profound changes in cellular Ca2+ handling, mitochondrial function (oxygen consumption rate, ATP production, mitochondrial potential maintenance) declined severely, while autophagic flux was increased."
    explanation: >-
      Directly measures severe mitochondrial bioenergetic dysfunction after CISD2
      loss in human iPSC-derived cortical neurons.
- name: Impaired Neuronal Development
  biological_scale: CELLULAR
  subtypes:
  - WS1
  description: >-
    WFS1 down-regulation in neurons delays development downstream of
    endoplasmic-reticulum stress, calcium dyshomeostasis, and disturbed
    mitochondrial dynamics.
    Interventions at each upstream level improve the downstream steps, supporting
    a causal developmental branch rather than an imaging correlation alone.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: neuron development
    term:
      id: GO:0048666
      label: neuron development
    modifier: DECREASED
  downstream:
  - target: Brainstem and Cerebellar Volume Loss
    description: >-
      Stalled neuronal and white-matter development contributes to early regional
      brain-volume deficits.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:27434582
    reference_title: "Role of Mitochondrial Dynamics in Neuronal Development: Mechanism for Wolfram Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We show that down-regulation of WFS1 in neurons leads to dramatic changes in mitochondrial dynamics (inhibited mitochondrial fusion, altered mitochondrial trafficking, and augmented mitophagy), delaying neuronal development."
    explanation: >-
      Directly reports delayed neuronal development after WFS1 down-regulation.
  - reference: PMID:27434582
    reference_title: "Role of Mitochondrial Dynamics in Neuronal Development: Mechanism for Wolfram Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Importantly, ER stress, impaired Ca2+ homeostasis, altered mitochondrial dynamics, and delayed neuronal development are causatively related events because interventions at all these levels improved the downstream processes."
    explanation: >-
      Intervention at each upstream level supports the causal ordering of the
      developmental defect.
- name: Cytosolic Calcium Dysregulation
  biological_scale: CELLULAR
  subtypes:
  - WS1
  description: >-
    WFS1-knockout insulinoma cells have impaired intracellular calcium homeostasis
    and Akt signaling, with reduced viability and glucose-stimulated insulin
    secretion. Re-expressing WFS1, overexpressing NCS1, or treating with a calpain
    inhibitor or ibudilast reverses these deficits. Because the quoted experiments
    do not directly quantify calpain activation, this node records only the
    demonstrated calcium dysregulation.
  cell_types:
  - preferred_term: pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  downstream:
  - target: Beta Cell Apoptosis
    description: >-
      Calcium dyshomeostasis reduces beta-cell viability.
    causal_link_type: DIRECT
  - target: Insulin Deficiency
    description: >-
      Calcium dyshomeostasis reduces glucose-stimulated insulin secretion.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:32632005
    reference_title: Calpain inhibitor and ibudilast rescue β cell functions in a cellular model of Wolfram syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Knockout (KO) of WFS1 in rat insulinoma (INS1) cells impaired calcium homeostasis and protein kinase B/Akt signaling and, subsequently, decreased cell viability and glucose-stimulated insulin secretion."
    explanation: >-
      Links WFS1 loss to calcium dyshomeostasis and to the two beta cell functional
      readouts that matter clinically.
  - reference: PMID:32632005
    reference_title: Calpain inhibitor and ibudilast rescue β cell functions in a cellular model of Wolfram syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Targeting calcium homeostasis with reexpression of WFS1, overexpression of WFS1's interacting partner neuronal calcium sensor-1 (NCS1), or treatment with calpain inhibitor and ibudilast reversed deficits observed in WFS1-KO cells."
    explanation: >-
      Four independent rescues of the same node establish calcium dyshomeostasis as
      causally upstream of the beta cell deficits.
- name: Beta Cell Apoptosis
  biological_scale: CELLULAR
  subtypes:
  - WS1
  description: >-
    Chronic unresolvable endoplasmic reticulum stress and calcium dyshomeostasis
    converge on intrinsic apoptosis in pancreatic beta cells. The loss is
    non-autoimmune and progressive. This node is restricted to demonstrated cell
    death; the downstream hormone deficit is represented separately so that
    replacement insulin does not appear to reverse apoptosis.
  cell_types:
  - preferred_term: pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: intrinsic apoptotic signaling in response to ER stress
    term:
      id: GO:0070059
      label: intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress
    modifier: INCREASED
  downstream:
  - target: Insulin Deficiency
    description: >-
      Progressive non-autoimmune beta-cell loss reduces endogenous insulin supply.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:20160352
    reference_title: Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Wolfram syndrome is an autosomal-recessive disorder characterized by insulin-dependent diabetes mellitus, caused by nonautoimmune loss of beta cells, and neurological dysfunctions."
    explanation: >-
      States that the diabetes of Wolfram syndrome arises from non-autoimmune beta
      cell loss.
- name: Insulin Deficiency
  biological_scale: CELLULAR
  subtypes:
  - WS1
  - WS2
  description: >-
    Endogenous insulin supply falls through two related but non-identical routes.
    Progressive non-autoimmune beta-cell loss dominates WFS1, whereas CISD2 loss in
    beta cells also impairs beta-granule synthesis, calcium-mediated secretory
    signaling, and glucose-stimulated insulin secretion. The hormone deficit is the
    immediate mechanism producing diabetes mellitus and the mechanism restored by
    exogenous insulin.
  cell_types:
  - preferred_term: pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: insulin secretion
    term:
      id: GO:0030073
      label: insulin secretion
    modifier: DECREASED
  downstream:
  - target: Diabetes Mellitus
    description: >-
      Insufficient endogenous insulin produces insulin-requiring diabetes.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-autoimmune, insulin-deficient diabetes mellitus presented at a median age of 6 years, followed by optic atrophy (11 years)."
    explanation: >-
      Provides the median onset ages and confirms the insulin-deficient,
      non-autoimmune character in a national cohort.
  - reference: PMID:40189101
    reference_title: Wolfram syndrome 2 gene (CISD2) deficiency disrupts Ca(2+)-mediated insulin secretion in β-cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Cisd2 deficiency leads to impairment of glucose-induced extracellular Ca2+ influx, which compromises Ca2+-mediated insulin secretory signaling, causing mitochondrial dysfunction and, thereby impairing insulin secretion in the MIN6-Cisd2KO β-cells."
    explanation: >-
      Defines the calcium-dependent insulin-secretory failure caused by CISD2 loss
      in a beta-cell model.
- name: Retinal Ganglion Cell and CNS Neuron Degeneration
  biological_scale: CELLULAR
  subtypes:
  - WS1
  - WS2
  description: >-
    Cell-intrinsic stress, calcium-transfer defects, and mitochondrial dysfunction
    reduce the survival of retinal ganglion cells and long-projection central
    neurons. Retinal ganglion cell loss thins the retinal nerve fiber layer and
    produces the bilateral progressive optic atrophy that, paired with early
    diabetes, defines the syndrome clinically. WFS1 evidence directly links
    endoplasmic-reticulum stress to cell death; CISD2-knockout human cortical
    neurons show markedly reduced resilience to an apoptosis inducer.
  cell_types:
  - preferred_term: retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  biological_processes:
  - preferred_term: neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  downstream:
  - target: Optic Atrophy
    description: >-
      Loss of retinal ganglion cells produces progressive bilateral optic atrophy.
    causal_link_type: DIRECT
  - target: Brainstem and Cerebellar Volume Loss
    description: >-
      Degeneration of long-projection central neurons contributes to brainstem and
      cerebellar tissue loss.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:22792385
    reference_title: Early brain vulnerability in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "WFS is caused by mutations in the WFS1 gene, which lead to endoplasmic reticulum (ER) stress-mediated cell death."
    explanation: >-
      Attributes the neuronal loss of Wolfram syndrome to endoplasmic reticulum
      stress-mediated cell death.
  - reference: PMID:41299767
    reference_title: "CISD2 ensures adequate ER-mitochondrial coupling, critically supporting mitochondrial function in neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Overall, these deficiencies further impact the resilience of Cisd2-deficient cortical neurons to cell stress as Cisd2-KO neurons were highly sensitive to staurosporine, an inducer of apoptosis."
    explanation: >-
      Links CISD2 loss to reduced survival under apoptotic stress in human
      iPSC-derived cortical neurons.
- name: Hypothalamic Magnocellular Neuron Loss
  biological_scale: CELLULAR
  subtypes:
  - WS1
  description: >-
    Human neuropathology in WS1 shows gliosis and severe loss of magnocellular
    neurons in the supraoptic and paraventricular hypothalamic nuclei. Loss of
    these vasopressin-producing neurons supplies the tissue-level link between the
    molecular WFS1 defect and central diabetes insipidus; the upstream molecular
    steps that create this selective vulnerability are not yet resolved.
  locations:
  - preferred_term: hypothalamus
    term:
      id: UBERON:0001898
      label: hypothalamus
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Diabetes Insipidus
    description: >-
      Loss of hypothalamic magnocellular neurons depletes central vasopressin
      output and produces central diabetes insipidus.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:39202345
    reference_title: "Wolfram Syndrome 1: A Neuropsychiatric Perspective on a Rare Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In some WS1 cases, the hypothalamus exhibited gliosis and a severe loss of magnocellular neurons in the supraoptic and paraventricular nuclei"
    explanation: >-
      A recent review of human postmortem findings directly localizes the
      magnocellular-neuron loss in WS1.
- name: Cochlear and Auditory Pathway Degeneration
  biological_scale: TISSUE
  subtypes:
  - WS1
  description: >-
    Human WS1 neuropathology shows a continuous pattern of auditory-system injury:
    loss of the organ of Corti in basal cochlear turns, cochlear-nerve fibers, and
    neurons in the cochlear nuclei and inferior colliculus. This regional lesion
    connects WFS1 deficiency to the progressive sensorineural hearing phenotype
    without assuming that every affected person has injury at every listed site.
  locations:
  - preferred_term: cochlea
    term:
      id: UBERON:0001844
      label: cochlea
  downstream:
  - target: Sensorineural Hearing Impairment
    description: >-
      Degeneration of the organ of Corti, cochlear nerve, and central auditory
      nuclei impairs auditory signal transduction and transmission.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:39202345
    reference_title: "Wolfram Syndrome 1: A Neuropsychiatric Perspective on a Rare Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The auditory pathways are characterized by the loss of the organ of Corti in the basal turns of the cochlea, as well as the loss of fibers in the cochlear nerve and neurons in the cochlear nuclei and inferior colliculus"
    explanation: >-
      A recent review of human neuropathology directly describes the peripheral
      and central auditory lesions in WS1.
- name: Lower Urinary Tract Neural Dysfunction
  biological_scale: TISSUE
  subtypes:
  - WS1
  description: >-
    Neurologic and autonomic involvement in WS1 disrupts lower-urinary-tract
    control. Urodynamic studies show both hypocontractile detrusor and
    detrusor-sphincter dyssynergia, explaining how the neural disease produces
    neurogenic bladder and, secondarily, upper-tract dilatation.
  locations:
  - preferred_term: urinary bladder
    term:
      id: UBERON:0001255
      label: urinary bladder
  downstream:
  - target: Neurogenic Bladder
    description: >-
      Impaired detrusor contraction or detrusor-sphincter coordination produces
      the clinically recognized neurogenic bladder.
    causal_link_type: DIRECT
  - target: Hydronephrosis
    description: >-
      Chronic bladder dysfunction can propagate pressure and urinary stasis to the
      upper urinary tract, producing ureterohydronephrosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:38465704
    reference_title: Long term clinical follow up of four patients with Wolfram syndrome and urodynamic abnormalities.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "two of them had hypocontractile detrusor and another had sphincter-detrusor dyssynergia."
    explanation: >-
      Prospective urodynamic testing directly identifies the detrusor and sphincter
      abnormalities represented by this intermediate node.
  - reference: PMID:39527371
    reference_title: SID/SIEDP expert consensus on optimizing clinical strategies for early detection and management of wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These include ureterohydronephrosis due to bladder dysfunction, as confirmed by urodynamic testing, and autonomic neuropathy."
    explanation: >-
      Expert consensus links urodynamically confirmed bladder dysfunction and
      autonomic neuropathy to upper-tract dilatation.
- name: Brainstem and Cerebellar Volume Loss
  biological_scale: TISSUE
  description: >-
    Volume loss centers on the brainstem, ventral pons, and cerebellum, and it is
    already measurable at the earliest clinical presentation, in the youngest
    patients with the mildest symptoms. Longitudinal morphometry separates two
    processes that clinical intuition tends to blur: controls gained white matter
    volume where the Wolfram group was flat in the optic radiations or shrinking in
    the brainstem and ventral pons, so there is failed developmental growth as well
    as frank degeneration. That distinction is not academic. Because part of the
    deficit is growth that never happened, a disease-modifying therapy plausibly
    has to start before or around the time diabetes is diagnosed to capture the
    full benefit. Progressive bulbar dysfunction and central apnea from this
    territory are what ultimately kill.
  locations:
  - preferred_term: brainstem
    term:
      id: UBERON:0002298
      label: brainstem
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Brain Atrophy
    description: >-
      Regional volume loss is part of a broader pattern of brain atrophy.
  - target: Myoclonus
    description: >-
      Myoclonus accompanies cerebellar ataxia in the neurological phase.
  - target: Ataxia
    description: >-
      Cerebellar and brainstem tissue loss produces gait ataxia.
  - target: Dysarthria
    description: Bulbar involvement produces dysarthria.
  - target: Dysphagia
    description: Bulbar involvement produces dysphagia.
  - target: Central Apnea
    description: >-
      Brainstem degeneration can disrupt central respiratory drive.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:22792385
    reference_title: Early brain vulnerability in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared to healthy and type 1 diabetic control groups, the WFS group had smaller intracranial volume and preferentially affected gray matter volume and white matter microstructural integrity in the brainstem, cerebellum and optic radiations."
    explanation: >-
      Localizes the structural abnormality to brainstem, cerebellum, and optic
      radiations against both healthy and diabetic controls.
  - reference: PMID:22792385
    reference_title: Early brain vulnerability in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormalities were detected in even the youngest patients with mildest symptoms, and some measures did not follow the typical age-dependent developmental trajectory."
    explanation: >-
      Establishes that the abnormality is present at the earliest clinical stage
      and departs from a normal developmental trajectory.
  - reference: PMID:30979932
    reference_title: Evidence for altered neurodevelopment and neurodegeneration in Wolfram syndrome using longitudinal morphometry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Controls had uniformly increasing volume in white matter, whereas the Wolfram group had stable (optic radiations) or decreasing (brainstem, ventral pons) white matter volumes."
    explanation: >-
      Longitudinal comparison separating failed white-matter growth from frank
      degeneration.
  - reference: PMID:30979932
    reference_title: Evidence for altered neurodevelopment and neurodegeneration in Wolfram syndrome using longitudinal morphometry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These patterns suggest that there may be early, stalled white matter development in Wolfram syndrome, with additional degenerative processes in both white and gray matter."
    explanation: >-
      States the authors' own two-process interpretation, which is the basis for
      the neurodevelopmental limb of this node.
phenotypes:
- name: Diabetes Mellitus
  category: Endocrine
  description: >-
    Insulin-requiring, autoantibody-negative diabetes mellitus, usually the first
    manifestation, presenting at a median age of 6 years. Antibody-negative
    insulin-dependent diabetes in a child is the single highest-yield trigger for
    considering this diagnosis.
  phenotype_term:
    preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-autoimmune, insulin-deficient diabetes mellitus presented at a median age of 6 years, followed by optic atrophy (11 years)."
    explanation: >-
      Establishes diabetes mellitus as the first manifestation with a median onset
      of 6 years in a national cohort.
  - reference: PMID:20301750
    reference_title: WFS1 Spectrum Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic WFS1-SD, a progressive neurodegenerative disorder, is characterized by onset of diabetes mellitus and optic atrophy before age 16 years."
    explanation: >-
      GeneReviews states diabetes mellitus before age 16 as a defining feature of
      classic disease, supporting a VERY_FREQUENT band.
- name: Optic Atrophy
  category: Ophthalmologic
  description: >-
    Progressive bilateral optic atrophy from retinal ganglion cell loss, presenting
    at a median age of 11 years and progressing to legal blindness. With diabetes
    mellitus it forms the diagnostic pair.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Juvenile-onset diabetes mellitus and optic atrophy are the best available diagnostic criteria for Wolfram syndrome, the differential diagnosis of which includes other causes of neurodegeneration."
    explanation: >-
      Establishes optic atrophy alongside juvenile diabetes as the diagnostic
      criterion pair.
  - reference: PMID:20301750
    reference_title: WFS1 Spectrum Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic WFS1-SD, a progressive neurodegenerative disorder, is characterized by onset of diabetes mellitus and optic atrophy before age 16 years."
    explanation: >-
      GeneReviews states optic atrophy before age 16 as a defining feature of
      classic disease.
  - reference: PMID:41870390
    reference_title: "Optic Atrophy in Wolfram Syndrome Type 1: A Retrospective Analysis of Visual Outcomes and Biomarker Correlates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-six patients (22 women, 14 men; median age 20 years) were identified. Median mutation severity score was 3.5. Vision loss occurred in 31 patients; in 3 patients it was the only major symptom, in 5 patients it preceded DM, and in 6 patients it occurred without DM."
    explanation: >-
      A recent genetically confirmed WS1 cohort documents vision loss in 31 of 36
      patients and shows that it can precede diabetes.
- name: Diabetes Insipidus
  subtype: WS1
  category: Endocrine
  description: >-
    Central (cranial) diabetes insipidus from involvement of the
    hypothalamo-neurohypophyseal axis, typically appearing in the second decade. On
    MRI the posterior pituitary bright spot is absent.
  phenotype_term:
    preferred_term: Diabetes insipidus
    term:
      id: HP:0000873
      label: Diabetes insipidus
    clinical_course: PROGRESSIVE
  frequency: FREQUENT
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cranial diabetes insipidus occurred in 33 patients (73%) with sensorineural deafness (28, 62%) in the second decade; renal-tract abnormalities (26, 58%) presented in the third decade followed by neurological complications"
    explanation: >-
      Cranial diabetes insipidus in 73% of 45 patients, within the FREQUENT band of
      30 to 79%.
- name: Sensorineural Hearing Impairment
  category: Otologic
  description: >-
    Slowly progressive sensorineural hearing loss, high-frequency in recessive
    Wolfram syndrome, typically appearing in the second decade. Cochlear
    implantation is used with reported good outcomes.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
    clinical_course: PROGRESSIVE
  frequency: FREQUENT
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cranial diabetes insipidus occurred in 33 patients (73%) with sensorineural deafness (28, 62%) in the second decade; renal-tract abnormalities (26, 58%) presented in the third decade followed by neurological complications"
    explanation: >-
      Sensorineural deafness in 62% of 45 patients, within the FREQUENT band.
- name: Abnormality of the Sense of Smell
  category: Neurologic
  description: >-
    Objective olfactory defects, including reduced or absent smell, are common and
    can be clinically overlooked.
  phenotype_term:
    preferred_term: Abnormality of the sense of smell
    term:
      id: HP:0004408
      label: Abnormality of the sense of smell
  frequency: FREQUENT
  evidence:
  - reference: PMID:23981289
    reference_title: Phenotypic characteristics of early Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seventeen (94%) had optic disc pallor and defects in color vision, 14 (78%) had hearing loss and 13 (72%) had olfactory defects, eight (44%) had impaired vibration sensation."
    explanation: >-
      Olfactory defects occurred in 13 of 18 participants (72%), within the
      FREQUENT band.
- name: Impaired Vibratory Sensation
  category: Neurologic
  description: >-
    Loss of vibration sensation is an early peripheral sensory finding in a
    substantial minority of patients.
  phenotype_term:
    preferred_term: Impaired vibratory sensation
    term:
      id: HP:0002495
      label: Impaired vibratory sensation
  frequency: FREQUENT
  evidence:
  - reference: PMID:23981289
    reference_title: Phenotypic characteristics of early Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seventeen (94%) had optic disc pallor and defects in color vision, 14 (78%) had hearing loss and 13 (72%) had olfactory defects, eight (44%) had impaired vibration sensation."
    explanation: >-
      Impaired vibration sensation occurred in 8 of 18 participants (44%), within
      the FREQUENT band.
- name: Hyporeflexia
  category: Neurologic
  description: >-
    Reduced deep-tendon reflexes are a frequent neurologic examination finding.
  phenotype_term:
    preferred_term: Hyporeflexia
    term:
      id: HP:0001265
      label: Hyporeflexia
  frequency: FREQUENT
  evidence:
  - reference: PMID:29728875
    reference_title: Natural history and clinical characteristics of 50 patients with Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 16.7% of the patients had positive albuminuria (urinary albumin/creatinine ratio > 30 mg/g) and 72.2% had hyporreflexia."
    explanation: >-
      Hyporeflexia was present in 72.2% of this molecularly studied cohort, within
      the FREQUENT band.
- name: Nystagmus
  category: Ophthalmologic
  description: >-
    Nystagmus accompanies the broader neuro-ophthalmic phenotype in a minority of
    patients.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:23981289
    reference_title: Phenotypic characteristics of early Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormalities in visual acuity and color vision were present in 17 (94%). Abnormal pupillary response, nystagmus, and cataracts were present in 11 (61%), five (28%), and five (28%), respectively."
    explanation: >-
      Nystagmus occurred in 5 of 18 participants (28%), within the OCCASIONAL band.
- name: Cataract
  category: Ophthalmologic
  description: >-
    Cataracts are a non-core but recurrent ophthalmic finding and should not be
    conflated with the optic neuropathy that defines the syndrome.
  phenotype_term:
    preferred_term: Cataract
    term:
      id: HP:0000518
      label: Cataract
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:23981289
    reference_title: Phenotypic characteristics of early Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormalities in visual acuity and color vision were present in 17 (94%). Abnormal pupillary response, nystagmus, and cataracts were present in 11 (61%), five (28%), and five (28%), respectively."
    explanation: >-
      Cataracts occurred in 5 of 18 participants (28%), within the OCCASIONAL band.
- name: Tremor
  category: Neurologic
  description: >-
    Tremor, including intention tremor, occurs within the progressive neurologic
    phenotype. A legacy HPO annotation reports a grouped frequency, but the
    underlying individual frequency could not be verified from accessible source
    text, so no frequency band is assigned here.
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: PMID:23981289
    reference_title: Phenotypic characteristics of early Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Increased tone lower extremities; intention tremor"
    explanation: >-
      Direct neurologic examination documented intention tremor in an affected
      participant; the study text does not support a population frequency band.
- name: Peripheral Neuropathy
  category: Neurologic
  description: >-
    Peripheral neuropathy is part of the neurologic spectrum and is represented
    separately from the directly quantified impaired vibration sensation and
    hyporeflexia findings.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:9817917
    reference_title: "Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Wolfram syndrome is an autosomal recessive disorder characterized by juvenile diabetes mellitus, diabetes insipidus, optic atrophy and a number of neurological symptoms including deafness, ataxia and peripheral neuropathy."
    explanation: >-
      The WFS1 gene-identification cohort explicitly includes peripheral neuropathy
      in the neurologic phenotype.
- name: Cognitive Impairment
  category: Neurologic
  description: >-
    Cognitive impairment can accompany early or extensive neurologic disease but
    is not a universal core feature. The available 32% estimate applies only to
    patients who already had neurologic signs, so it is not converted to a
    whole-disease frequency band.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:21446023
    reference_title: Neurologic features and genotype-phenotype correlation in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cognitive impairment, which was not frequent in previous reports, was observed in 32% of patients with neurologic signs."
    explanation: >-
      Directly quantifies cognitive impairment within the neurologically affected
      subgroup while precluding a whole-cohort frequency inference.
- name: Seizure
  category: Neurologic
  description: >-
    Epileptic seizures occur in a minority and cluster in patients whose neurologic
    manifestations begin before age 15. A disease-wide frequency is not assigned
    because the accessible primary abstract does not provide one.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:21446023
    reference_title: Neurologic features and genotype-phenotype correlation in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Like epilepsy, it was mainly found in patients who developed neurologic signs before 15 years of age."
    explanation: >-
      Links epilepsy to the early-neurologic-onset subgroup in the 59-patient
      neurologic cohort.
- name: Growth Delay
  category: Growth
  description: >-
    Growth retardation and growth hormone deficiency are reported, although most
    affected individuals reach an adult height within the normal range and a
    robust disease-wide frequency is not established.
  phenotype_term:
    preferred_term: Growth delay
    term:
      id: HP:0001510
      label: Growth delay
  evidence:
  - reference: PMID:39527371
    reference_title: SID/SIEDP expert consensus on optimizing clinical strategies for early detection and management of wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some individuals with WFS experience growth retardation, although most achieve an adult height within the normal range. Cases of growth hormone deficiency have been reported, highlighting another aspect of the syndrome’s complexity."
    explanation: >-
      Current expert consensus directly supports growth retardation while noting
      normal adult height in most patients.
- name: Neurogenic Bladder
  category: Genitourinary
  description: >-
    Atonic neurogenic bladder appearing in the third decade, with hydroureter and
    hydronephrosis. Lower urinary tract dysfunction can progress to obstructive
    uropathy and renal failure; urodynamic evaluation and clean intermittent
    catheterization are used for hypocontractile bladder.
  phenotype_term:
    preferred_term: Neurogenic bladder
    term:
      id: HP:0000011
      label: Neurogenic bladder
    clinical_course: PROGRESSIVE
  frequency: FREQUENT
  evidence:
  - reference: PMID:29728875
    reference_title: Natural history and clinical characteristics of 50 patients with Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The remaining criteria were present with a variable frequency: 77% had diabetes insipidus, 66.7% auditory alterations, 77.8% neurogenic bladder, 61.1% neurological involvement, and 27.8% hypogonadism."
    explanation: >-
      Neurogenic bladder itself occurred in 77.8% of the cohort, within the
      FREQUENT band; this replaces an indirect grouped renal-tract statistic.
  - reference: PMID:38465704
    reference_title: Long term clinical follow up of four patients with Wolfram syndrome and urodynamic abnormalities.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with hypocontractile bladder were taught clean intermittent catheterization and the use of overnight drain."
    explanation: >-
      Directly documents clean intermittent catheterization for urodynamically
      confirmed hypocontractile bladder in a prospective case series.
- name: Hydronephrosis
  category: Renal
  description: >-
    Upper urinary tract dilatation secondary to bladder atony and outflow
    obstruction, with recurrent urinary tract infection and progression to renal
    impairment.
  phenotype_term:
    preferred_term: Hydronephrosis
    term:
      id: HP:0000126
      label: Hydronephrosis
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cranial diabetes insipidus occurred in 33 patients (73%) with sensorineural deafness (28, 62%) in the second decade; renal-tract abnormalities (26, 58%) presented in the third decade followed by neurological complications"
    explanation: >-
      The cohort reports renal-tract abnormalities as a category. PARTIAL because
      hydronephrosis specifically is not separately enumerated, so no frequency
      band is assigned here.
- name: Ataxia
  category: Neurologic
  description: >-
    Cerebellar ataxia appearing with the neurological phase in the fourth decade,
    alongside myoclonus, and tracking the cerebellar and brainstem volume loss
    visible on imaging far earlier.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cranial diabetes insipidus occurred in 33 patients (73%) with sensorineural deafness (28, 62%) in the second decade; renal-tract abnormalities (26, 58%) presented in the third decade followed by neurological complications (cerebellar ataxia, myoclonus [28, 62%]) in the fourth decade."
    explanation: >-
      Places ataxia among the fourth-decade neurological complications. The 62%
      figure applies to neurological complications as a group, so this entry does
      not assign an individual ataxia frequency.
- name: Myoclonus
  category: Neurologic
  description: >-
    Myoclonus appears alongside cerebellar ataxia as part of the neurological
    phase in the fourth decade. Its individual frequency was not reported in the
    UK national cohort.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "renal-tract abnormalities (26, 58%) presented in the third decade followed by neurological complications (cerebellar ataxia, myoclonus [28, 62%]) in the fourth decade."
    explanation: >-
      Names myoclonus among the fourth-decade neurological complications. The 62%
      figure applies to neurological complications as a group, so this entry does
      not assign an individual myoclonus frequency.
- name: Dysarthria
  category: Neurologic
  description: >-
    Bulbar dysfunction from brainstem involvement produces progressive dysarthria
    in advanced disease.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:39527371
    reference_title: SID/SIEDP expert consensus on optimizing clinical strategies for early detection and management of wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "WFS is also associated with central nervous system abnormalities like anosmia, ataxia, seizures, nystagmus, gaze palsies, dysarthria, dysphagia, psychiatric disturbances, cognitive impairment, and others."
    explanation: >-
      Current expert consensus explicitly includes dysarthria among the central
      nervous system manifestations.
- name: Dysphagia
  category: Gastrointestinal
  description: >-
    Swallowing difficulty from brainstem and bulbar involvement in advanced
    disease, carrying aspiration risk.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:39527371
    reference_title: SID/SIEDP expert consensus on optimizing clinical strategies for early detection and management of wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "WFS is also associated with central nervous system abnormalities like anosmia, ataxia, seizures, nystagmus, gaze palsies, dysarthria, dysphagia, psychiatric disturbances, cognitive impairment, and others."
    explanation: >-
      Current expert consensus explicitly includes dysphagia among the central
      nervous system manifestations.
- name: Gastrointestinal Dysmotility
  category: Gastrointestinal
  description: >-
    Constipation, diarrhea, gastroparesis, and other intestinal motility disorders
    form a distinct autonomic gastrointestinal phenotype.
  phenotype_term:
    preferred_term: Gastrointestinal dysmotility
    term:
      id: HP:0002579
      label: Gastrointestinal dysmotility
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other abnormalities included gastrointestinal dysmotility in 11 (24%), and primary gonadal atrophy in seven of ten males investigated."
    explanation: >-
      Gastrointestinal dysmotility occurred in 11 of 45 participants (24%), within
      the OCCASIONAL band.
- name: Central Apnea
  subtype: WS1
  category: Respiratory
  description: >-
    Loss of central respiratory drive from brainstem degeneration is a severe late
    neurologic manifestation and contributes to the characteristic respiratory
    mortality. A precise phenotype-specific frequency is not available.
  phenotype_term:
    preferred_term: Central apnea
    term:
      id: HP:0002871
      label: Central apnea
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:39527371
    reference_title: SID/SIEDP expert consensus on optimizing clinical strategies for early detection and management of wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological and autonomic disorders include central apnea, ataxia, dysphagia, areflexia, epilepsy, decreased ability to taste and detect odors, headaches, orthostatic hypotension, hyperpyrexia, hypothermia, constipation, gastroparesis."
    explanation: >-
      Current expert consensus explicitly identifies central apnea as a neurologic
      and autonomic manifestation.
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Median age at death (commonly central respiratory failure with brain-stem atrophy) was 30 years (range 25-49)."
    explanation: >-
      Links loss of central respiratory drive to brainstem atrophy and mortality in
      the national cohort.
- name: Peptic Ulcer
  subtype: WS2
  category: Gastrointestinal
  description: >-
    Peptic ulcer disease is a characteristic discriminator of CISD2-related
    Wolfram syndrome 2.
  phenotype_term:
    preferred_term: Peptic ulcer
    term:
      id: HP:0004398
      label: Peptic ulcer
  evidence:
  - reference: PMID:28335035
    reference_title: A novel CISD2 mutation associated with a classical Wolfram syndrome phenotype alters Ca2+ homeostasis and ER-mitochondria interactions.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The defining diagnostic criteria for WFS2 also consist of optic atrophy and diabetes mellitus, but unlike WFS1, this phenotypic subgroup has been associated with peptic ulcer disease and an increased bleeding tendency."
    explanation: >-
      Directly identifies peptic ulcer disease as a WFS2-associated discriminator.
- name: Abnormal Bleeding
  subtype: WS2
  category: Hematologic
  description: >-
    Increased bleeding tendency is a characteristic discriminator of
    CISD2-related Wolfram syndrome 2.
  phenotype_term:
    preferred_term: Abnormal bleeding
    term:
      id: HP:0001892
      label: Abnormal bleeding
  evidence:
  - reference: PMID:28335035
    reference_title: A novel CISD2 mutation associated with a classical Wolfram syndrome phenotype alters Ca2+ homeostasis and ER-mitochondria interactions.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The defining diagnostic criteria for WFS2 also consist of optic atrophy and diabetes mellitus, but unlike WFS1, this phenotypic subgroup has been associated with peptic ulcer disease and an increased bleeding tendency."
    explanation: >-
      Directly identifies increased bleeding tendency as a WFS2-associated
      discriminator.
- name: Brain Atrophy
  category: Neurologic
  description: >-
    Reduced intracranial volume with preferential brainstem, ventral pontine, and
    cerebellar loss, detectable on MRI even in the youngest and mildest patients.
    Bound to the compartment-neutral HP:0012444 rather than the forebrain-specific
    cerebral atrophy term, because the affected territory here is brainstem and
    cerebellum, and the brainstem is the compartment that determines survival.
  phenotype_term:
    preferred_term: Brain atrophy
    term:
      id: HP:0012444
      label: Brain atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:22792385
    reference_title: Early brain vulnerability in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results establish that WFS is associated with smaller intracranial volume with specific abnormalities in the brainstem and cerebellum, even at the earliest stage of clinical symptoms."
    explanation: >-
      Documents reduced intracranial volume with regional brainstem and cerebellar
      abnormality at the earliest clinical stage.
- name: Depression
  category: Psychiatric
  description: >-
    Psychiatric involvement is substantial and under-recognized. Depression and
    anxiety are prominent, alongside psychosis, memory deficits, irritability, and
    impulsive aggression, and suicide is a documented cause of death. Proactive
    depression screening and suicide-risk assessment are arguably the most
    under-implemented preventive measure in this disease.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:22792385
    reference_title: Early brain vulnerability in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared to normative data, the WFS group had intact cognition, significant anxiety and depression, and gait abnormalities."
    explanation: >-
      Documents significant anxiety and depression against normative data, with
      cognition intact at this stage.
  - reference: PMID:12707947
    reference_title: "Wolfram syndrome and suicide: Evidence for a role of WFS1 in suicidal and impulsive behavior."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is evidence suggesting that subjects affected with the Wolfram syndrome (WFS) and normal carriers present an increased risk of psychiatric disorders, particularly depression and suicidal behavior."
    explanation: >-
      Records the elevated psychiatric and suicidality risk in Wolfram syndrome.
      PARTIAL because this study's own measurements were made in a general
      suicide-victim cohort genotyped at WFS1 rather than in patients with Wolfram
      syndrome, so it substantiates a role for WFS1 rather than a rate in this
      disease.
- name: Anxiety
  subtype: WS1
  category: Psychiatric
  description: >-
    Anxiety is a prominent psychiatric manifestation of WS1. A recent narrative
    review reports a 77% estimate from prior patient literature; because the
    review does not reproduce the cohort denominator or ascertainment method, the
    value supports a broad frequency band rather than a precise disease-wide rate.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  frequency: FREQUENT
  evidence:
  - reference: PMID:39202345
    reference_title: "Wolfram Syndrome 1: A Neuropsychiatric Perspective on a Rare Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some authors found that 77% of WS1 patients had anxiety as their prevalent symptom."
    explanation: >-
      The review reports anxiety in 77% of WS1 patients, within the FREQUENT band;
      the secondary-source context precludes treating 77% as a pooled prevalence.
- name: Obstructive Sleep Apnea
  subtype: WS1
  category: Respiratory
  description: >-
    Obstructive sleep apnea is reported in adults and children with WS1. The adult
    estimate of 29.4% lies in the OCCASIONAL band; a reported 100% pediatric rate
    comes from a separate, evidently small age-stratified sample and is not applied
    as an all-ages frequency.
  phenotype_term:
    preferred_term: Obstructive sleep apnea
    term:
      id: HP:0002870
      label: Obstructive sleep apnea
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:39202345
    reference_title: "Wolfram Syndrome 1: A Neuropsychiatric Perspective on a Rare Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adults and children with WS1 had significantly higher OSA rates than the general population (29.4% vs. 2–7% for adults, and 100% vs. 1–5% for children)."
    explanation: >-
      The adult WS1 rate of 29.4% supports OCCASIONAL; the distinct pediatric
      estimate is retained in the explanation rather than conflated into one
      disease-wide percentage.
- name: Testicular Atrophy
  category: Endocrine
  description: >-
    Primary gonadal atrophy, reported in the majority of males investigated in the
    UK national cohort, with menstrual irregularity described in females.
  phenotype_term:
    preferred_term: Testicular atrophy
    term:
      id: HP:0000029
      label: Testicular atrophy
  frequency: FREQUENT
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other abnormalities included gastrointestinal dysmotility in 11 (24%), and primary gonadal atrophy in seven of ten males investigated."
    explanation: >-
      Primary gonadal atrophy in 7 of 10 males investigated (70%), within the
      FREQUENT band of 30 to 79%.
biochemical:
- name: Elevated Serum Neurofilament Light Chain
  presence: INCREASED
  context: >-
    Serum neurofilament light chain, a marker of neuroaxonal damage, is elevated in
    Wolfram syndrome relative to parents, unaffected siblings, and individuals with
    and without newly diagnosed type 1 diabetes, whereas glial fibrillary acidic
    protein is not. The specificity is informative about the biology, since it
    points to axonal injury rather than reactive astrogliosis. Its utility as a
    progression marker is limited, however, because levels did not change over time
    and did not correlate reliably with clinical or neuroimaging severity.
  evidence:
  - reference: PMID:41929703
    reference_title: Neurofilament light chain but not glial fibrillary acidic protein serum levels are elevated in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NfL levels were higher in the Wolfram group relative to all control groups (p < 0.001, η p 2  = 0.51) after adjusting for age and sex, whereas GFAP levels were not different between any of the groups."
    explanation: >-
      Establishes elevated serum neurofilament light chain with unchanged glial
      fibrillary acidic protein.
  - reference: PMID:41929703
    reference_title: Neurofilament light chain but not glial fibrillary acidic protein serum levels are elevated in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Within the Wolfram group, neither NfL nor GFAP levels changed over time, and NfL levels did not correlate reliably with any measures of clinical disease severity or neurodegeneration (p > 0.05 after excluding outliers)."
    explanation: >-
      Qualifies the marker: elevated but not tracking progression, so it is a state
      marker rather than a monitoring biomarker.
genetic:
- name: WFS1 Biallelic Loss of Function
  gene_term:
    preferred_term: WFS1
    term:
      id: hgnc:12762
      label: WFS1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: WS1
  features: >-
    WFS1 lies at chromosome 4p16.1 and encodes wolframin, an endoplasmic reticulum
    transmembrane glycoprotein. More than 200 distinct variants have been reported,
    the majority loss of function (nonsense, frameshift, splice-site) with a
    substantial missense contingent in the C-terminal luminal domain. Biallelic
    loss of function accounts for roughly 90% of Wolfram syndrome. Genotype and
    phenotype correlation is emerging rather than settled.
  frequency: OBLIGATE
  evidence:
  - reference: PMID:9771706
    reference_title: A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in a novel gene (WFS1) encoding a putative transmembrane protein were found in all affected individuals in six WFS families, and these mutations were associated with the disease phenotype."
    explanation: >-
      Establishes WFS1 variants as causative in all affected individuals across six
      families.
  - reference: PMID:23429432
    reference_title: "Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More than 200 different variations in WFS1 have been described in patients with Wolfram syndrome, which complicates the establishment of clear genotype-phenotype correlation."
    explanation: >-
      Documents the allelic heterogeneity that makes genotype and phenotype
      correlation difficult.
  - reference: PMID:23429432
    reference_title: "Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "(i) 15% of published patients do not fulfill the current -inclusion criterion; (ii) genotypic prevalence differences may exist among countries; (iii) diabetes mellitus and optic atrophy might not be the first two clinical features in some patients; (iv) mutations are nonuniformly distributed in WFS1; (v) age at onset of diabetes mellitus, hearing defects, and diabetes insipidus may depend on the patient's genotypic class; and (vi) disease progression rate might depend on genotypic class."
    explanation: >-
      Meta-analysis of 412 patients reporting that onset age and progression rate
      may depend on genotypic class, and that the canonical presentation order is
      not universal.
- name: CISD2 Biallelic Loss of Function
  gene_term:
    preferred_term: CISD2
    term:
      id: hgnc:24212
      label: CISD2
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: WS2
  features: >-
    CISD2 (also ZCD2, ERIS, Miner1) encodes a small protein of the
    mitochondria-associated endoplasmic reticulum membrane. The originally
    described homozygous missense change acts not through the amino acid
    substitution but by disrupting splicing, eliminating exon 2 and introducing a
    premature stop codon. CISD2 variants cause Wolfram syndrome 2 in families
    mapped to 4q22-25 who have no WFS1 variant.
  evidence:
  - reference: PMID:17846994
    reference_title: "A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A single missense mutation was identified in a novel, highly conserved zinc-finger gene, ZCD2, in three consanguineous families of Jordanian descent with Wolfram syndrome (WFS)."
    explanation: >-
      The gene-identification study for Wolfram syndrome 2.
  - reference: PMID:17846994
    reference_title: "A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mutation was found to disrupt messenger RNA splicing by eliminating exon 2, and it results in the introduction of a premature stop codon."
    explanation: >-
      Establishes that the functional consequence is a splicing defect producing a
      premature stop, not a missense effect.
inheritance:
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Classic Wolfram syndrome, both WFS1-related and CISD2-related, is autosomal
    recessive. UK family studies indicate a carrier frequency of about 1 in 354,
    with no maternal history of diabetes or deafness and no mitochondrial tRNA-Leu
    3243 variant, which is what separates this from the maternally inherited
    mitochondrial mimics. Consanguinity is a major driver of case load in regions
    where it is common. Heterozygous WFS1 variants cause a separate, dominantly
    inherited spectrum that is out of scope for this entry.
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Family studies indicate autosomal recessive inheritance with a carrier frequency of one in 354, an absence of a maternal history of diabetes or deafness, and an absence of the mitochondrial tRNA Leu (3243) mutation."
    explanation: >-
      Establishes autosomal recessive inheritance and the carrier frequency, and
      excludes the mitochondrial mimic.
prevalence:
- population: United Kingdom
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_per_100000: 0.13
  notes: >-
    One per 770,000 from a UK nationwide cross-sectional case-finding study
    identifying 45 patients. Carrier frequency about 1 in 354.
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified 45 patients with Wolfram syndrome--a prevalence of one per 770,000."
    explanation: >-
      Gives the UK nationwide prevalence estimate.
- population: Messina district, north-eastern Sicily
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 1.84
  notes: >-
    One in 54,478 in the Messina district of Sicily against one in 1,351,000 for
    Italy nationally and one in 770,000 for the UK. The roughly 25-fold spread
    between a consanguineous or founder population and a national estimate is a
    finding about population structure, not measurement noise, so a prevalence
    figure for this disease should never be quoted without the population attached.
  evidence:
  - reference: PMID:39527371
    reference_title: SID/SIEDP expert consensus on optimizing clinical strategies for early detection and management of wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More recently, the estimated prevalence was 1 in 54.478 in the Messina district of north-eastern Sicily, 1 in 805.000 in Northern India, and 1 in 1.351.000 in Italy [7–9]."
    explanation: >-
      Gives the Sicilian, Northern Indian, and Italian national prevalence
      estimates side by side, which is what makes the spread visible.
progression:
- phase: First decade - diabetes and optic atrophy
  subtype: WS1
  notes: >-
    Insulin-requiring non-autoimmune diabetes mellitus at a median of 6 years,
    followed by optic atrophy at a median of 11 years. Brainstem and cerebellar
    volume abnormalities are already measurable at this stage, before the
    corresponding symptoms appear.
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-autoimmune, insulin-deficient diabetes mellitus presented at a median age of 6 years, followed by optic atrophy (11 years)."
    explanation: >-
      Gives the median onset ages of the two defining features.
- phase: Second decade - diabetes insipidus and deafness
  subtype: WS1
  notes: >-
    Cranial diabetes insipidus and sensorineural deafness appear in the second
    decade, in 73% and 62% of the UK cohort respectively.
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cranial diabetes insipidus occurred in 33 patients (73%) with sensorineural deafness (28, 62%) in the second decade; renal-tract abnormalities (26, 58%) presented in the third decade followed by neurological complications"
    explanation: >-
      Gives the decade-by-decade order and frequencies of the later features.
- phase: Third and fourth decades - urological and neurological
  subtype: WS1
  notes: >-
    Renal-tract abnormalities in the third decade (58%), then neurological
    complications including cerebellar ataxia and myoclonus in the fourth decade
    (62%). Death, most often from central respiratory failure with brainstem
    atrophy, occurred at a median age of 30 years with a range of 25 to 49 in the
    UK cohort.
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Median age at death (commonly central respiratory failure with brain-stem atrophy) was 30 years (range 25-49)."
    explanation: >-
      Gives median age and cause of death in the UK national cohort.
clinical_burden:
  burden_level: HIGH
  rationale: >-
    By the third decade a typical WS1 patient carries insulin-dependent diabetes, legal
    blindness, significant hearing loss, incontinence, and progressive gait and
    speech impairment at the same time, and these do not merely add: losing vision
    and hearing together removes both compensatory channels at once. Median age at
    death was 30 years in the UK national cohort, usually from central respiratory
    failure with brainstem atrophy, and suicide is a documented additional cause.
    No approved disease-modifying therapy exists anywhere.
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The natural history of Wolfram syndrome suggests that most patients will eventually develop most complications of this progressive, neurodegenerative disorder."
    explanation: >-
      Establishes the cumulative, multi-domain nature of the disability.
  - reference: PMID:39202345
    reference_title: "Wolfram Syndrome 1: A Neuropsychiatric Perspective on a Rare Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The rapid clinical course of WS1 results in death by the age of 30. Severe brain atrophy leads to central respiratory failure, which is the main cause of death in WS1 patients."
    explanation: >-
      States the age at death and the dominant mechanism of mortality.
diagnosis:
- name: Clinical Diagnostic Criteria
  description: >-
    Insulin-requiring diabetes mellitus plus optic atrophy, both with onset before
    age 16 and no alternative explanation, is the operative clinical rule. The
    diabetes workup is what separates this from type 1 diabetes: islet
    autoantibodies are negative, there is no HLA-DR3 or DR4 risk association, and
    C-peptide is preserved longer.
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Juvenile-onset diabetes mellitus and optic atrophy are the best available diagnostic criteria for Wolfram syndrome, the differential diagnosis of which includes other causes of neurodegeneration."
    explanation: >-
      States the clinical criterion pair and flags the neurodegenerative
      differential.
- name: Molecular Genetic Testing
  description: >-
    Sequencing of WFS1 is the diagnostic gold standard when the picture is classic,
    with multigene panels for partial presentations and exome or genome sequencing
    for atypical cases, which is also how CISD2 cases are found. Chromosomal
    microarray, karyotype, and repeat-expansion testing have no role; mitochondrial
    DNA testing is indicated only to exclude mimics. The current Italian expert
    consensus explicitly recommends folding genetic testing into the diagnostic
    protocol rather than treating it as confirmatory afterthought.
  evidence:
  - reference: PMID:20301750
    reference_title: WFS1 Spectrum Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis is established in a proband with suggestive findings and biallelic pathogenic (or likely pathogenic) variants in WFS1 identified by molecular genetic testing."
    explanation: >-
      GeneReviews states that molecular identification of biallelic WFS1 variants
      establishes the diagnosis.
  - reference: PMID:39527371
    reference_title: SID/SIEDP expert consensus on optimizing clinical strategies for early detection and management of wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The consensus recommends the revision of diagnostic protocols to include genetic testing and comprehensive multidisciplinary evaluations to ensure accurate diagnosis of WFS, advocates for personalized management plans tailored to the unique needs of each patient, with an emphasis on exploring new potential drug therapies."
    explanation: >-
      Current expert consensus recommending genetic testing within the diagnostic
      protocol.
- name: Brain MRI
  description: >-
    MRI shows an absent posterior pituitary bright spot on T1, the hallmark of
    central diabetes insipidus, together with brainstem, ventral pontine, and
    cerebellar atrophy and thinning of the optic nerves, chiasm, and tracts. Volume
    abnormalities are detectable at the earliest clinical stage, which makes serial
    imaging the leading candidate progression measure for trials.
  evidence:
  - reference: PMID:22792385
    reference_title: Early brain vulnerability in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results establish that WFS is associated with smaller intracranial volume with specific abnormalities in the brainstem and cerebellum, even at the earliest stage of clinical symptoms."
    explanation: >-
      Supports MRI detection of the characteristic regional abnormalities from the
      earliest clinical stage.
- name: Optical Coherence Tomography
  description: >-
    Optical coherence tomography quantifies retinal nerve fiber layer and ganglion
    cell complex thinning. Together with best-corrected visual acuity, these
    structural measures support longitudinal monitoring of optic neuropathy; their
    prognostic role remains promising rather than fully validated.
  evidence:
  - reference: PMID:41870390
    reference_title: "Optic Atrophy in Wolfram Syndrome Type 1: A Retrospective Analysis of Visual Outcomes and Biomarker Correlates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BCVA correlated inversely with RNFL thickness ( P = 0.0017, R 2 = 0.14), GCC thickness ( P = 0.0018, R 2 = 0.29), and mutation severity score ( P = 0.031, R 2 = 0.14)."
    explanation: >-
      Correlations in a retrospective WS1 cohort support OCT measures as monitoring
      biomarkers, but do not yet validate them as surrogate endpoints.
treatments:
- name: Insulin Therapy
  description: >-
    Insulin replacement, by multiple daily injections or pump, with continuous
    glucose monitoring. The diabetes is insulin-deficient and non-autoimmune, so
    management follows type 1 diabetes practice while the underlying beta cell loss
    is mechanistically different. Insulin replaces the missing hormone and does
    nothing to slow beta cell loss.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Insulin Deficiency
    treatment_effect: RESTORES
    description: >-
      Exogenous insulin restores the hormone that surviving beta cells can no
      longer supply, without acting on the cell loss itself.
  evidence:
  - reference: PMID:39527371
    reference_title: SID/SIEDP expert consensus on optimizing clinical strategies for early detection and management of wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nearly all diagnosed individuals require insulin therapy to manage their condition."
    explanation: >-
      Current expert consensus directly states that nearly all diagnosed
      individuals require insulin therapy.
- name: Desmopressin for Central Diabetes Insipidus
  description: >-
    In WS1, desmopressin replaces vasopressin lost with degeneration of the
    hypothalamo-neurohypophyseal axis. In a prospective four-patient case series,
    three children with persistent polyuria and polydipsia despite optimized
    glycemic control were diagnosed with diabetes insipidus and treated with
    desmopressin.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:38465704
    reference_title: Long term clinical follow up of four patients with Wolfram syndrome and urodynamic abnormalities.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three children had persistent polyuria and polydipsia despite having optimum glycemic control; hence were diagnosed to have DI and treated with desmopressin."
    explanation: >-
      Directly documents desmopressin treatment of central diabetes insipidus in a
      prospective Wolfram syndrome case series.
- name: Multidisciplinary Supportive Care
  description: >-
    There is no cure. Care is supportive and multidisciplinary, spanning diabetes
    care, endocrinology, ophthalmology and low vision, audiology and cochlear
    implantation, speech and language therapy, neurology, pulmonology, psychiatry,
    urology, gastroenterology, social work, and medical genetics, with regular
    surveillance for emerging manifestations. Urodynamic assessment with clean
    intermittent catheterization for hypocontractile bladder and proactive
    psychiatric and suicide-risk assessment are important components.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301750
    reference_title: WFS1 Spectrum Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is no cure for WFS1-SD."
    explanation: >-
      States plainly that no curative therapy exists, which is why care is
      supportive.
  - reference: PMID:20301750
    reference_title: WFS1 Spectrum Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Surveillance: For both classic and nonclassic WFS1-SD, regular monitoring of existing manifestations, the response of an individual to supportive care, and the emergence of new manifestations is recommended."
    explanation: >-
      Establishes regular surveillance as the recommended management framework.
  - reference: PMID:38465704
    reference_title: Long term clinical follow up of four patients with Wolfram syndrome and urodynamic abnormalities.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with hypocontractile bladder were taught clean intermittent catheterization and the use of overnight drain."
    explanation: >-
      Provides direct clinical evidence for catheter-based management of
      hypocontractile bladder.
- name: Genetic Counseling and Cascade Testing
  description: >-
    Autosomal recessive counseling with a 25% recurrence risk per pregnancy for
    carrier couples, plus cascade testing of siblings, which is the population in
    whom early diagnosis is actually achievable. Prenatal and preimplantation
    testing are possible once the familial variants are known. Counseling arithmetic
    differs completely if the family variant belongs to the dominant WFS1 allelic
    series, and misclassifying which series a family is in is a real counseling
    error.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301750
    reference_title: WFS1 Spectrum Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "If both parents are known to be heterozygous for a WFS1 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of inheriting neither of the familial pathogenic variants."
    explanation: >-
      Gives the recurrence risk figures that drive counseling.
  - reference: PMID:20301750
    reference_title: WFS1 Spectrum Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Evaluation of relatives at risk: It is appropriate to clarify the genetic status of apparently asymptomatic at-risk relatives in order to identify as early as possible those who would benefit from prompt initiation of treatment for the earliest manifestations of WFS1-SD: diabetes mellitus, optic atrophy, and sensorineural hearing loss."
    explanation: >-
      Supports cascade testing of at-risk relatives as the route to early
      intervention.
- name: Dantrolene Sodium
  description: >-
    A ryanodine-receptor blocker trialed on the endoplasmic-reticulum-calcium
    stabilizer rationale, and the first clinical trial ever conducted in Wolfram
    syndrome. It was safe and well tolerated, and it did not work: beta cell
    function was not significantly improved overall, and neither visual acuity nor
    neurological function improved at six months. Recorded here because a negative
    result in a disease with no therapy is information, not an absence of it.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Cytosolic Calcium Dysregulation
    treatment_effect: INHIBITS
    description: >-
      Dantrolene inhibits ryanodine-receptor-mediated endoplasmic reticulum calcium
      efflux, the intended point of action on this node. The pharmacology is
      unambiguous; the clinical trial nonetheless showed no benefit.
  evidence:
  - reference: PMID:34185708
    reference_title: A phase Ib/IIa clinical trial of dantrolene sodium in patients with Wolfram syndrome.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Dantrolene sodium was well tolerated by Wolfram syndrome patients. Overall, β cell functions were not significantly improved, but there was a significant correlation between baseline β cell functions and change in β cell responsiveness (R2, P = 0.004) after 6-month dantrolene therapy."
    explanation: >-
      Reports tolerability but no significant overall improvement in beta cell
      function, refuting an efficacy claim.
  - reference: PMID:34185708
    reference_title: A phase Ib/IIa clinical trial of dantrolene sodium in patients with Wolfram syndrome.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Visual acuity and neurological functions were not improved by 6-month dantrolene sodium."
    explanation: >-
      Directly refutes benefit on the visual and neurological endpoints.
- name: Sodium Phenylbutyrate and Taurursodiol
  description: >-
    An oral combination of a chemical chaperone and an endoplasmic-reticulum-stress
    and apoptosis modulator, acting on the pathway wolframin normally regulates.
    The HELIOS trial reported improved or stabilized pancreatic function, vision,
    and symptom burden at 24 and 48 weeks: stimulated C-peptide (the primary
    endpoint) and the glycemic secondary endpoints improved from baseline, visual
    acuity trended toward stabilization, and every assessable participant was a
    responder on both global-impression scales. Tolerability was acceptable —
    adverse events in eleven of twelve participants, all mild or moderate and
    mostly gastrointestinal, with dose interruption or reduction in three each but
    no discontinuations, serious events, or deaths. The design ceiling has to
    travel with the result: single-center, single-arm, open-label, twelve
    participants, no placebo. Graded PARTIAL for that reason, and the objective
    endpoints are curated separately from the unblinded global-impression scales
    because the latter are the ones open-label expectancy most easily inflates.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Unrestrained ER Stress Signaling Through ATF6-alpha
    treatment_effect: MODULATES
    description: >-
      Phenylbutyrate acts as a chemical chaperone and taurursodiol modulates
      endoplasmic reticulum stress and apoptosis, targeting the pathway wolframin
      normally restrains. MODULATES rather than INHIBITS because the human
      evidence is a single-arm open-label trial that cannot establish the
      direction of effect on this node.
  - target: Mitochondrial Dysfunction
    treatment_effect: MODULATES
    description: >-
      The combination is described as targeting dysfunctional mitochondrial
      pathways alongside the endoplasmic-reticulum arm, taurursodiol being the
      component associated with mitochondrial effects. This link records the
      second half of the drug's stated mechanism, which the entry previously left
      unattached. MODULATES for the same reason as the ER node: no trial readout
      measures mitochondrial function.
    evidence:
    - reference: PMID:42138079
      reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "An investigational oral combination of sodium phenylbutyrate and taurursodiol (PB&TURSO) targets dysfunctional ER and mitochondrial pathways to reduce pancreatic β cell and neuronal death"
      explanation: >-
        Names the mitochondrial arm of the mechanism. PARTIAL because this is the
        trial report's mechanistic framing citing prior work, not a measurement
        made in this trial.
  - target: Beta Cell Apoptosis
    treatment_effect: INHIBITS
    description: >-
      The stated purpose of acting on the ER and mitochondrial pathways is to
      reduce pancreatic beta cell death. INHIBITS is used here, unlike the two
      upstream nodes, because the trial's primary endpoint is a direct functional
      readout of surviving beta cell mass — stimulated C-peptide — and it improved
      from baseline at both 24 and 48 weeks. The uncontrolled design still means
      this is a within-participant change, not a demonstrated causal effect.
      One caveat belongs on the direction itself: reduced apoptosis predicts
      arrested decline, whereas C-peptide *improving* from baseline is at least as
      consistent with recovered secretory function in beta cells that were still
      alive. The INHIBITS direction therefore rests on the drug's stated mechanism,
      which names cell death explicitly, with the C-peptide result as functional
      corroboration rather than as a measurement of apoptosis.
    evidence:
    - reference: PMID:42138079
      reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "An investigational oral combination of sodium phenylbutyrate and taurursodiol (PB&TURSO) targets dysfunctional ER and mitochondrial pathways to reduce pancreatic β cell and neuronal death"
      explanation: >-
        The only statement in the source that names beta cell death, and therefore
        what the INHIBITS direction is evidenced on. PARTIAL because it is the trial
        report's mechanistic framing citing prior work, not a measurement made here.
    - reference: PMID:42138079
      reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The primary efficacy endpoint — C-peptide response at 120 minutes during a mixed-meal tolerance test (MMTT) — showed overall improvement from baseline at weeks 24 and 48."
      explanation: >-
        Functional corroboration: the primary endpoint indexes residual beta cell
        mass. It does not measure apoptosis, and is PARTIAL for the further reason
        that a single-arm open-label design cannot separate treatment effect from
        natural variation.
  - target: Retinal Ganglion Cell and CNS Neuron Degeneration
    treatment_effect: MODULATES
    description: >-
      The same mechanism sentence names reduction of neuronal death as an intended
      effect, and the trial's visual-acuity readout is the clinical correlate of
      this node. Visual acuity trended toward stabilization rather than improving,
      and the authors themselves note that natural history includes periods of
      stability — so this link is deliberately MODULATES with a stabilization
      claim only.
    evidence:
    - reference: PMID:42138079
      reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Best-corrected visual acuity trended toward stabilization over 48 weeks in both analysis sets (Figure 1E), consistent with periods of stability in natural history cohorts."
      explanation: >-
        Records stabilization rather than improvement, and carries the authors' own
        natural-history caveat that makes this the weakest of the four links.
  evidence:
  - reference: PMID:42138079
    reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PB&TURSO was associated with improved or stabilized pancreatic function, vision, and overall symptom burden in individuals with Wolfram syndrome, a rare and progressive degenerative disease."
    explanation: >-
      Reports the positive result. PARTIAL because the trial is single-arm and
      open-label with twelve participants, which cannot establish disease
      modification.
  - reference: PMID:42138079
    reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 24- and 48-week results from the ongoing HELIOS trial (ClinicalTrials.gov NCT05676034), a single-center, single-arm, open-label, phase II trial of PB&TURSO."
    explanation: >-
      Documents the trial design, which is the basis for the PARTIAL grading of the
      efficacy claim above.
  - reference: PMID:42138079
    reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Secondary measures including HbA1c and time in target glucose range improved from baseline at weeks 24 and 48 (Figure 1, C and D)."
    explanation: >-
      Objective glycemic secondary endpoints, recorded separately from the
      subjective global-impression measures because they are the outcomes least
      vulnerable to the open-label design.
  - reference: PMID:42138079
    reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All participants with available data were classified as responders on both Participant and Clinician Global Impression of Change (PGI-C and CGI-C) scales at weeks 24 and 48 (Figure 1F)."
    explanation: >-
      The global-impression result. Graded PARTIAL and kept distinct from the
      objective endpoints above: unblinded participant- and clinician-reported
      impressions are the measures most susceptible to open-label expectancy.
  - reference: PMID:42138079
    reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eleven participants experienced ≥1 treatment-emergent adverse events (TEAEs; Supplemental Table 3), all mild or moderate and mostly gastrointestinal."
    explanation: >-
      Safety and tolerability: adverse events were near-universal but none severe,
      with a predominantly gastrointestinal profile.
  - reference: PMID:42138079
    reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TEAEs led to treatment interruption or reduction in 3 participants each, but not to discontinuations. No serious TEAEs or deaths were reported."
    explanation: >-
      Completes the tolerability picture: dose interruption or reduction in a
      quarter of participants, but no discontinuations, serious events, or deaths.
  - reference: PMID:42138079
    reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Limitations include the open-label, single-arm design and small sample size, reflecting WS rarity."
    explanation: >-
      The authors' own statement of the design ceiling this entry grades against.
- name: GLP-1 Receptor Agonists
  description: >-
    A strong preclinical package has not yet translated into demonstrated clinical
    benefit. Dulaglutide, exenatide, and related agents improve beta-cell and
    neuronal readouts in WFS1-deficient models. In the largest human evaluation,
    30 of 84 registry participants had received a GLP-1 receptor agonist, but paired
    retrospective analyses found no glycemic or visual benefit over one to two
    years and gastrointestinal adverse effects were common. The uncontrolled,
    clinically selected sample makes that result preliminary rather than a
    definitive efficacy test.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Beta Cell Apoptosis
    treatment_effect: INHIBITS
    description: >-
      GLP-1 receptor agonism improves beta cell function and prevents apoptosis in
      WFS1-deficient human beta cell models. The evidence is preclinical.
  evidence:
  - reference: PMID:36995380
    reference_title: GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the long-lasting GLP-1R agonist dulaglutide reverses impaired glucose tolerance in WFS1-deficient mice"
    explanation: >-
      Isolates the intact-mouse metabolic result from the human in-vitro findings
      reported in the same source sentence.
  - reference: PMID:36995380
    reference_title: GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "exenatide and dulaglutide improve beta cell function and prevent apoptosis in different human WFS1-deficient models including iPSC-derived beta cells from people with Wolfram syndrome."
    explanation: >-
      Isolates the human WFS1-deficient beta-cell-model result without implying
      that these patient-derived cells constitute clinical treatment evidence.
  - reference: PMID:36995380
    reference_title: GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Exenatide improved mitochondrial function, reduced oxidative stress and prevented apoptosis in Wolfram syndrome iPSC-derived neural precursors and cerebellar neurons."
    explanation: >-
      Extends the preclinical benefit to the neuronal arm of the disease.
  - reference: PMID:42597412
    reference_title: Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty of the 84 participants (35.7%) had received a GLP-1 RA in addition to insulin. No statistically significant changes in HbA1c or body mass index were observed at one or two years. Best-corrected visual acuity (LogMAR) declined significantly at two years, consistent with expected disease progression. Gastrointestinal adverse effects were common (56.7% of users) and were the leading cause of discontinuation."
    explanation: >-
      Refutes an observed one-to-two-year glycemic or visual benefit in the largest
      available human cohort while documenting common gastrointestinal adverse
      effects. The retrospective, uncontrolled design prevents a definitive causal
      conclusion.
animal_models:
- name: Wfs1 exon-8 knockout mouse
  species: Mus musculus
  genotype: Wfs1 exon-8 knockout
  publication: PMID:41998758
  genes:
  - preferred_term: Wfs1
    term:
      id: MGI:1328355
      label: Wfs1
  description: >-
    The Estonian Wfs1 exon-8 knockout mouse develops progressive visual-acuity
    loss, optic-disc pallor, and severe optic-nerve damage. Intravitreal AAV2
    delivery of human WFS1 provides a direct rescue experiment for the retinal
    ganglion-cell branch.
  associated_phenotypes:
  - Optic Atrophy
  modeled_mechanisms:
  - target: Retinal Ganglion Cell and CNS Neuron Degeneration
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      The knockout reproduces progressive visual-acuity loss, optic-disc pallor,
      retinal thinning, and severe optic-nerve axon damage; rescue by retinal
      delivery of human WFS1 strengthens the causal interpretation.
    limitations: >-
      This link is restricted to the retinal and optic-nerve branch. The model did
      not show significant retinal-ganglion-cell soma loss at the studied age and
      does not establish fidelity for the broader human CNS phenotype.
    readouts:
    - name: Visual-acuity loss and optic-nerve damage
      target: Retinal Ganglion Cell and CNS Neuron Degeneration
      direction: INCREASED
      interpretation: >-
        Progressive visual loss, pallor, and optic-nerve damage are functional and
        structural readouts of the modeled retinal neurodegeneration.
      evidence:
      - reference: PMID:41998758
        reference_title: WFS1 gene delivery rescues visual function in a mouse model of Wolfram syndrome.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "the Wfs1 knockout mice produced by the Estonian group, in which exon 8 of the Wfs1 gene was disrupted, exhibit a progressive loss of visual acuity, optic disc pallor and severe optic nerve damage."
        explanation: >-
          Directly states the genotype and the functional and structural retinal
          phenotypes represented by this model link.
    evidence:
    - reference: PMID:41998758
      reference_title: WFS1 gene delivery rescues visual function in a mouse model of Wolfram syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "the Wfs1 knockout mice produced by the Estonian group, in which exon 8 of the Wfs1 gene was disrupted, exhibit a progressive loss of visual acuity, optic disc pallor and severe optic nerve damage."
      explanation: >-
        Establishes that the mouse recapitulates the optic-neuropathy branch.
  evidence:
  - reference: PMID:41998758
    reference_title: WFS1 gene delivery rescues visual function in a mouse model of Wolfram syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our results provide the first evidence that intravitreal injection of human WFS1 has significant neuroprotective effects on retinal ganglion cells and their axons and slows the loss of visual acuity."
    explanation: >-
      AAV2-WFS1 rescue of retinal ganglion-cell structure and visual function
      provides causal model support for the optic-neuropathy branch.
- name: Beta-cell-specific Cisd2 knockout mouse
  species: Mus musculus
  genotype: Beta-cell-specific Cisd2 knockout
  publication: PMID:40189101
  genes:
  - preferred_term: Cisd2
    term:
      id: MGI:1914256
      label: Cisd2
  description: >-
    Ins1-Cre-mediated beta-cell Cisd2 knockout mice develop glucose intolerance
    with impaired first- and second-phase glucose-stimulated insulin secretion but
    unchanged insulin sensitivity, modeling the WFS2 beta-cell secretory defect.
  associated_phenotypes:
  - Diabetes Mellitus
  modeled_mechanisms:
  - target: Insulin Deficiency
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Beta-cell-restricted Cisd2 loss impairs both phases of glucose-stimulated
      insulin secretion and disrupts systemic glucose homeostasis without changing
      insulin sensitivity.
    limitations: >-
      A beta-cell-specific knockout isolates the secretory arm of WFS2 and does not
      model optic atrophy, hearing impairment, ulceration, bleeding, or the effects
      of specific human CISD2 alleles.
    readouts:
    - name: Biphasic glucose-stimulated insulin secretion
      target: Insulin Deficiency
      direction: DECREASED
      interpretation: >-
        Defects in both phases of glucose-stimulated insulin secretion are the
        direct intact-animal readout for the insulin-deficiency node.
      evidence:
      - reference: PMID:40189101
        reference_title: Wolfram syndrome 2 gene (CISD2) deficiency disrupts Ca(2+)-mediated insulin secretion in β-cells.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "our results reveal that there are defects during both phases of GSIS in the Cisd2 βKO mice"
        explanation: >-
          Directly reports impaired first- and second-phase insulin secretion in
          the beta-cell-specific knockout mouse.
    evidence:
    - reference: PMID:40189101
      reference_title: Wolfram syndrome 2 gene (CISD2) deficiency disrupts Ca(2+)-mediated insulin secretion in β-cells.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "β-cell specific Cisd2KO in mice disrupts systemic glucose homeostasis via impairing β-granules synthesis and insulin secretion; hypertrophy of the β-islets and the presence of a loss of identity that affects certain β-cells."
      explanation: >-
        Establishes the in-vivo secretory defect and systemic glucose consequence
        represented by the model link.
  evidence:
  - reference: PMID:40189101
    reference_title: Wolfram syndrome 2 gene (CISD2) deficiency disrupts Ca(2+)-mediated insulin secretion in β-cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Firstly, β-cell specific Cisd2KO in mice disrupts systemic glucose homeostasis via impairing β-granules synthesis and insulin secretion; hypertrophy of the β-islets and the presence of a loss of identity that affects certain β-cells."
    explanation: >-
      Directly demonstrates impaired insulin synthesis and secretion after
      beta-cell-specific Cisd2 loss in vivo.
experimental_models:
- name: CRISPR-corrected patient iPSC-derived beta cells
  experimental_model_type: IPSC_DERIVED_MODEL
  description: >-
    CRISPR-Cas9 correction of a pathogenic WFS1 variant in induced pluripotent stem
    cells from a patient with Wolfram syndrome, differentiated to stem-cell-derived
    beta cells. This is the most concrete route to replacing beta cells rather than
    protecting them, and it demonstrates that the beta cell defect is reversible at
    the genetic level.
  publication: PMID:32321868
  modeled_mechanisms:
  - target: Insulin Deficiency
    relationship: RESCUES
    fidelity: MODERATE
    description: >-
      Correcting the WFS1 variant restored robust dynamic insulin secretion in
      vitro. Transplantation of the corrected human beta cells separately reversed
      streptozotocin-induced diabetes in mice.
    limitations: >-
      Transplantation was into mice with streptozocin-induced diabetes rather than
      into patients, so the therapeutic claim is preclinical and the diabetes
      reversed was chemically induced rather than WFS1-driven. The model addresses
      only the beta cell arm and says nothing about the neurodegenerative arm,
      which is what determines survival.
    readouts:
    - name: Glucose-responsive insulin secretion in corrected beta cells
      target: Insulin Deficiency
      direction: RESTORED
      interpretation: >-
        Dynamic insulin secretion in response to glucose is the direct in-vitro
        functional readout for relief of the insulin-deficiency node.
      evidence:
      - reference: PMID:32321868
        reference_title: Gene-edited human stem cell-derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "corrected WS SC-β cells performed robust dynamic insulin secretion in vitro in response to glucose"
        explanation: >-
          Isolates the human beta-cell in-vitro secretion result from the mouse
          transplantation result reported in the same source sentence.
    - name: Diabetes after corrected beta-cell transplantation
      target: Insulin Deficiency
      direction: RESTORED
      interpretation: >-
        Reversal of streptozotocin-induced diabetes is an intact-animal functional
        readout of insulin delivery by the transplanted corrected cells.
      evidence:
      - reference: PMID:32321868
        reference_title: Gene-edited human stem cell-derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "reversed preexisting streptozocin-induced diabetes after transplantation into mice."
        explanation: >-
          Restricts this evidence item to the in-vivo recipient result and does not
          present it as a human therapeutic outcome.
    evidence:
    - reference: PMID:32321868
      reference_title: Gene-edited human stem cell-derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "corrected WS SC-β cells performed robust dynamic insulin secretion in vitro in response to glucose"
      explanation: >-
        Directly supports restoration of insulin secretion in the corrected human
        beta-cell model.
    - reference: PMID:32321868
      reference_title: Gene-edited human stem cell-derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "reversed preexisting streptozocin-induced diabetes after transplantation into mice."
      explanation: >-
        Separately supports the intact-mouse transplantation result.
  - target: Unrestrained ER Stress Signaling Through ATF6-alpha
    relationship: RESCUES
    fidelity: MODERATE
    description: >-
      Genetic correction decreased expression of genes associated with
      endoplasmic reticulum stress in patient-derived beta cells.
    limitations: >-
      The transcriptomic readout is an ER-stress-associated gene set rather than a
      direct ATF6-alpha or HRD1 assay, so it supports relief of this graph branch
      without proving that every molecular step in the node was normalized.
    readouts:
    - name: Endoplasmic reticulum stress gene expression in corrected beta cells
      target: Unrestrained ER Stress Signaling Through ATF6-alpha
      direction: DECREASED
      interpretation: >-
        Reduced expression of ER-stress-associated genes after isogenic correction
        is the measured molecular correlate of relief of the ER-stress node.
      evidence:
      - reference: PMID:32321868
        reference_title: Gene-edited human stem cell-derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "Single-cell transcriptomics showed that corrected SC-β cells displayed increased insulin and decreased expression of genes associated with endoplasmic reticulum stress."
        explanation: >-
          Reports the measured reduction in ER-stress-associated gene expression
          after correction in the human beta-cell model.
    evidence:
    - reference: PMID:32321868
      reference_title: Gene-edited human stem cell-derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Single-cell transcriptomics showed that corrected SC-β cells displayed increased insulin and decreased expression of genes associated with endoplasmic reticulum stress."
      explanation: >-
        Supports the distinct ER-stress rescue assertion without conflating it
        with the insulin-secretion or mouse-transplantation readouts.
- name: CISD2-knockout human iPSC-derived cortical neurons
  experimental_model_type: IPSC_DERIVED_MODEL
  description: >-
    Isogenic CRISPR-Cas9 CISD2-knockout human induced pluripotent stem cells
    differentiated into cortical neurons. The model isolates complete CISD2 loss
    and directly measures organelle contacts, calcium responses, mitochondrial
    bioenergetics, autophagic flux, and stress-induced apoptosis.
  publication: PMID:41299767
  modeled_mechanisms:
  - target: ER-Mitochondria Contact and Calcium Transfer Dysregulation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      CISD2-knockout neurons lose endoplasmic-reticulum to mitochondria contact
      sites and show severe loss of glutamate-evoked cytosolic calcium responses
      and mitochondrial calcium uptake.
    limitations: >-
      Complete engineered knockout may not reproduce every patient missense
      variant; one patient-derived fibroblast model showed increased rather than
      decreased contact-site abundance.
    evidence:
    - reference: PMID:41299767
      reference_title: "CISD2 ensures adequate ER-mitochondrial coupling, critically supporting mitochondrial function in neurons."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "However, studying the impact of Cisd2 deficiency in human induced pluripotent stem cell -derived cortical neurons revealed a severe loss of glutamate-evoked Ca2+ responses in cytosol and associated uptake in mitochondria due to loss of ER-mitochondria contact sites."
      explanation: >-
        Directly reports the contact-site and calcium-transfer phenotype in the
        disease-relevant human neuronal model.
discussions:
- discussion_id: wfs_genotype_phenotype_tension
  kind: CONTROVERSY
  prompt: >-
    Are there established genotype-phenotype correlations in Wolfram syndrome, or
    only emerging ones?
  attaches_to:
  - genetic#WFS1 Biallelic Loss of Function
  rationale: >-
    GeneReviews takes the conservative position that no correlations are
    established, and that remains defensible. A meta-analysis of 412 published
    patients reported genotypic-class correlations, and a 2026 registry analysis
    found a six-level WFS1 severity score informative for diabetes onset and more
    modestly for optic atrophy, but not for hearing loss or central diabetes
    insipidus. The newer analysis lacked time-to-event censoring and derived its
    three-tier simplification in the same dataset, so the score is a research
    instrument rather than a validated individual prognostic test.
  evidence:
  - reference: PMID:23429432
    reference_title: "Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "New genotype-phenotype correlations were established, disease progression rate for the general population and for the genotypic classes has been calculated, and new diagnostic criteria have been proposed."
    explanation: >-
      The meta-analysis states that it established new correlations, which is the
      claim in tension with the conservative position.
  - reference: PMID:42524523
    reference_title: "Genotype-based severity scoring system in Wolfram Syndrome: correlation with onset of cardinal symptoms and WFS1 gene variant types."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The genotype-based severity score is most informative for diabetes mellitus, modestly informative for optic atrophy, and not currently useful for hearing loss or central diabetes insipidus."
    explanation: >-
      A large recent registry analysis supports phenotype-specific predictive
      signal but not a general genotype-to-course prediction; PARTIAL reflects its
      exploratory, internally assessed design.
- discussion_id: wfs_neurodevelopment_vs_neurodegeneration
  kind: OPEN_QUESTION
  prompt: >-
    How much of the brain deficit in Wolfram syndrome is failed development rather
    than degeneration, and what does that imply for when a disease-modifying
    therapy must start?
  attaches_to:
  - pathophysiology#Brainstem and Cerebellar Volume Loss
  rationale: >-
    Longitudinal morphometry shows both stalled white-matter growth and frank
    degeneration, and abnormalities are present in the youngest and mildest
    patients. If a meaningful share of the deficit is growth that never happened,
    then a neuroprotective therapy started after symptoms appear can at best halt
    decline and can never recover what was not built, which moves the therapeutic
    window earlier than a purely degenerative model implies. The relative
    contribution of the two processes has not been quantified.
  evidence:
  - reference: PMID:30979932
    reference_title: Evidence for altered neurodevelopment and neurodegeneration in Wolfram syndrome using longitudinal morphometry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These patterns suggest that there may be early, stalled white matter development in Wolfram syndrome, with additional degenerative processes in both white and gray matter."
    explanation: >-
      States the two-process interpretation whose relative weighting is the open
      question.
- discussion_id: wfs_gene_environment_interaction
  kind: KNOWLEDGE_GAP
  prompt: >-
    Does environmental or metabolic stress that raises the unfolded-protein load
    accelerate disease in WFS1-deficient cells in humans?
  attaches_to:
  - pathophysiology#Unrestrained ER Stress Signaling Through ATF6-alpha
  rationale: >-
    Because wolframin's job is buffering endoplasmic reticulum stress, any stressor
    that raises the unfolded-protein load (glucotoxicity, inflammation, hypoxia)
    should in principle hit harder in a WFS1-null cell. There is preclinical
    support in that WFS1 deficiency produces a chronic proinflammatory state, but
    no human data measure whether glycemic control or inflammatory burden modifies
    the rate of neurodegeneration. Until they do, better glycemic control should
    not be curated as a protective factor for the neurological disease.
  proposed_experiments:
  - experiment_id: wfs_glycemic_burden_vs_progression
    name: Glycemic and inflammatory burden versus neurodegeneration rate
    description: >-
      In an existing longitudinal Wolfram cohort with serial brain morphometry,
      relate cumulative glycemic exposure and circulating inflammatory markers to
      the rate of brainstem and ventral pontine volume loss, to test whether
      modifiable stress load changes the neurodegenerative trajectory.
  evidence:
  - reference: PMID:33693650
    reference_title: Novel mutations in the WFS1 gene are associated with Wolfram syndrome and systemic inflammation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The identification of a state of systemic chronic inflammation associated with WFS1 deficiency may pave the way to innovative and personalized therapeutic interventions in WS."
    explanation: >-
      Establishes the chronic inflammatory state that makes the gene-environment
      question mechanistically plausible.
- discussion_id: wfs_nfl_as_progression_marker
  kind: KNOWLEDGE_GAP
  prompt: >-
    Can serum neurofilament light chain serve as a treatment-response marker in
    Wolfram syndrome, given that it is elevated but does not track progression?
  attaches_to:
  - biochemical#Elevated Serum Neurofilament Light Chain
  rationale: >-
    Neurofilament light chain is clearly elevated and glial fibrillary acidic
    protein is not, which is a clean biological signal about axonal injury. But
    within the Wolfram group it did not change over time and did not correlate with
    clinical severity or neuroimaging measures, so it fails as a monitoring
    biomarker on the evidence available. Whether it moves under an effective
    therapy is a different question and remains untested, and the field needs a
    progression marker badly because every trial so far has had to rely on slow
    clinical endpoints.
  evidence:
  - reference: PMID:41929703
    reference_title: Neurofilament light chain but not glial fibrillary acidic protein serum levels are elevated in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Future studies may be warranted to determine if NfL could be a treatment-response marker in Wolfram syndrome clinical trials."
    explanation: >-
      States the open question in the authors' own terms.
- discussion_id: wfs_cisd2_treatment_generalization
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Does the PB&TURSO result in WFS1-related Wolfram syndrome generalize to the
    CISD2-related subtype, which this entry models as reaching the same
    organelle-contact and calcium-transfer compartment by an independent route?
  attaches_to:
  - pathophysiology#Loss of CISD2 at Organelle Contact Membranes
  - pathophysiology#ER-Mitochondria Contact and Calcium Transfer Dysregulation
  - pathophysiology#Mitochondrial Dysfunction
  rationale: >-
    The HELIOS trial restricted enrollment to WFS1 Wolfram syndrome deliberately,
    to reduce heterogeneity, and the authors state that CISD2 Wolfram syndrome
    shares similar pathophysiology and may benefit. That is a hypothesis, not a
    result: no CISD2 participant was treated. The question matters here more than
    it would in most entries, because this entry already models CISD2 as an
    independent route into the shared ER-mitochondria contact compartment rather
    than as a WFS1 phenocopy — so convergence at that node is exactly the premise
    the generalization rests on, and exactly what an untested extrapolation would
    be assuming. Note also that the two subtypes diverge clinically (CISD2 disease
    notably lacks diabetes insipidus and adds bleeding tendency), so shared
    upstream mechanism does not by itself predict a shared treatment response
    profile across endpoints.

    The contact-site direction sharpens this further, and cuts against a simple
    read-across. WFS1-null patient fibroblasts show *reduced* ER-mitochondria
    interactions and calcium exchange; a CISD2 missense variant causing classical
    Wolfram phenotype instead shows *increased* ER-mitochondria contact with a
    hyperfused mitochondrial network and no overt ER stress, while complete CISD2
    loss in human cortical neurons shows loss of contact sites again. So the
    direction of the contact-site abnormality is not uniform even within CISD2, let
    alone shared with WFS1 — which is exactly why this entry models the convergence
    node as direction-neutral dysregulation. A chemical chaperone and ER-stress
    modulator tuned to the WFS1 arm has no guaranteed effect on a lesion that
    perturbs the same compartment in the opposite direction, and the CISD2 missense
    finding explicitly reports the absence of overt ER stress that PB&TURSO is meant
    to relieve.
  proposed_experiments:
  - experiment_id: exp_wfs_cisd2_pbturso_response
    name: PB&TURSO response in CISD2-related Wolfram syndrome
    description: >-
      Extend an open-label PB&TURSO cohort to genetically confirmed CISD2 Wolfram
      syndrome with residual beta cell function, using the same stimulated
      C-peptide primary endpoint, and compare the response trajectory against the
      WFS1 cohort. Given the rarity, an n-of-1 series with pre-treatment
      natural-history run-in is more realistic than a parallel-group design.
    decision_criterion: >-
      Whether a stimulated C-peptide response in CISD2 participants falls within
      the range observed in the WFS1 cohort discriminates convergence at the
      shared contact-site node from a WFS1-specific chaperone effect.
    supporting_outcome:
    - >-
      A comparable stimulated C-peptide and glycemic response in CISD2
      participants, supporting the shared-compartment premise and licensing
      subtype-agnostic treatment claims.
    refuting_outcome:
    - >-
      Absent or markedly attenuated response in CISD2 participants, which would
      indicate the benefit depends on something specific to wolframin loss rather
      than on the shared ER-mitochondria contact defect.
  evidence:
  - reference: PMID:42138079
    reference_title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The trial focused on WFS1 WS to reduce heterogeneity, though CISD2 WS shares similar pathophysiology and may benefit."
    explanation: >-
      The authors' own statement of both the restriction and the untested
      generalization, which is what makes this a gap rather than a finding.
  - reference: PMID:28335035
    reference_title: A novel CISD2 mutation associated with a classical Wolfram syndrome phenotype alters Ca2+ homeostasis and ER-mitochondria interactions.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "This Ca2+ dysregulation was associated with increased ER-mitochondria contact, a swollen ER lumen and a hyperfused mitochondrial network in the absence of overt ER stress."
    explanation: >-
      The CISD2 missense arm perturbs the shared compartment in the opposite
      direction from WFS1 loss and without overt ER stress, which is the concrete
      reason a WFS1-tuned ER-stress modulator may not transfer.
  - reference: PMID:30352948
    reference_title: ER-mitochondria cross-talk is regulated by the Ca(2+) sensor NCS1 and is impaired in Wolfram syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In addition, we found that NCS1 abundance was reduced in WFS1-null patient fibroblasts, which showed reduced ER-mitochondria interactions and Ca2+ exchange."
    explanation: >-
      The WFS1 comparator direction — reduced interactions and exchange — against
      which the CISD2 missense finding is opposite.
  notes: >-
    Recorded as a gap, not as a treatment claim: PB&TURSO is deliberately not
    curated onto the CISD2 subtype anywhere in this entry, and should not be until
    a CISD2 participant has actually been treated.
differential_diagnoses:
- name: Type 1 Diabetes Mellitus
  description: >-
    The commonest misdiagnosis, and the reason Wolfram syndrome is typically
    identified years late. Distinguished by autoimmunity: islet autoantibodies are
    positive in type 1 diabetes and negative here, HLA risk haplotypes are present
    there and absent here, and C-peptide falls faster. Genetic testing of every
    child with autoantibody-negative, non-HLA-associated insulin-dependent diabetes
    is the highest-yield case-finding intervention available.
  distinguishing_features:
  - Islet autoantibodies positive in type 1 diabetes, negative in Wolfram syndrome
  - HLA-DR3 and DR4 risk haplotypes present in type 1 diabetes only
  - Optic atrophy, diabetes insipidus, and deafness do not occur in isolated type 1 diabetes
  evidence:
  - reference: PMID:20160352
    reference_title: Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Wolfram syndrome is an autosomal-recessive disorder characterized by insulin-dependent diabetes mellitus, caused by nonautoimmune loss of beta cells, and neurological dysfunctions."
    explanation: >-
      The non-autoimmune basis of the beta cell loss is what separates this from
      type 1 diabetes.
- name: Mitochondrial Diabetes and Deafness
  description: >-
    Maternally inherited diabetes and deafness from the m.3243A>G variant overlaps
    clinically and was historically confused with Wolfram syndrome. Distinguished
    by maternal inheritance, the mitochondrial tRNA-Leu 3243 variant, and the
    absence of the autosomal recessive family pattern.
  distinguishing_features:
  - Maternal inheritance pattern rather than autosomal recessive
  - Mitochondrial tRNA-Leu 3243 variant present
  - Optic atrophy is not the typical visual lesion
  evidence:
  - reference: PMID:7490992
    reference_title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Family studies indicate autosomal recessive inheritance with a carrier frequency of one in 354, an absence of a maternal history of diabetes or deafness, and an absence of the mitochondrial tRNA Leu (3243) mutation."
    explanation: >-
      Explicitly excludes the mitochondrial mimic on both inheritance pattern and
      genotype.
- name: Nonclassic (Dominant) WFS1 Spectrum Disorder
  description: >-
    Heterozygous WFS1 variants cause a distinct, dominantly inherited spectrum:
    DFNA6/14/38 low-frequency sensorineural hearing loss, Wolfram-like syndrome
    with adult-onset diabetes plus hearing loss and juvenile optic atrophy, and a
    de novo neonatal diabetes with congenital deafness and cataracts. The
    inheritance, the audiogram shape (low-frequency dominant versus high-frequency
    recessive), and the molecular mechanism (dominant-negative versus null) all
    differ. This entry deliberately covers only the recessive disease; the dominant
    spectrum belongs in separate entries.
  distinguishing_features:
  - Single heterozygous WFS1 variant with dominant transmission
  - Low-frequency rather than high-frequency sensorineural hearing loss
  - Milder or partial phenotype without the full DIDMOAD sequence
  evidence:
  - reference: PMID:20301750
    reference_title: WFS1 Spectrum Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nonclassic WFS1-SD. The diagnosis is established in a proband with suggestive findings and a heterozygous pathogenic (or likely pathogenic) variant identified by molecular genetic testing."
    explanation: >-
      GeneReviews formalizes the heterozygous, nonclassic spectrum as a separate
      diagnostic category from classic biallelic disease.
notes: >-
  Scope. This entry covers classic, autosomal recessive Wolfram syndrome under the
  umbrella MONDO term, with WFS1-related (WS1) and CISD2-related (WS2) forms as
  subtypes. The dominantly inherited nonclassic WFS1 spectrum (DFNA6/14/38,
  Wolfram-like syndrome, and the de novo neonatal diabetes-deafness-cataract
  presentation) is deliberately excluded and recorded as a differential instead.
  Inheritance, audiogram shape, and molecular mechanism all differ between the two,
  and blending them into one entry would misstate all three.

  TREATWOLFRAM. The randomized, double-blind, placebo-controlled sodium valproate
  trial (NCT03717909) is the most rigorous study the field has run, and it is
  reported to have missed its primary endpoint on the rate of visual acuity loss.
  At the time of curation only the trial protocol (PMID:40010822) is indexed in
  PubMed; there is no peer-reviewed results paper to cite. Valproate is therefore
  deliberately absent from treatments rather than being listed with a snippet that
  cannot support the claim, and the reported negative result is recorded here
  instead. It should be curated properly once the results paper appears.

  Nonclassic WFS1 disease accounts for roughly 15% of molecularly confirmed cases
  in UK specialist clinics per GeneReviews, so the recessive-only scope of this
  entry is a real restriction on coverage rather than a technicality.

  Deep research. Curated from a claude_code deep-research report
  (research/Wolfram_Syndrome-deep-research-claude_code.md), whose own reference
  validation reported 51/51 references verified with a confabulation rate of 0.0.
  Every snippet used here was independently re-verified against the cached PubMed
  record.
clinical_trials:
- name: NCT02829268
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Open-label phase Ib/IIa trial of dantrolene sodium, the first clinical trial
    ever conducted in Wolfram syndrome. Safety and tolerability were the primary
    objective, with beta cell function, visual acuity, and neurological function
    as secondary. Published as PMID:34185708. Dantrolene was well tolerated and
    did not improve beta cell function, visual acuity, or neurological function.
  target_phenotypes:
  - preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  - preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: clinicaltrials:NCT02829268
    reference_title: A Phase 1b/2a Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome."
    explanation: >-
      Registry record establishing the trial and its primary objective.
  - reference: PMID:34185708
    reference_title: A phase Ib/IIa clinical trial of dantrolene sodium in patients with Wolfram syndrome.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Visual acuity and neurological functions were not improved by 6-month dantrolene sodium."
    explanation: >-
      The published result, which was negative on the efficacy endpoints.
- name: NCT05676034
  phase: PHASE_II
  status: ACTIVE_NOT_RECRUITING
  description: >-
    HELIOS, a single-center, single-arm, open-label phase II trial of AMX0035
    (sodium phenylbutyrate and taurursodiol) in twelve adults with Wolfram
    syndrome. Reported improved or stabilized pancreatic function, vision, and
    symptom burden at 24 and 48 weeks (PMID:42138079). The uncontrolled design is
    the reason the entry grades that result PARTIAL.
  target_phenotypes:
  - preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  - preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: clinicaltrials:NCT05676034
    reference_title: A Phase II Study of Safety and Efficacy of AMX0035 in Adult Patients With Wolfram Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome."
    explanation: >-
      Registry record establishing the open-label single-arm design that qualifies
      the reported result.
- name: NCT03717909
  phase: PHASE_II
  status: COMPLETED
  description: >-
    TREATWOLFRAM, a randomized double-blind placebo-controlled trial of sodium
    valproate across six international centers, and the most rigorous study the
    field has run. Recruitment was stopped in November 2022 with 63 of a planned
    70 patients enrolled. The trial is reported to have missed its primary
    endpoint on the rate of visual acuity loss, but only the protocol paper
    (PMID:40010822) is indexed in PubMed at the time of curation, so that result
    is recorded in the entry notes rather than as evidence, and valproate is
    deliberately absent from treatments.
  target_phenotypes:
  - preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: clinicaltrials:NCT03717909
    reference_title: "A Pivotal, International, Randomised, Double-blind, Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "70 paediatric and adult patients were initially planned to be randomised 2:1 to receive either sodium valproate or placebo at 6 international centres. 63 patients were recruited when a decision was made to stop the study recruitment in November 2022."
    explanation: >-
      Registry record establishing the randomized placebo-controlled design and
      the actual enrollment, which is the design context for the reported but
      unpublished negative result.
- name: NCT02882477
  phase: PHASE_III
  status: UNKNOWN
  description: >-
    A combined phase II/III single-group study in genetically diagnosed WFS2 that
    offered deferiprone plus acetylcysteine, with incretin-based therapy added for
    participants with diabetes. The registry status is UNKNOWN as of 2026-08-19,
    and no peer-reviewed efficacy result was identified; this is a trial record,
    not a treatment recommendation.
  target_phenotypes:
  - preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  - preferred_term: Abnormal bleeding
    term:
      id: HP:0001892
      label: Abnormal bleeding
  evidence:
  - reference: clinicaltrials:NCT02882477
    reference_title: Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients who are genetically diagnosed with the recently reported and rare Wolfram syndrome type 2 ( WFS2) and have the degenerative and symptomatic disease including signs such as diabetes, platelet aggregation defect or visual problems will be asked to participate in this study."
    explanation: >-
      Establishes that the study is specifically WFS2 and targets diabetes,
      bleeding-related platelet dysfunction, and visual disease.
- name: NCT04940572
  phase: PHASE_II
  status: UNKNOWN
  description: >-
    AUDIOWOLF, a nonrandomized open-label phase II study of three years of sodium
    valproate in participants with biallelic WFS1 disease and sensorineural hearing
    loss. The registry status is UNKNOWN as of 2026-08-19, and no peer-reviewed
    efficacy result was identified.
  target_phenotypes:
  - preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: clinicaltrials:NCT04940572
    reference_title: "AUDIOWOLF: A Phase II, Open-label, Efficacy Study of Daily Administration of Sodium Valproate in Patients Clinically Affected by Wolfram Syndrome Due to Monogenic Mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Open label, phase II study non randomized single group assignment of 20 evaluable patients 13 years and older, over 37,5 kg body-weight, with sensorineural hearing loss of at least 20 dB at 8 kHz in high frequency average (HFA), and with documented genetic mutations in the WFS1 gene and with at least one other major documented clinical symptom pertaining to Wolfram syndrome (i.e. diabetes mellitus, diabetes insipidus, optic atrophy)."
    explanation: >-
      Establishes the WFS1 genotype requirement, hearing-loss endpoint population,
      and uncontrolled phase II design.
- name: NCT05659368
  phase: PHASE_II
  status: UNKNOWN
  description: >-
    A prospective nonrandomized single-group phase II trial of tirzepatide in WFS1,
    designed to assess endogenous insulin production and glycemic lability. The
    registry status is UNKNOWN as of 2026-08-19, and no efficacy result was
    identified; the study does not establish tirzepatide as treatment.
  target_phenotypes:
  - preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  evidence:
  - reference: clinicaltrials:NCT05659368
    reference_title: "Towards a Personalized Precision Medicine in Rare Disease: Tirzepatide (a Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 Receptor Agonist) Monotherapy in Patients With Wolfram Syndrome Type 1"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It will be a prospective phase 2, non-randomized, single group assignment, intervention trial to determine the efficacy of tirzepatide (GIP/GLP-1 receptor agonist) in increasing endogenous insulin production and correcting glycemic lability in patients with Wolfram syndrome type 1 (WS1)."
    explanation: >-
      Directly states the WFS1 scope, phase, design, intervention, and intended
      metabolic endpoints.
- name: NCT02841553
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >-
    The international registry and natural-history study for Wolfram syndrome and
    WFS1-related disorders. ClinicalTrials.gov listed it as recruiting with an
    estimated enrollment of 5,000 on 2026-08-19. It supplies longitudinal clinical
    and genetic data rather than testing a therapeutic intervention.
  target_phenotypes:
  - preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  - preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: clinicaltrials:NCT02841553
    reference_title: Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Aim 1. Establish and maintain a registry of patients with Wolfram syndrome. An Internet based registry will be employed to enroll participants with the clinical diagnosis of Wolfram syndrome (insulin dependent DM and bilateral OA). Clinical information regarding age of diagnosis and progression of the disease will be collated and analyzed to better define its natural history, along with potential metabolic phenotypes such as glucose intolerance of heterozygous parents and unaffected sibs."
    explanation: >-
      Establishes the registry, enrollment phenotype, and natural-history purpose.
datasets:
- accession: geo:GSE139535
  title: Single Cell Sequencing Analysis for Wolfram Syndrome (WS4) Unedited and Corrected Stem Cell-Derived Beta Cells
  description: >-
    Single-cell transcriptomic comparison of unedited Wolfram patient
    stem-cell-derived beta cells and CRISPR-corrected isogenic beta cells, directly
    linked to the genetic-rescue experimental model in this entry.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_count: 2
  publication: PMID:32846125
  notes: >-
    Accession, title, organism, sequencing type, and two GEO samples were verified
    against NCBI GEO on 2026-08-19. GEO metadata links this accession to
    PMID:32846125, the stem-cell-derived islet maturation study. The
    disease-specific CRISPR-correction report (PMID:32321868) describes the
    WS4corr model but is not the publication assigned to this GEO record.
references:
- reference: PMID:20301750
  title: WFS1 Spectrum Disorder.
  tags:
  - GeneReviews
- reference: PMID:9771706
  title: A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome).
- reference: PMID:7490992
  title: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome."
- reference: PMID:17846994
  title: "A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2."
- reference: PMID:20160352
  title: Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells.
- reference: PMID:30352948
  title: ER-mitochondria cross-talk is regulated by the Ca(2+) sensor NCS1 and is impaired in Wolfram syndrome.
- reference: PMID:27434582
  title: "Role of Mitochondrial Dynamics in Neuronal Development: Mechanism for Wolfram Syndrome."
- reference: PMID:32632005
  title: Calpain inhibitor and ibudilast rescue β cell functions in a cellular model of Wolfram syndrome.
- reference: PMID:22792385
  title: Early brain vulnerability in Wolfram syndrome.
- reference: PMID:30979932
  title: Evidence for altered neurodevelopment and neurodegeneration in Wolfram syndrome using longitudinal morphometry.
- reference: PMID:23429432
  title: "Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotype."
- reference: PMID:34185708
  title: A phase Ib/IIa clinical trial of dantrolene sodium in patients with Wolfram syndrome.
- reference: PMID:42138079
  title: Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome.
- reference: PMID:32321868
  title: Gene-edited human stem cell-derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice.
- reference: PMID:32846125
  title: Single-Cell Transcriptome Profiling Reveals β Cell Maturation in Stem Cell-Derived Islets after Transplantation.
- reference: PMID:36995380
  title: GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models.
- reference: PMID:33693650
  title: Novel mutations in the WFS1 gene are associated with Wolfram syndrome and systemic inflammation.
- reference: PMID:39202345
  title: "Wolfram Syndrome 1: A Neuropsychiatric Perspective on a Rare Disease."
- reference: PMID:41929703
  title: Neurofilament light chain but not glial fibrillary acidic protein serum levels are elevated in Wolfram syndrome.
- reference: PMID:39527371
  title: SID/SIEDP expert consensus on optimizing clinical strategies for early detection and management of wolfram syndrome.
- reference: PMID:12707947
  title: "Wolfram syndrome and suicide: Evidence for a role of WFS1 in suicidal and impulsive behavior."
- reference: PMID:23981289
  title: Phenotypic characteristics of early Wolfram syndrome.
- reference: PMID:9817917
  title: "Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein."
- reference: PMID:21446023
  title: Neurologic features and genotype-phenotype correlation in Wolfram syndrome.
- reference: PMID:28335035
  title: A novel CISD2 mutation associated with a classical Wolfram syndrome phenotype alters Ca2+ homeostasis and ER-mitochondria interactions.
- reference: PMID:29728875
  title: Natural history and clinical characteristics of 50 patients with Wolfram syndrome.
- reference: PMID:38465704
  title: Long term clinical follow up of four patients with Wolfram syndrome and urodynamic abnormalities.
- reference: PMID:40010822
  title: "Sodium valproate, a potential repurposed treatment for the neurodegeneration in Wolfram syndrome (TREATWOLFRAM): trial protocol for a pivotal multicentre, randomised double-blind controlled trial."
- reference: PMID:40189101
  title: Wolfram syndrome 2 gene (CISD2) deficiency disrupts Ca(2+)-mediated insulin secretion in β-cells.
- reference: PMID:41299767
  title: "CISD2 ensures adequate ER-mitochondrial coupling, critically supporting mitochondrial function in neurons."
- reference: PMID:41870390
  title: "Optic Atrophy in Wolfram Syndrome Type 1: A Retrospective Analysis of Visual Outcomes and Biomarker Correlates."
- reference: PMID:41998758
  title: WFS1 gene delivery rescues visual function in a mouse model of Wolfram syndrome.
- reference: PMID:42524523
  title: "Genotype-based severity scoring system in Wolfram Syndrome: correlation with onset of cardinal symptoms and WFS1 gene variant types."
- reference: PMID:42597412
  title: Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients.

📚